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Abstract 
 
The studies presented in this thesis aimed to investigate the effects of nutritional 
modulation and age-associated changes on insulin sensitivity. Four separate studies 
were performed; three of these had insulin sensitivity as the primary outcome. Existing 
studies show that ageing is associated with insulin resistance, but data may be 
confounded by several factors that also occur with increasing age, such as increased 
adiposity, skeletal muscle lipid accumulation and reduced physical activity. To elucidate 
this further the first study compared body composition, skeletal muscle lipid content, fat 
metabolism during light-intensity exercise and whole-body and skeletal muscle insulin 
sensitivity between 7 healthy young and 14 older males. Ageing and insulin resistance 
are also associated with impaired skeletal muscle protein synthesis, however the effects 
of insulin resistance per se on amino acid metabolism and associated insulin signalling 
pathways are not really known. The second study involved 8 young healthy males and 
aimed to explore the effect of insulin resistance on the protein synthetic response to 
amino acid ingestion and muscle protein signalling pathway in humans. Dietary intake 
has been shown to affect insulin sensitivity; however it is unclear if diet composition 
affects liver fat content independent of energy balance. Therefore the third study aimed 
to investigate the effects of hyperenergetic diets high in fat or carbohydrate on liver fat 
and insulin sensitivity. The study involved 23 healthy but overweight and obese males 
who initially consumed an isoenergetic diet for one week, and then were randomised to 
2 weeks of either hyperenergetic (+25% excess) high fat or high carbohydrate diets. 
Liver fat content, abdominal visceral fat, skeletal muscle fat content, hepatic lipid 
metabolism and insulin sensitivity were assessed before and after the 2 week 
intervention period. Whilst dietary excess can exacerbate insulin resistance, certain 
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micronutrients may improve insulin sensitivity. Carnitine has shown encouraging 
outcomes in relation to promoting fatty acid oxidation, metabolism and modulating 
body composition in healthy young volunteers. However the effects on older people 
have never been explored. This formed the basis of the fourth study that investigated the 
effects of 6 months of oral carnitine supplementation or placebo in 14 older (≥65 years 
of age) healthy males in relation to fatty acid metabolism, skeletal muscle lipid and 
insulin sensitivity. 
The main findings are summarised. Irrespective of age, adiposity and physical 
activity are associated with impaired fatty acid oxidation, greater skeletal muscle lipid 
accumulation and reduced insulin sensitivity. However ageing per se appears to increase 
the sympathetic response to exercise and enhance systemic fatty acid delivery and 
adipose tissue lipolysis. Insulin resistance induced by acute elevation of lipid was found 
to affect the skeletal muscle protein synthetic response to amino acid ingestion, and this 
impairment appeared to occur downstream from the Akt insulin signalling pathway. 
Energy excess per se increases liver fat content and affects liver metabolism but there 
were no differential effects of carbohydrate or fat on hepatic insulin sensitivity and liver 
fat content.  Finally, oral carnitine ingestion for 6 months successfully increased skeletal 
muscle total carnitine content of older healthy people and resulted in increased fatty 
acid oxidation and intramyocellular lipid (IMCL) utilisation during light-intensity 
exercise, but no effect on skeletal muscle insulin sensitivity was seen.  
These studies have increased mechanistic insight into the associations between ageing, 
nutrients and insulin sensitivity, paving the way to further research.     
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CHAPTER 1: INTRODUCTION 
 
 
‘Der Mensch ist, was er iBt’ 
‘Man is what he eats’ 
 
Ludwig Andreas Feuerbach 1863 
Concerning Spiritualism and Materialism 
 
Coined over 150 years ago, the expression that man is what he eats and that the food 
one eats has bearing of ones’ state of health and mind still holds true to today.  
What has become very apparent in modern times is the increasing prevalence of Type 2 
Diabetes (T2DM), which is strongly associated with diet and lifestyle. This has been 
demonstrated in large-scale population studies (Tuomilehto et al. 2001, Knowler et al. 
2002, Li et al. 2008). A plethora of studies have attempted to shed light on the 
fundamental question of how diet and nutrition drive the development of insulin 
resistance. However what remains uncertain and has given rise to conflicting study 
outcomes is what aspect of diet exerts the greater influence; increased energy intake or 
change in the proportion of the macronutrient. Further, can introducing certain 
micronutrients improve insulin sensitivity? How does insulin resistance as a result of 
acute and chronic manipulation of the diet affect human metabolism?  
In line with diet and insulin resistance, the obesity epidemic is also of concern, 
afflicting people of all ages. In particular, the 21
st
 century and beyond will see an 
increased prevalence of ageing and development of diabetes, with a growing number of 
studies examining underlying mechanisms and strategies to impede or even ‘reverse’ 
2 
 
the development of insulin resistance associated with ageing. However overweight and 
obesity and other changes in metabolism occur with ageing and not necessarily due to 
ageing per se, so it is not entirely clear what directly influences insulin sensitivity as 
people age. 
An analysis of evidence in the literature reveals inconsistent results on the effects of 
dietary modulation, obesity and ageing per se on insulin sensitivity, but cautious 
consideration to interpreting these results has to be taken due to confounding variables 
and difficulty in conducting nutritional and age-related studies in controlled settings.  
This thesis presents new and unique evidence to the discussion and topical issues 
surrounding the association of diet, ageing, obesity, insulin sensitivity and metabolism, 
and attempts to reconcile differing concepts in insulin resistance development.  
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1.1 Historical perspective  
 Figure 1.1: Concepts of diet and development of insulin resistance over the last 60 
years. 
1.1.1 Concepts and hypotheses on nutrients and insulin sensitivity 
The association between diet and insulin sensitivity has been a matter of much interest, 
debate and controversy for more than 60 years. The first major and well-known 
prospective study investigating risk factors for heart disease (Framingham, 
Massachusetts) began in 1948 and probably led to the term ‘lifestyle disease’ whereby 
over-nutrition and low physical activity led to positive energy balance and obesity 
(Dawber, Kannel et al. 1959).  
Until the end of the 19th century, at least a proportion of the population in developed 
countries were struggling with famine and malnutrition, considered a major cause of 
industrial unproductivity (Fogel, Proceedings of the World Food Programme/United 
Nations University Seminar; 1997). In the early 20th century studies of poor children 
indicated that adding carbohydrate and fat to their diets improved growth and this was 
beneficial in improving malnutrition and industrial productivity (Boyd-Orr 1937). The 
1948 
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epidemic 
1962  
Neel's Thrifty 
Hypothesis 
1980-90s  
O'Dea Revised 
Hypotheses 
1994  
Brand-Miller & 
Colaguiri's  
Carnivore 
Connection 
Theory 
2001 
Diabesity 
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US Food and Agriculture Organisation was an important protagonist; one of their major 
aims was to increase low-cost calorie foods, namely fats and sugars. Following this, by 
2002 global food production reached 2600 kilocalories (kcal) per day per capita, and is 
projected to reach 3000 kcal by 2030 (FAO. Rome, Italy: Food and Agriculture 
Organization of the United Nations; 2002. World agriculture: towards 2015/ 2030).  
Understanding the significance of the growing prevalence of obesity arose in the early 
20th century, when life insurance companies used body weight data to determine 
premiums, having identified an association between excess weight and premature death 
(Caballero 2007). Breslow (1952) proposed a direct link between the increasing 
prevalence of obesity and increasing rates of cardiovascular disease in the US 
population which then became a recurrent theme with emphasis in US government 
reports in the 1960s and 1970s (US Department of Health. Washington, DC: US Public 
Health Service; 1966. Obesity and health (Report no.1485). Data over the past 30 years 
continue to show an alarming rise in obesity prevalence (Harlan, Landis et al. 1988) and 
by the year 2000, 65 percent of the adult population in the United States had a body 
mass index (BMI) above 25, and 30 percent had a BMI above 30 (Hedley, Ogden et al. 
2004). The projected global number of people who will be overweight or obese is 
estimated at 1.4 billion and 570 million respectively by 2030 (Kelly, Yang et al. 2008).     
1.1.2 Concepts and hypotheses linking diet, nutrition and insulin resistance 
Several hypotheses in the development of the insulin resistance syndrome have been 
postulated ever since an association with nutrition, overweight and insulin resistance 
was recognised (Figure 1.1). Indeed it is difficult not to mention obesity in the same 
context as insulin resistance or diabetes.  
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In 1962, Neel hypothesised that a genotype in diabetes existed (Neel 1962), a condition 
that suited conditions of ‘feast’ and ‘famine’, and this simply evolved over time due to 
changes in diet and lifestyle. The ‘thrifty gene hypothesis’ puts forth the notion that 
some people possess a ‘thrifty tendency and flexibility’ to minimise energy loss and 
encourage storage of energy as fat during the ‘feast’ period, and produce energy to aid 
survival during periods of ‘famine’. When the hypothesis was first proposed, it was 
thought that only small numbers of populations were highly susceptible to diabetes 
particularly in the West, but more recently it has become evident that obesity and 
insulin resistance are ‘consistent sequelae of lifestyle transition’ (Rowley, Best et al. 
1997). The increased availability of food and overconsumption, so characteristic of 
urbanisation and modern lifestyle have led to increased fat storage, obesity and 
associated insulin resistance.  
Over the years the thrifty gene hypothesis underwent refinements through studies 
carried out in populations with a high prevalence of T2DM. For example whilst 
investigating indigenous people and other populations in Australia, O’Dea recognised 
that besides food stored during the ‘feast’ period, other food were readily available 
(termed subsistence diet) (O’Dea 1991).  Therefore a transition from a traditional to a 
Westernised lifestyle occurred, characterised by a change to diets high in refined 
carbohydrates and fat that were readily available, coupled by reduced physical activity 
levels. However, O’Dea also demonstrated in population studies that development of 
insulin resistance could be reversed. When the traditional lifestyle consisting of 
ingesting high- protein, low- carbohydrate diet and increased physical activities was 
simulated over 2 weeks, glucose tolerance improved significantly and hyperinsulinemia 
was reduced. A subsequent study by the same group showed that when subjects with 
diabetes followed a low-fat diet consisting of lean meat for a period of 7 weeks and 
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increased physical activity, mean fasting blood glucose levels fell from 11.6 to 6.6 
mmol/L, with a mean weight loss of 8 kilograms (kg) (O’Dea et al. 1992).   
 Another one of the most intensely studied population group in the aetiology of T2DM 
is that of the Pima Indians of the Gila River Indian Community in Arizona. This 
community has participated in longitudinal studies since the 1960s (Knowler 1979) and 
their clinical characteristics have defined T2DM across most populations (Knowler 
1990). In fact T2DM diagnostic criteria adopted by the World Health Organisation 
(WHO) were initially established in this tribe. Whilst their traditional diet consisted of 
high carbohydrate but low fat nutrients (24% saturated fat of total energy) (Hesse F 
1959, Boyce et al. 1993), by the mid-20
th
 century they had begun conforming to modern 
lifestyle changes, consuming diets of fat that contributed up to 40% of total energy and 
became less physically active. This tribe is now one of the most obese in the world, with 
50% or more of the population developing diabetes. Despite little genetic disparity 
between Pima Indians in Mexico and Arizona and non-Pima Mexicans, Mexican Pima 
Indians have a much lower prevalence of T2DM and obesity providing evidence that 
lifestyle changes play an important role in the development of diabetes (Schulz et al. 
2006). 
Brand-Miller and Colagiuri in 1994 proposed the ‘carnivore connection’ theory, where 
insulin resistance evolved as a consequence of scarcity of carbohydrates and high intake 
of animal protein. This provided an advantage to populations that adapted to high-
protein but low carbohydrate diets, but proved deleterious in a high-carbohydrate 
environment. Perhaps the switch to consuming high-carbohydrate and fat diets in 
modern times has facilitated an increase in insulin resistance rates. In this context it is of 
interest to note that populations that have changed dietary high-protein ‘hunter gatherer’ 
intakes to modern high carbohydrate diets relatively later than their European 
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counterparts have shown a proportionally greater increase in the incidence of 
developing T2DM, compared to European descent populations who switched to high 
carbohydrates thousands of years ago. A prime example is China. The prevalence of 
diabetes in the 1980s was 1%, but by 2008, around 10% of the population developed 
diabetes (Yang, Lu et al. 2010). However, the relationship between overweight, obesity 
and diabetes varies between different populations. In Asia diabetes appears to develop 
at a lower BMI and younger age, a modest increase in weight appears to lead to rapid 
development of insulin resistance (Yoon, Lee et al. 2006). It could be that the greater 
tendency for populations in Asia to develop increased abdominal adiposity but less 
muscle mass increases risk of insulin resistance. Indeed tomography has shown greater 
visceral fat in Asians compared to White Europeans despite similar waist 
circumferences (Lear, Humphries et al. 2007). 
Nevertheless overweight and obesity appear to be the prime drivers of insulin 
resistance. The association between obesity and diabetes is so strong that the term 
‘diabesity’ emerged around the turn of the century (Zimmet P 2012).  
In summary, the association between diet and insulin sensitivity has been 
established for at least the past half century, interspersed with various concepts and 
hypotheses that attempt to describe the emerging global prevalence of diabetes. 
‘Diabesity’ has become a great concern of the 21st century with growing diabetes and 
obesity rates. Insulin resistance appears to be associated with changes in dietary intake 
that predisposes to adiposity, particularly in these times of increased availability and 
easy access to food. The following sub-chapters attempt to define insulin resistance, 
examine the mechanisms involved in impaired insulin sensitivity and how certain 
nutrients might contribute to the development of insulin resistance. How diets and 
exercise improve insulin sensitivity will also be discussed. 
8 
 
1.2 Mechanisms of Insulin Signalling and action 
Understanding the mechanisms underlying normal insulin action is paramount to 
appreciating how insulin resistance develops and what influences insulin homeostasis.  
 One would have predicted that when Banting and Best first purified insulin and treated 
a patient with diabetes in 1922, a mechanism that explained insulin action would soon 
follow. Almost a century later the mechanism has proven complex, still not completely 
understood and is continuously being unraveled.    
  
 
 
 
 
 
 
 
     
 
 
Figure 1.2: Mechanism of insulin signalling pathway: Early work by Saltiel and Kahn (2001) 
describes the binding of insulin to the insulin receptors, phosphorylating serine-threonine 
protein systems of insulin receptor substrates (IRS-1-4). These then become coupled to protein 
kinase signal systems of phosphatidylinositol 3 kinase (PI3k) and formation of PI (3,4,5) 
Phosphate 3 (PIP3). PIP3 then binds to the surface membrane and associates with PDK-1 
leading to phosphorylation and activation of protein kinase b/Akt). Akt is phosphorylated by 
phosphoinositide-dependent protein kinase -1 and mammalian target of rapamycin complex 2 
(mTORc2) (Shepherd P 2005). 
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What is well established is that insulin action is initiated by the binding of the hormone 
insulin to its membrane receptor consisting two α and two β subunits (Freychet P 1971, 
Kahn CR, 1985). The insulin receptor is present in varying quantities in almost all 
mammalian tissues, with the greatest concentration seen on adipose tissue and liver 
cells. Insulin binds to the α-subunits, stimulating tyrosine phosphorylation of the 
intracellular portion of the β-subunit such as tyrosine, serine and threonine – IRS 1 to 4. 
At least until the end of the 1980s, it was uncertain how the receptor kinase ultimately 
transmitted its signal. Models proposed and largely accepted as playing a central role 
include receptor autophosphorylation (Herrera R et al. 1985) or dephosphorylation of 
cellular enzymes and conformational change of beta-subunit receptor (White MF, Kahn 
CR 1986) leading to interaction of secondary effector systems such as PI3k activity and 
phospholipase C (Sale et al. 1986, Machicao and Wieland 1984). So it became clear that 
activation of PI3-K associates with phosphoinositol dependent kinase 1 (PDK1) leading 
to phosphorylation of protein-kinase B (Akt).  
 
The relatively recent discovery of novel insulin receptor products indicates that there are 
more undiscovered receptors and mechanisms involved in insulin signalling. Activation 
of inositol hexakisphosphate (IP6) kinase (IP6K1) yields 5-diphospho-
inositolpentakisphosphate (5-PP-IP5) or IP7 that binds to Akt, inactivating it and 
preventing its function as a substrate for mTORC2 and PDK1 phosphorylation  
(Chakraborty et al. 2010, Manning B et al. 2010). mTOR is a nuclear serine/threonine 
protein kinase found in two complexes (mTORC1 and mTORC2) in most of the body's 
tissues.  These appear to be essential in the regulation of metabolism, including 
organization of the insulin and growth factor signals.   
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Insulin resistant states such as T2DM are characterised by reduced receptor numbers 
due to down-regulation, altered kinase activity and reduction in insulin-receptor 
autophosphorylation. These appear to be regulatory in nature (Bar et al. 1979). 
 
1.3 Role of insulin in nutrient metabolism  
 
1.3.1 Role of insulin in carbohydrate metabolism 
Insulin is the hormone central to glucose homeostasis on ingestion of nutrients 
particularly dietary carbohydrates (Bessessen 2001). Post-prandial, glucose is taken up 
by hepatocytes via GLUT-2 transporters (Guyton 1996) and phosphorylated to glucose-
6-phosphate by the enzyme glucokinase. This process is not regulated by insulin but is 
reliant on the glucose concentration outside the hepatocyte (Frayn 1999). Insulin 
stimulates glycogen synthase which polymerises glucose to glycogen (Petersen et al. 
1998) and inhibits glycogen phosphorylase. When glucose metabolism in liver exceeds 
hepatocyte glycogen-storing capacity, insulin and glucose promote conversion of excess 
glucose into fatty acids via the transcription factors sterol regulatory element-binding 
protein-1c and carbohydrate response element-binding protein-1c respectively, a 
process known as de novo-lipogenesis (DNL) (Postic C 2007).  DNL is limited in 
humans under normal conditions (<5% of triacylglycerol pool); (Diraison 2003) 
compared to people with non-alcoholic fatty liver disease (NAFLD) with 25% of the 
triacylglycerol pool (Donelly 2005). Hepatic glucose production originates from 
glycogenolysis and gluconeogenesis, the breakdown of which depends on glycogen 
phosphorylase and glucose-6-phosphate. Insulin inhibits glucagon secretion, lipolysis 
and proteolysis in muscle and lipolysis in adipose tissue.  
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1.3.2 Role of insulin in lipid metabolism 
Insulin’s role on lipid metabolism is evident by the immediate reduction in lipidaemia and 
acetonuria following insulin administration in an individual with diabetes (Fonseca 1924, 
Killian 1923).  
Insulin controls fatty acid and triacylglycerol synthesis through activation of pyruvate 
dehydrogenase and acetyl-coenzyme A (acetyl-coA) carboxylase by promoting its 
polymerisation, and appears to regulate esterification of fatty acids to triacylglycerol. Fatty acids 
taken up by the liver also go through beta-oxidation (Frayn K 1999). Through the process of 
beta-oxidation, non-esterified fatty acids (NEFA) are split into acetyl-coA which enters the 
tricarboxylic cycle for energy production or alternatively condensed into ketone bodies. Insulin 
promotes storage of NEFA in the form of triglycerides through reesterification.  It is well-
documented that insulin possesses a potent inhibiting effect on adipose tissue lipolysis via 
activation of insulin receptors (IR) expressed on these cells (Fain, J et al. 1966; Lavis, V and 
Williams, R 1973). 
 
1.3.3 Effect of insulin on Protein metabolism 
A classical action of insulin is stimulation of protein synthesis. This is exemplified in untreated 
Type 1 Diabetes (T1DM) where lack of insulin leads to weight loss, muscle loss and growth 
cessation (Kimball and Farrell et al. 2002; Proud and Denton 1997).  Insulin is widely described 
as a potent stimulus for muscle protein, indeed hyperinsulinaemia can increase muscle protein 
synthesis particularly when muscle amino acid availability is also increased (Bennet, Connacher 
et al. 1990). However insulin has been regarded to have a permissive rather than a modulatory 
role in muscle protein synthesis (MPS), and it is the availability of amino acids rather than 
insulin that appears to regulate rate of protein synthesis (Cuthbertson et al. 2005). Insulin has 
been shown to stimulate growth of cell cultures in vitro due in part to insulin binding to 
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receptors for insulin growth factor (IGF)-1 and IGF-2, demonstrating its role in tissue protein 
synthesis. Its effects are complex involving changes in synthesis and degradation; its 
mechanisms are beyond the remit of this thesis. Briefly the effects of insulin on protein take 
place over several timeframes. The rapid actions of insulin on protein metabolism involve 
increases in messenger ribonucleic acid (mRNA) translation.  Insulin controls several 
translation factors. In particular, the relatively newly-discovered protein-signalling system based 
on the Ser/Thr protein kinase, mTOR has been found to have a major role in the control of 
mRNA translation. Indeed similar signalling elements involved in protein metabolism have 
been found to be utilised in carbohydrate metabolism.   Specifically, mTOR has been shown to 
be controlled by the PI3-k pathway, an important mediator of the metabolic actions of insulin 
stimulates biosynthesis of certain proteins such as albumin, acetyl coA-carboxylase, fatty acid 
synthase, glucose-6 phosphate dehydrogenase, and pyruvate dehydrogenase, amino acid uptake, 
translation factors, and alterations in phosphorylation state of proteins involved in protein 
metabolism. Insulin activates protein synthesis by activating translational factors and 
increasing cellular ribosomes mediated primarily through phosphoinositide 3-kinase and 
activation of protein kinase B.This allows for overall activation of protein synthesis 
through its regulation of mammalian target of rapamycin (mTOR) and 4E-BP1, both of 
which are mainly involved in synthesis of protein (Proud 2006).  
Other signalling pathways in skeletal muscle cells involved in MPS include in particular 
the mTORc1 that targets and activates kinases such as S6K1 that ultimately results in 
ribosomal biogenesis and translation.  
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Figure 1.3 from Haran, Rivas et al. 2012.    
Anabolic stimuli (amino acids, growth factors (insulin, IGF-1), and exercise (not 
shown) act through the mTOR and Akt signalling pathways. mTORC1 is involved in 
the phosphorylation and activation of S6K1 and phosphorylation and inactivation of 4E-
BP1, resulting in ribosome biogenesis, increase in translational efficiency, and 
heightened MPS. The energy sensor AMPK inhibits this pathway, and is active when 
the AMP/ATP ratio is high. Growth factor stimulates activation of the PI3K pathway as 
well as mTORc2; both eventually activate Akt, which can inhibit stress signalling and 
apoptosis through inactivation of FOXO1/O3 transcription factors. Akt also plays a role 
in carbohydrate metabolism. P- phosphorylation, activation or inactivation; PI3K- 
phosphoinositide 3 kinase; Akt- protein kinase B; FOXO- forkhead protein box O; 
AMPK -AMP-activated kinase; 4E-BP1- eIF4E-binding protein 1; S6K1- S6 kinase 1 
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1.4 Defining Insulin Resistance 
Harold Percival Himsworth, who as author of the pivitol paper ‘Diabetes mellitus: its 
differentiation into insulin-sensitive and insulin-insensitive types’ was perhaps the first 
person to introduce the concept of insulin resistance. (Himsworth, 1936). Through 
insulin administration to different subjects with diabetes and comparing the rate and 
extent of fall in blood glucose levels, Himsworth was able to classify diabetes into two 
types: “those in whom insulin produced an immediate suppression of hyperglycaemia 
following glucose intake, that is subjects who are insulin-sensitive but appeared to be 
insulin deficient; and those in whom insulin had little or no effect in suppressing 
hyperglycaemia, described as insulin-insensitive.” He proposed that the observed 
insulin insensitivity was through restriction of a then unknown sensitising factor which 
in normal healthy humans produces a response to insulin in the presence of 
carbohydrate. It is now recognised that several possible mechanisms exist to explain this 
phenomena, as discussed in the subsections before. Of interest and significance is that 
Himsworth preferred the term insulin insensitivity to resistance, as he found no 
convincing evidence of a factor that ‘resists’ the action of insulin per se. The term 
insulin resistance had also been used to refer to preceding observations of an individual 
requiring more insulin than expected to produce hypoglycaemic symptoms or when vast 
amounts of insulin were insufficient to prevent the development of diabetic coma 
(Joslin 1935, Root 1929) and patients on insulin requiring increasing large amounts of 
insulin to control hyperglycaemia (Kahn CR, Rosenthal AS 1979). The term is now 
used interchangeably to describe the precursor or preceding state of diabetes.       
Following on from what is now regarded ‘a seminal contribution’(Reaven 2011), further 
experimental works from Himsworth published in the late 1930s to 60s did not have as 
much impact, and it was not until the 1970s when work by Reaven, whose experimental 
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methods in quantifying insulin-mediated glucose rekindled interest in insulin resistance. 
He found insulin resistance to be characteristic of patients with glucose intolerance 
(Shen S 1970) and later to the association of insulin resistance and different human 
diseases (Reaven 1988) and the development of clinical syndromes such as the 
metabolic syndrome (Reaven 2005).  
At its simplest level insulin resistance can be defined as decreased sensitivity or 
responsiveness to the metabolic actions of endogenous or exogenous insulin to increase 
whole body glucose uptake and utilisation (Lebovitz 2001) characterized by higher 
fasting and post-glucose loading insulin levels (Kelley 2000). No universally-agreed 
definition of insulin resistance exists but various descriptions have been proposed 
according to methods of assessments in vivo. Using fasting plasma insulin to measure 
insulin action on a population, the definition of insulin resistance used to identify at risk 
individuals in a study by Salazar et al. 2011 was based on results of a study where 25% 
of an apparently healthy population with highest insulin concentrations developed 
glucose intolerance, hypertension and coronary vascular disease to a greater degree than 
the remaining 75% of the population.   
The term insulin resistance has now been widely used and closely associated with a 
cluster of metabolic and cardiovascular abnormalities that define the metabolic 
syndrome (DeFronzo RA, 1991). This close association is acknowledged by the fact 
that the Adult Treatment Panel III (ATP III) have in their diagnostic guidelines used the 
terms ‘Metabolic Syndrome’, ‘Syndrome X’ and ‘insulin resistance syndrome’ 
synonymously. Although there appears to be a close affiliation, the metabolic syndrome 
is by no means a defining term for insulin resistance. In fact using criteria diagnostic of 
the metabolic syndrome (MetS) based on the harmonized version of the Adult 
Treatment Panel III (ATP III) and International Diabetes Federation (IDF) (see Figure 
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1.4), a number of studies (Cheal et al. 2004, Liao et al. 2004, Siera-Johnson et al. 2006, 
Salazar et al. 2011) concluded that MetS criteria did not provide an effective way of 
identifying individuals who are insulin resistant and that care should be taken when 
referring to a state of insulin resistance based on these factors. 
 Waist Circumference : ≥ 94 cm in men and ≥ 80 cm in women 
 HDL-C: <1.0 mmol/L (40 mg/dl) in men and <1.3 mmol/L (50 mg/dl) in 
women 
 Triglycerides: ≥1.7 mmol/L (150 mg/dl) 
 Systolic BP ≥130 mmHg or Diastolic BP ≥ 85 mmHg 
 Glucose: ≥6.1 mmol/L (110 mg/dl) 
 
Figure 1.4: Harmonised version of ATP III and IDF diagnostic criteria of MetS. 3 out 
of 5 criteria are required to diagnose MetS. 
1.4.1 Insulin resistance and its association with cardiovascular disease. 
Perhaps the concept of an association between clusters of cardiovascular risk factors and 
diabetes was best described by Reaven in 1988, who identified a clear relationship 
between hyperinsulianemia, glucose intolerance and hypertension, and also led to the 
descriptive term ‘Syndrome X’. However this probably had its origins much earlier in 
1923 when Kylin described the clustering of hyperglycaemia, hypertension and 
hyperuricaemia (Kylin E 1923). This was followed by others who associated obesity 
(Vague 1947) and hyperlipidaemia (Avogaro and Crepaldi 1965) with diabetes.  
Hypertension is more common in obesity as these individuals tend to be 
hyperinsulinaemic, and those who underwent exercise training experienced a decline in 
blood pressure limited exclusively to those who also had reducing insulin levels. The 
possible pathogenesis underlying this are that increases in insulin concentration 
promotes an increase in catecholamine levels and therefore sympathetic activity. Insulin 
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has also been shown to act on the kidney at the level of the renal tubules in promoting 
sodium resorption and proximal tubule to promote volume resorption (Reaven GM 
1988). Other metabolic associations with insulin resistance are listed in Figure 1.4. 
Epidemiological studies suggest that hyperinsulinaemia is a risk factor for Coronary 
Artery Disease (CAD). However the mechanisms are not entirely clear. 
Hypertriglyceridaemia appears to be secondary to insulin resistance. An inverse 
relationship between high-density lipoprotein cholesterol concentration and glucose 
intolerance and direct relationship between triglycerides and hyperinsulinaemia are 
observed.  These clusters of risk factors of CAD may be important in the development 
of CAD and in the early days have been termed Syndrome X. This included resistance 
to insulin-stimulated glucose uptake or insulin resistance, glucose intolerance, 
hyperinsulinaemia, increased VLDL triglyceride and decreased high-density lipoprotein 
cholesterol and hypertension. The common feature is insulin resistance, which has often 
led to some groups referring to insulin resistance as Syndrome X or metabolic syndrome 
(Reaven 1988).     
1.4.2 Metabolic syndrome 
As alluded to earlier, the terms metabolic syndrome, Syndrome X (Reaven 1988), 
insulin resistance syndrome (Haffner 1992); and less so the plurimetabolic syndrome 
and the deadly quartet (Kaplan 1989) have been used interchangeably to describe the 
risk factors associated with insulin resistance and cardiovascular disease. As a 
consequence, the prevalence and indeed the identification of the syndrome vary among 
different studies given the lack of unifying and accepted criteria as a definition. The 
insulin resistance syndrome appears to be widely accepted as insulin resistance is a 
common denominator seen in descriptions of the syndrome. However the term has also 
raised differing and sometimes controversial views on what constitutes an accepted 
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definition. In 1998 the World Health Organisation (WHO) agreed on the term metabolic 
syndrome, supported by the third report of the National Cholesterol Education Programs 
Adult Treatment Panel (ATP III) but with different definitions. The ATP definition or 
factors used to define the metabolic syndrome is the most widely used in literature 
(Figure 1.4), however some argue that criteria to define the syndrome remain 
ambiguous. Doubt also remains over whether all patients that meet criteria of the 
metabolic syndrome are indeed insulin resistant. Unsurprisingly it became difficult to 
directly compare data from research studies using different definitions of the syndrome. 
The International Diabetes Federation (IDF) 2005 current definition attempts to address 
both the clinical and research needs establishing a ‘platinum standard’ of diagnostic 
criteria. However not all groups or associations were on board with the new definition, 
with the ADA/EASD questioning as to whether the syndrome was indeed a ‘syndrome’, 
if it actually served a purpose and whether the term was ‘medicalising’ people 
unnecessarily, driven by industry to create markets for pharmacological intervention 
(Kahn et al. 2005).  Despite the differences in opinion the IDF’S criteria is strongly felt 
to identify individuals at high risk of developing T2DM and cardiovascular disease, 
advocating  lifestyle changes over drug treatment (IDF 2005, Alberti, Zimmet, Shaw 
2005). Further research in this area will clearly identify more accurate predictive indices 
for the future.    
1.4.3 Role of insulin resistance in the development of Type 2 Diabetes 
Two major conclusions were reached from a series of experiments utilising insulin 
clamps conducted by Himsworth et al. (1939). First, insulin-stimulated uptake of 
glucose is significantly lower in people with impaired glucose tolerance and T2DM 
compared to normal healthy subjects. The degree to which this is reduced was 
comparable between those with IGT and T2DM, indicating no relationship between 
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fasting plasma glucose concentration and insulin resistance in these groups. This 
observation was in line with studies carried out on Pima Indians. Secondly, it was 
showed that there was almost a three-fold variance in insulin-stimulated uptake in 
glucose in individuals with normal glucose tolerance. Around a quarter of the normal 
population would exhibit insulin resistance to a similar degree of severity seen in 
individuals of impaired glucose toleranc (IGT) and T2DM, regardless of degrees of 
hyperglycaemia. These apparent inconsistencies are explained by the extent of insulin 
that can be secreted to compensate for insulin resistance. The individuals’ rate and 
sustainability of beta-cell insulin secretion determines their ability to stimulate glucose 
uptake and maintain glucose levels. It is not clear why the amount of insulin secreted 
differs from one person to another, but what is clear is that the beta cells play a crucial 
role in determining the degree of glucose tolerance and maintaining glucose 
homeostasis and that the inability to maintain hyperinsulinaemia leads to development 
of hyperglycaemia seen in IFG and T2DM. Elevated FFA concentrations can also 
inhibit insulin-stimulated glucose uptake (Ferrannini 1983). There is a direct 
relationship between plasma FFA concentrations and hepatic glucose production and 
plasma glucose concentration (Golay et al. 1987). An increase in FFA flux to the liver 
augments hepatic glucose production in humans and rat liver and causes 
hyperglycaemia by stimulating gluconeogenesis. This relationship is further supported 
by evidence showing agents that interfere with hepatic fatty acid oxidation can lower 
plasma glucose concentration (Ratheiser K et al. 1991, Hubinfer A et al. 1997). 
Administration of a potent inhibitor of the hepatic carnitine palmitoyl transferase (CPT) 
system lowered plasma glucose concentrations in rats with experimental diabetes (Conti 
R et al. 2001). It is also interesting to note that with the etoximir, FFA concentrations 
increased whilst insulin concentrations remained the same, indicating that the fall in 
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glucose was not entirely due to enhanced beta-cell function but inhibition of hepatic 
FFA oxidation.  
 
1.4.4 Liver fat and development of insulin resistance 
Excess energy is stored as glycogen and in particular as fat in liver, adipose tissue and 
muscle. Excessive accumulation of fat in liver has been linked to hepatic insulin 
resistance and indeed whole-body insulin resistance. The presence of liver fat 
independent of other cardiovascular risk factors has been shown to predict the onset of 
T2DM, and observed to be present before the onset of T2DM (Yki-Jarvinen 2005). This 
is because fatty liver overproduces very low density lipoprotein (VLDL), glucose, C-
reactive protein (CRP), fibrinogen and coagulation factors, well-known cardiovascular 
risk factors. In contrast, reduction in liver fat content is associated with an improvement 
in insulin suppression of glucose production and fasting plasma glucose (Petersen et al. 
2005). Carbohydrate (sucrose) overfeeding for 3 weeks has been shown to increase liver 
fat content and liver enzymes of overweight individuals that were reversible following 
reverting to a hypoenergetic diet (Sevastianova et al. 2012). Higher plasma insulin 
levels are associated with and to an extent influences the rate of hepatic DNL (Petersen 
et al. 2012, Schwarz et al. 2003). This is further substantiated by studies showing 
hypoenergetic diet (Nobili et al. 2007), physical activity (Perseghin et al. 2007) and 
thiazolinedione (Ravikumar et al. 2005) use reduces insulin secretion and decreases 
liver fat content. 
DNL following carbohydrate intake causes transport of free fatty acids into 
mitochondria.  But because malonyl-CoA (produced during DNL) inhibits oxidation, 
newly produced triacylglycerol is preferentially directed towards storage or export, 
contributing to increased liver fat and VLDL (Taylor 2013).  Accumulation of liver fat 
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also occurs when oxidation of fatty acids is perturbed or reduced. Hepatic insulin 
resistance develops when fatty acids are esterified to diacylglycerol (DAG, an 
intermediate of triacylglycerol and phospholipid metabolism), which activates protein 
kinase C epsilon type (PKCε) that in turn inhibits the signalling pathway from the 
insulin receptor to IRS-1 (Samuel et al. 2010). This effect on the first post- receptor step 
is underscored by disruption to the insulin signalling pathway, an important part of the 
mechanism involved in insulin action as described in Subchapter 1.2. In obesity 
intrahepatic DAG correlates with hepatic insulin sensitivity (Magkos et al. 2012).  
Ceramides (a derivative of sphingomyelin) cause sequestration of Akt2 and activation 
of gluconeogenesis, but no relationship to hepatic insulin resistance in humans could be 
demonstrated (Kumashiro et al. 2011). Despite a strong relationship between increased 
liver fat and insulin resistance, high levels of liver fat do not inevitably correlate with 
hepatic insulin resistance. This observation is analogous to normal insulin sensitivity 
seen in trained athletes despite raised intramuscular triacylglycerol (van Loon and 
Goodpaster 2006) and in muscle of mice overexpressing the enzyme DGAT-1(Liu et al. 
2009). 
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Figure 1.5: Mechanism of interaction between excess amounts of fatty acids, 
diacylglycerol and ceramide and insulin action within the hepatocyte. DAG activates 
PKCε and inhibits activation of IRS-1 by the insulin receptor. Ceramides cause 
sequestration of Akt2 by PKCζ and inhibit insulin control of gluconeogenesis (Taylor, 
Diabetes Care 2013).  
 
 Figure 1.6: Twin cycle hypothesis in the development of T2DM (Taylor, Diabetologia 
2008). 
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So now the increased liver fat not only causes resistance to insulin suppression of 
hepatic glucose production, but increases fasting plasma glucose over a period of time 
and thus basal insulin. Chronic hyperinsulinaemia promotes lipogenesis and increases 
conversion of excess energy to fatty acids, and so begins the cycle of hyperinsulinaemia 
and blunted suppression of hepatic glucose production. VLDL triglycerol increases 
delivery of fatty acids to tissues, including the islet cells of pancreas.  Excess fatty acid 
availability in the pancreatic islet impairs the acute insulin secretion in response to 
nutrients, and at a certain level of fatty acid exposure, postprandial hyperglycemia 
ensues. Hyperglycaemia further increases insulin secretion rates, enhances hepatic 
lipogenesis, and further drives the liver and pancreatic cycle. Eventually, the fatty acid 
and glucose inhibitory effects on the islets reach a trigger level that leads to a relatively 
sudden decompensation into clinical diabetes (Taylor 2008).  
1.4.5 Skeletal muscle insulin resistance 
Although Taylor touched upon the contribution of muscle insulin resistance albeit a 
chronic pre-existing contribution to the twin cycle hypothesis and recognised that 
muscle insulin resistance reflects whole body insulin resistance as the earliest predictor 
of onset of T2DM (Petersen et al. 2007), it would appear that he did not regard muscle 
to exert as large of an influence on development of T2DM than the liver or pancreas. 
Taylor argues that resumption of normal or near-normal blood glucose control leads to 
improvement of liver insulin sensitivity and not muscle, and this is supported by early 
animal studies. Mice with absent skeletal muscle insulin receptors do not develop 
diabetes (Bruning et al. 1998). Moreover humans with the PPP1R3A genetic variant of 
muscle glycogen synthase who cannot store glycogen in muscle after meals are not 
necessarily hyperglycemic (Savage et al. 2008). Normoglycemic individuals have been 
shown to maintain normoglycaemia with a degree of muscle insulin resistance identical 
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to those with T2DM (Taylor 2008). He also maintained that mitochondrial defects in 
muscle of insulin resistant individuals/people with diabetes (Petersen et al. 2004) were 
irrelevant to the aetiology of T2DM. It is not difficult to comprehend why Taylor was 
opposed to muscle insulin resistance as a major contributor to development of T2DM as 
he argues it is not muscle insulin resistance per se that causes blood glucose to rise but 
chronic hyperinsulinaemia that expedites accumulation of fatty acids, causing rise to 
chronic hyperglycaemia and ultimately insulin resistance.  
This brings us to discussing how muscle insulin resistance develops, giving rise to 
whole body insulin resistance, perhaps adding to part of Taylor’s theory that it is liver 
fat and the pancreas that acutely trigger onset of overt diabetes.  
 De Fronzo and Tripathy (2009) considered skeletal muscle insulin resistance as the 
initiating factor for development of T2DM long before beta cell failure of the pancreas 
(Lillioja et al. 1998, Warram et al. 1990) with impaired muscle glycogen synthesis as 
the primary defect in the development of insulin resistance. Under hyperinsulinaemic 
clamp conditions, around 75-80% of insulin-mediated glucose uptake occurs in skeletal 
muscle (Thiebaud et al. 1982, DeFronzo et al. 1981) whilst the remainder 20-25% of 
insulin-stimulated muscle glucose disposal is oxidised to CO2 and H20 (De Fronzo 
1997).  The earliest metabolic manifestation in the pathogenesis of T2DM appears to be 
moderate to severe insulin resistant muscle, demonstrated by examining lean, normal 
glucose tolerant, first degree relatives of people with T2DM (Warram et al. 1990) and 
long-term follow-up of normal glucose tolerant individuals as they progress from 
impaired glucose tolerance to overt diabetes (McCance et al. 1994). This approach 
provides a robust examination of development of diabetes as it excludes confounding 
factors such as obesity and hyperglycaemia. The earliest detectable metabolic 
abnormality seen in humans in T2DM is impairment of glycogen synthesis secondary to 
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reduced glycogen synthase activity (Bogardus 1984, DeFronzo 1997). In non-glucose 
tolerant offspring of parents with T2DM, using the two-step euglycaemic insulin clamp, 
impairment of glucose uptake was entirely accounted for by non-oxidative glucose 
metabolism (which represents glycogen synthesis). No defect was noted in the 
suppression of hepatic glucose production by insulin (Gulli et al. 1992). Insulin 
secretion was significantly increased excluding a primary defect in beta cell function. 
Perseghin et al. (2007) directly quantified the defect in muscle glycogen synthesis over 
time in (non-glucose tolerant) NGT offspring of parents with diabetes using nuclear 
magnetic resonance (NMR) spectroscopy and demonstrated that reduced glycogen 
synthesis accounted for almost all of the decrease in insulin-stimulated muscle glucose 
disposal. Using the triple isotope method of 
12
C mannitol, 
13
CO methylglucose and 
3
H 
glucose and euglycaemic clamp, defects in muscle glucose transport and 
phosphorylation were seen in NGT offspring of T2DM parents, similar to that seen in 
T2DM individuals. Using 
14
C NMR, a similar defect along the glucose 
transport/phosphorylation pathway in particular the glucose-6-phosphate levels were 
seen by Rothman et al. (1995). A follow-up prospective study on Pima Indians (Weyer 
et al. 1999) found that at-risk individuals were resistant to insulin but at the stage of 
NGT, beta cells were able to secrete sufficient insulin to offset the insulin resistance. 
Over time progressors (at-risk individuals who progressed to T2DM) and non-
progressors (at-risk individuals who remained as NGT) experienced further reduction in 
insulin sensitivity (11-14%). However an interesting observation was that progressors 
were able to off-set muscle insulin resistance by augmenting insulin secretion by 30% 
whilst non-progressors were associated with almost an 80% decline in the acute insulin 
response to the intravenous glucose challenge. As the majority of glucose disposal after 
intravenous glucose administration occurs in muscle, this provides compelling evidence 
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that insulin resistance in muscle is the earliest demonstrable defect in the development 
of T2DM. However for overt T2DM to occur, beta cells must be at a stage where they 
are unable to compensate for the defect in insulin action (Gastaldelli 2004, Abdul-Ghani 
et al. 2006).  
The molecular mechanisms involved in the aetiology of skeletal muscle insulin 
resistance in genetically-predisposed individuals have been identified and appear to 
manifest at an early stage in NGT insulin resistant offspring of parents with T2DM. 
Using the euglycaemic insulin clamp and skeletal muscle biopsies, defects in IRS-1 
tyrosine phosphorylation and PI-3 kinase and Akt activation were consistently 
demonstrated in T2DM subjects (Krook et al. 2000, Cusi et al. 2000, Bouzakri 2003). 
Basal and insulin-stimulated IRS-1 tyrosine phosphorylation (a requisite for glucose 
transport and glycogen synthesis) and PI-3 kinase activity are significantly reduced in 
NGT subjects with a strong family history of T2DM (Morino et al. 2005). A similar 
significant reduction in PI-3 kinase activity has been observed during conditions of 
elevated FFA levels induced in lean healthy subjects during insulin-mediated glucose 
disposal (Belfort, Mandarino et al. 2005) 
NGT offspring of parents with T2DM were shown to possess muscle insulin resistance 
but normal sensitivity to the suppressive effects of insulin on hepatic glucose production 
(Gulli et al.).  Elevated fasting plasma FFA concentration during conditions of fasting 
hyperinsulinaemia and impaired suppression of plasma FFA during the euglycaemic 
insulin clamp indicate the presence of adipocyte resistance to the anti-lipolytic effects of 
insulin. Impaired insulin –mediated suppression of whole-body lipid oxidation was also 
present. The accumulation of lipid in muscle (IMCL) has been demonstrated in 
offspring of T2DM (Petersen et al. 2005), and as elaborated below is one of the primary 
drivers to the development of muscle insulin resistance as a result of accumulation of 
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lipid metabolites (ceramides, DAG and long-chain fatty acyl-coAs) that interfere with 
the insulin-signalling pathway (Hotamisligil et al. 1996, Schmitz-Peiffer 2000). In 
relation to this, accumulation of lipid in muscle is associated with skeletal muscle 
insulin resistance (Phillips, Caddy et al. 1996). Ceramides and DAG have been shown 
to be elevated in obese insulin resistant rat muscle with increased intra-myocellular lipid 
(IMCL) content (Turinsky, O'Sullivan et al. 1990) . DAG and ceramide act as second 
messenger involved in intracellular signalling with roles in cPKC and nPKC –mediated 
activation and reduction in Akt and GLUT4 translocation respectively.   
However improvements in human skeletal muscle insulin sensitivity have also been 
seen with little or no change (Bruce, Thrush et al. 2006) and even an increase in IMCL 
concentrations (Phillips, Green et al. 1996).  For example, master athletes have been 
shown to have high levels of IMCL, yet they are insulin sensitive (Goodpaster, He et al. 
2001) , indicating it is not the quantity of  IMCL per se but the complex interplay and 
balance of lipid availability, uptake and oxidation. The significance of cellular uptake 
and oxidation despite differing FFA availability will be discussed in chapter 3.  
Lower fat oxidation has been demonstrated to occur in people with T2DM and in obese-
insulin resistant but non-diabetes individuals (Kelly DE 2005), suggesting impairment 
of mitochondrial oxidative capacity. NGT offspring of parents with diabetes had 
reduced expression of key mitochondrial genes involved in regulation of oxidative 
metabolism in skeletal muscle such as energy generation, glycolytic, tricarboxylic acid 
cycle and oxidative phosphorylation. Shulman and others demonstrated impaired 
mitochondrial activity via 
1
HNMR and postulated that mitochondrial dysfunction was a 
primary defect leading to accumulation of lipid metabolites as a result of reduced fat 
oxidation and subsequent insulin resistance. However, small increases in palmitoyl-
carnitine have been shown to impair ATP synthesis in mitochondria of human muscle, 
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therefore it is not clear which is the cause, and which is the effect (Abdul Ghani et al. 
2006). 
Plasma lipid concentrations determine the rate of muscle FFA uptake, during conditions 
of hyperinsulinaemia (Brechtel, Dahl et al. 2001). Obese and insulin resistant states are 
often accompanied by high levels of FFAs and in addition to reduced lipid oxidation 
seen in obese muscle is likely to lead to excess IMCL deposition(Kim, Hickner et al. 
2000).  Excess muscle FFAs are either converted to lipid droplets for energy use or 
signalling molecules (ceramides, DAG) which may play a central role in lipid-mediated 
insulin desensitisation. Fatty acids are converted into fuel for muscle use and for this to 
occur FFAs are converted to long-chain fatty acyl co-As (LCFA co-As). These are 
transported into mitochondria by carnitine acyltransferase for beta-oxidation. The 
importance and beneficial effects of carnitine and fatty acid metabolism will be 
discussed at length in Chapter 6.  
To summarise, although there is no universally-accepted definition for insulin 
resistance, it can simply be described as a state of reduced sensitivity to the metabolic 
effects of endogenous or exogenous insulin of glucose uptake and use. There are 
differing opinions on what should constitute the metabolic syndrome, but factors that 
appear to be mutually agreed upon include factors that increase cardiovascular risk such 
as impaired glucose tolerance/diabetes, overweight/obesity, hypertriglyceridaemia and 
hypertension. Mechanisms underlying hepatic and skeletal muscle insulin resistance 
contribute to development of T2DM.  
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1.5. Skeletal muscle, lipid accumulation and insulin resistance 
Elevated levels of FFA concentrations are associated with obesity and skeletal muscle 
insulin resistance, and may even predict development of T2DM (Jenssen et al. 1989, 
Poulisso et al. 2005, Samuel and Shulman 2012). Indeed, Randle et al., besides 
proposing their theory on the glucose-fatty acid cycle, were one of the first to 
demonstrate that elevated plasma FFA concentrations were responsible for the reduced 
insulin sensitivity in diabetes mellitus (Randle et al. 1967).  Randle’s proposal of the 
glucose-fatty acid cycle described FFA’s inhibitory effect on glucose metabolism in 
rat’s diaphragm and isolated heart, whereby under aerobic conditions increased FFA 
availability increases fatty acid oxidation. This results in mitochondrial citrate and 
acetyl-coenzyme A (CoA) build-up and a rise in the cytoplasmic NADH/NAD ratio. 
The increase in acetyl-coA thus inhibits pyruvate dehydrogenase activity and 
subsequent inhibition of phosphofructokinase. This would cause a rise in glucose-6-
phosphate, inhibition of hexokinase II activity, increase in intracellular glucose and 
subsequent reduction in glucose uptake (Randle 1998, Dresner et al. 1999). In muscle 
and adipose tissue, glucose promotes reesterification of circulating FFA, whereas FFA 
inhibits muscle glycolysis, thus restricting glucose utilisation.  
However in contrast to Randle’s hypothesis not all subsequent studies have yielded 
similar findings (Schonfeld and Kipnis 1968). Using lipid infusion, insulin clamp 
technique and nuclear magnetic resonance (Roden et al. 1996, 1999) demonstrated that 
in contrast to Randle’s theory, FFAs induced insulin resistance at the level of glucose 
transport/phosphorylation, which then leads to a reduction in muscle glycogen synthesis 
and carbohydrate oxidation.  In concert with these findings, others (Griffin et al. 1999, 
Rothman et al. 1992) showed that lipid infusion decreases intracellular glucose and 
glucose-6-phosphate content secondary to inhibition of skeletal muscle glucose uptake.  
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Plasma lipid concentrations determine the rate of muscle FFA uptake, during conditions 
of hyperinsulinaemia  (Brechtel, Dahl et al. 2001). Obese and insulin resistant states are 
often accompanied by high levels of FFAs and in addition to reduced lipid oxidation 
seen in obese muscle is likely to lead to excess IMCL (Kim, Hickner et al. 2000).  On a 
mechanistic level, lipid infusion during hyperinsulinaemic euglycaemic clamp has been 
demonstrated to affect the intracellular signalling pathways in skeletal muscle by 
reducing IRS- 1 tyrosine phosphorylation, IRS-1 and 2 associated PI3-kinase activity 
and Akt phosphorylation and activity (Kim et al. 2000, Yu et al. 2002). Mechanisms 
implicated include activation of kinases such as PKCs, IKKβ, and JNK and p38 MAP 
kinase, thought to reduce phosphorylation of tyrosine residues of IRS-1 by insulin, 
blocking its downstream signal transduction (Tirosh et al. 1999, Bloch-Damti 2005; 
Evans et al. 2005).    
Another putative mechanism underlying lipid-induced insulin resistance include 
accumulation of  DAG that can activate novel protein kinase C (PKC) isoforms that 
cause serine phosphorylation of insulin receptor substrate-1 (Samuel and Schulman 
2012) and  ceramides as a consequence of binding of fatty acids to Toll-like receptor 4 
(TLR-4), which impairs Akt activation (Bikman and Summers, 2012). High-fat diets 
and lipid and heparin infusion induced accumulation of intracellular DAG in muscle 
(Schmitz-Peiffer et al. 1997) and activation of PKC, caused by reduction in tyrosine 
phosphorylation of IRS-1. Ceramides on the other hand may affect insulin signalling by 
activation of activation of Akt dephosphorylation at threonine 308 and inhibition of its 
translocation to the plasma membrane (Summers 2010).   
There also appears to be a causal role for the inflammatory pathways and development 
of insulin resistance. Fatty acids, like the bacteria-derived lipopolysaccharide (LPS), 
may bind to TLR-4 on macrophages and adipocytes and activate the proinflammatory 
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pathways (Medzhitov 2007) promoting c-Jun NH(2)-terminal kinase (JNK) and Iκb 
kinase (IKK) complex activation. These kinases cause phosphorylation of serine 
residues on insulin IRS-1 and inhibition of the stimulatory phosphorylation of tyrosine 
residues (Hotamisligil et al. 1993, 2008). This results in inhibition of insulin action  
Ingestion of high-fat meals and infusion of low-dose LPS can raise circulating cytokines 
such as tumour necrosis-α (TNF-α), IL-1β and IL6 (Krogh-Madsen et al. 2008) which 
in turn could cause elevation of lipid metabolites (Bikman and Summers 2011).  
Reactive oxygen species (ROS) are involved in important physiological processes, 
produced in response to stimuli such as nutrient metabolism and signalling through 
plasma membrane receptors. High levels of ROS are associated with chronic elevation 
in plasma lipid levels and intramyocellular fatty acids (Carvalho-Filho et al. 2005) and 
can negatively affect various biological signalling pathways. Impairment of the insulin 
signalling pathway is not completely understood, but ROS has been demonstrated to 
induce IRS serine/threonine phosphorylation, decrease GLUT-4 gene transcription and 
decreasing mitochondrial activity (Bloch Damti 2005, Morino et al. 2005). Animals fed 
a high-fat diet were found to have increased ROS production and were insulin resistant. 
Conversely when treated with antioxidants this improved oxidative stress and insulin 
sensitivity (Ogihara et al. 2004; Blouet et al. 2007).  
Several studies have shown mitochondrial dysfunction to play a pivitol role in the 
development of insulin resistance, whilst others have not (Dela, Helge 2013). 
Mitochondrial content, function and oxidative capacity in muscle were found to be 
reduced in insulin resistant obese and in T2DM (Holloway 2007, Schrauwen-
Henderling et al. 2007). These findings are corroborated by studies involving high fat 
diet or lipid infusion to healthy humans and rodents, resulting in impaired oxidative 
phosphorylation and ATP synthesis (Chanseaume et al. 2006, Szendroedi et al. 2009).  
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With regards to the interaction between FFA and the liver, early studies have shown that 
FFA stimulates gluconeogenesis from lactate (Struck et al. 1966), alanine (Herrera et al. 
1966) or pyruvate (Friedman et al. 1967) in perfused rat liver.  A relatively new 
hypothesis proposed is the association between skeletal muscle insulin resistance and 
excessive fat oxidation rates and mitochondrial overload. According to this hypothesis, 
when beta-oxidation exceeds the mitochondrial’s capacity to utilise acetyl-coA in the 
TCA cycle, incompletely oxidised, short-chain fatty acid products such as acylcarnitines 
may impair skeletal muscle insulin sensitivity (Muoio et al. 2008). This proposal is 
supported by increased levels of partially oxidised acylcarnitines seen in skeletal muscle 
of insulin-resistant high fat diet (HFD)-fed mice and diabetic fatty rats. The mechanism 
however has not been largely explored and investigated in humans.  
 
1.6 Lipid infusion 
Several of the studies described above utilised intravenous lipid infusion and heparin. In 
at least the last five decades intravenous lipid infusion has been used as a means of 
examining the effects of an acute increase of FFA levels on glucose uptake and 
underlying mechanisms of insulin resistance development in healthy subjects. Felber 
and Vannotti (1964) were one of the earliest to observe that lipid infusion caused 
glucose intolerance in normal, healthy individuals. Several studies substantiating this 
finding show a reduction in rate of plasma glucose disappearance following lipid 
infusions (Schalch and Kipnis (1965), Balasse and Neef (1975)). 
Ferrannini et al. explored the effects of physiological elevations of FFA concentrations 
on glucose production and utilisation under controlled hyperinsulinaemic conditions and 
findings were shown to be compatible with Randle’s glucose fatty acid hypothesis 
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(Ferrannini et al. 1983). In this study, heparin was infused concurrently to raise FFAs 
three to four fold, by intravascular lipolysis of infused lipids which stimulates activity 
of lipoprotein lipase in blood. When FFA concentrations were raised following IV lipid 
infusion under hyperinsulinaemic euglycaemic conditions (where endogenous glucose 
production was entirely suppressed), total glucose uptake was significantly lower 
compared to control (lower M/I ratio; where M is glucose uptake and I is steady state 
insulin concentration). This clearly demonstrated that by acutely elevating FFA levels, 
insulin-stimulated glucose uptake is inhibited even in the presence of hyperglycaemia. 
When insulin levels were low, lipid infusion had no effect on glucose utilisation, 
thought to be due to uptake of glucose by non-insulin dependent tissues. It was also 
speculated that inhibition by FFAs occurred at a peripheral level, most likely muscle. In 
this regard, inhibition of glucose metabolism by FFA is more likely to occur in 
conditions where there is insulin present at particularly high levels, ie insulin resistant 
states or T2DM.   
     
1.7 High fat overfeeding 
The issue concerning high-fat diet and its association with insulin resistance is of topical 
interest and continues to be a matter of intense investigation, discussion and debate. But 
there is without doubt that high fat diets play a pivotal role in the subject of insulin 
sensitivity and is an independent risk factor for overweight and obesity (Astrup, 2001).   
The role of dietary fat in weight gain relies on the individual’s genetic background, 
environment and ability to oxidise dietary and endogenous fat (Giacco et al. 2004).      
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Data on interventional human studies investigating the effects of high-fat diets on 
metabolism and insulin sensitivity are plentiful but largely inconclusive given the short 
period of intervention and relatively small number of subjects. 
 
Whereas excessive intake of fat (>37% of daily energy intake) appears to impair insulin 
sensitivity irrespective of the composition of fatty acids in the diet (Thomas and Pfeiffer 
2011), substantial evidence from animal studies suggest that certain fats promote 
accumulation of intramuscular triglygeride (IMTG). In line with this the first way in 
which fatty acids can affect insulin sensitivity is the type or quality of fat. There appears 
to be ‘good’ and bad’ types of fatty acid that improve or reduce insulin sensitivity 
respectively (Marshall, Bessesen et al. 1997). Specifically a selective increase in 
saturated fat intake may impair insulin action (Maron et al. 1991, Parker et al. 1993; 
Mayer et al., Mayer-Davis et al. 1997) whereas increasing unsaturated fat (when total 
fat intake is low) has been linked to improving insulin sensitivity (Vessby et al. 1994, 
Pan et al.1995). One way by which fatty acids can influence insulin sensitivity is the 
fatty acid composition of cellular membrane which may influence cell insulin signalling 
(Inokuchi 2006). Fatty acid types in human diet; saturated fatty acids (SFAs), mono-
unsaturated fatty acids (MUFAs), polyunsaturated fatty acids (PUFAs), trans-
unsaturated FAs differ by spatial configuration and chemical property. The efficacy of 
molecular signalling and transduction is highly dependent on the complex positioning of 
various proteins within the fatty acid cellular membrane, and so intake of various lipid 
molecules that can affect membrane fluidity and rigidity could potentially alter the 
mechanism’s sensitivity to configurative changes. Animal studies (Storlien, Pan et al. 
1996) show that saturated fat–laden membranes promote insulin resistance, whereas 
more unsaturated membranes protect against it, a finding also noted in humans.  
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The monounsaturated fatty acids (MUFAs) may improve insulin sensitivity by exerting 
an effect on cell membrane FA composition, membrane fluidity, insulin receptor 
binding/affinity and up-regulation of glucose transporters (Riserus, Willett et al. 2009). 
It may also be that MUFA are preferentially oxidised over saturated fatty acids (SFA) 
that gradually accumulate in muscle (DeLany, Windhauser et al. 2000).  
 
PUFA may improve insulin sensitivity by its anti-inflammatory effects mediated by toll-
like receptors in particular TLR 2 and 4 (Thomas and Pfeiffer 2011). Other postulated 
effects of PUFA on insulin sensitivity include beneficial changes to membrane fluidity, 
increased binding affinity of the insulin receptor and increased glucose transport into 
cells and effects on triglycerides.  
 
The MUFAs may improve insulin sensitivity by exerting an effect on cell membrane FA 
composition, membrane fluidity, insulin receptor binding/affinity and up-regulation of 
glucose transporters (Riserus, Willett et al. 2009). MUFA diets have been found to 
prevent central fat redistribution and prevent insulin resistance from ingesting a 
carbohydrate-rich diet (Paniagua, Gallego de la Sacristana et al. 2007). 
 
In contrast SFAs have been shown to have a direct relationship with the incidence of 
insulin resistance and T2DM. Under conditions of hyperglycaemia SFA influence 
enzyme activities and transcription factors and serine kinases interfering with insulin 
signalling pathways and inflammatory pathways associated with impaired insulin 
sensitivity (Rioux and Legrand 2007; Poitout and Robertson 2008). Furthermore, high 
intakes of TFA may lead to insulin resistance and increased risk of cardiovascular 
events. (Axen, Dikeakos et al. 2003; Mozaffarian 2006). 
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With respect to ingestion of these different fatty acid types on muscle, it would appear 
that accumulated lipid metabolites may be influenced by the type of fat ingested, that 
may be detrimental to mechanisms involved in insulin signalling. Saturated fatty acids 
such as palmitate, stearate or arachidate induce ceramide and DAG synthesis, inhibit 
Akt activation (Storz, Doppler et al. 1999; Chavez, Knotts et al. 2003), reduce glucose 
uptake by desensitisation of insulin stimulation (DAG) (Montell, Turini et al. 2001) and 
inhibit IR or IRS-1 phosphorylation (palmitate)(Storz, Doppler et al. 1999). A 
mediterranean- style diet consisting 25-35% of fat, containing mostly monounsaturated 
fats, has been linked to preventing risk factors of metabolic disease. (Kastorini, Milionis 
et al. 2011).  
N-3 PUFAs found in fish oil have been shown to be beneficial against development of 
insulin resistance, although the reversal of insulin resistance by increasing intake is not 
definitive. Rats fed a high-fat diet enriched with n-3 PUFA maintained IR, IRS-1, PI3-k 
activity and GLUT-4 content in skeletal muscle. N-3 PUFA are also preferentially 
oxidised over saturated fatty acids, and can up-regulate genes involved in lipid 
oxidation such as PPARs. In contrast n-6 PUFA appear to exhibit effects opposite of 
that seen with n-3 PUFA.  
1.7.1 Fat overfeeding studies, liver fat and insulin resistance 
  One of the more pertinent studies involved overfeeding rats a high-fat diet for 3 days 
such that a model of  NAFLD was simulated to determine the effect of hepatic fat on 
hepatic insulin responsiveness without the possible confounding effect of peripheral 
insulin resistance (Shulman 2004).  After 3 days of overfeeding fat (59% fat, 26% 
carbohydrate, 15% protein), hepatic triglycerides and fatty acyl-coA content nearly 
tripled but remained unchanged in muscle. Therefore high fat overfeeding resulted in 
marked hepatic insulin resistance whilst peripheral (muscle and adipose tissue) insulin 
37 
 
sensitivity was unaltered. This was attributed in part to decreased insulin-stimulated 
tyrosine phosphorylation of IRS-1 and IRS-2 which may result from activation of PKC-
ε or JNK, limiting the ability of insulin to activate glycogen synthase.  
In humans ingestion of a 2 week isocaloric high-fat diet increased liver fat, but body 
weight and subcutaneous fat mass were unchanged implying possible uptake of excess 
fat by the  liver (Westerbacka et al. 2005). This was in accordance with a 3 week study 
incorporating isocaloric high-fat diet in overweight men (van Herpen et al. 2011). 
Although these studies demonstrate accumulation of liver fat, it would appear that this 
did not translate to hepatic insulin/peripheral insulin resistance or that to see a 
significant effect on insulin sensitivity a hyperenergetic diet and longer duration of 
overfeeding is required. In contrary, Brons et al showed that a hyperenergetic high fat 
diet for 5 days led to a significant increase in hepatic glucose production. 
1.8 High Carbohydrate feeding  
Fructose and glucose overconsumption have long been associated with fatty liver but 
there is still controversy as to whether it is the macronutrient or energy excess from 
increased consumption that contributes primarily to liver fat accumulation and insulin 
resistance. Fructose in particular has been related to fatty liver and severity of 
histological changes in people with NALFD (Kang et al. 2006) independent of obesity 
and total caloric intake.  However studies on the effect of excessive carbohydrate on 
liver fat content are relatively few. One of the first few studies examining this possible 
relationship showed no effect on liver fat after 4 weeks of fructose overfeeding in lean 
healthy men (Kang et al. 2006, Silbernagel 2011). Insulin sensitivity in the latter study 
also remained unchanged. In contrast, others shown that a high fructose diet does have a 
positive effect on increasing liver fat (Le at al. 2009, Ngo et al. 2010, Sobrecases H et 
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al. 2010). The reason for the discordance in results is not entirely known, however a 
possible explanation could be that some studies were conducted in lean healthy men 
with little or absence of liver fat at baseline. The use of isoenergetic vs. overfeeding 
diets in different studies should also be taken into consideration. When carbohydrate 
overfeeding (fructose/sucrose/glucose) was examined in overweight or offspring of 
people with T2DM, an increase in intrahepatic lipid content was observed, further 
suggesting that overweight (Sevastianova et al. 2012)  and offspring of T2DM subjects 
tended to have a predisposition towards increased TAG/liver fat content.  The I148M 
variant in the palatin-like phospholipase domain containing protein 3 (PNPLA3) gene is 
associated with liver fat (Sookoian and Pirola 2011) and mutant PNPLA3 is unable to 
hydrolyse intrahepatic triglycerides (He et al. 2010). Therefore possession of this 
genotype may exert an influence an individuals’ response to carbohydrate feeding. A 3 
week hyperenergetic high carbohydrate diet (1000kcal/day with 98% energy from 
carbohydrate) in overweight healthy men resulted in weight gain and a 27% increase in 
liver fat content from baseline (Sevastianova et al. 2012). This study did not primarily 
study the effects of high carbohydrate diet on insulin sensitivity, but no difference in 
fasting plasma glucose was seen post-overfeeding period although a trend in increased 
fasting serum insulin concentrations. Johnston et al. 2013 showed that overweight men 
on isocaloric high-fructose or high-glucose diets did not develop significant changes in 
hepatic concentration of TAGs; however under hyperenergetic conditions these diets 
produced significant increases in liver fat indicating an energy, rather than a specific 
macronutrient-mediated effect. No effect on hepatic insulin sensitivity was seen.  
 Fructose is a unique monosaccharide in that most of its metabolism and extraction (50-
70% of fructose delivery) takes place in the liver. Therefore increased availability of 
fructose places greater demands on hepatocytes and increase abnormal glucose flux. 
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There are data to suggest that high concentrations of fructose produce adaptations in the 
liver that include metabolic intermediates, gene expression and insulin action. Increased 
fructose supply has been shown to induce a hepatic stress response activation of stress-
activated protein kinases such as c-Jun N-terminal kinases (JNK) and subsequent 
hepatic insulin signalling. Hepatic DNL (fatty acid and triglyceride synthesis) 
contributes to fatty liver and NAFLD (Donnelly et al. 2005) and substrates involved 
include primarily glucose, fructose and amino acids.   
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Table 1.1: Studies of iso-or hyperenergetic high carbohydrate or fat diets 
Authors Study description Results 
Horton et al. 1995 14 days of high energy (+50%) fat or 
carbohydrate in 9 lean and 7 obese 
males 
Carbohydrate overfeeding increased energy expenditure and carbohydrate 
oxidation and less fat oxidation. Fat was more likely to be stored as excess 
energy. No differences in energy or nutrient balance were seen in both obese 
and lean subjects in response to fat overfeeding. Obese subjects had greater RQ 
and oxidised more carbohydrate. Insulin concentrations and FFA were higher 
and lower respectively in the carbohydrate-fed group.   
Lammert et al. 2000 Effects of  3 weeks of isoenergetic high 
carbohydrate and fat overfeeding on 
body composition, sleep calorimetry and 
DNL in 20 healthy non-obese males 
Both groups had similar weight and fat mass gain. Carbohydrate overfeeding 
caused a greater increase in fractional hepatic DNL compared to fat 
overfeeding. 
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Bisschop et al. 2001 6 healthy men on 3 different fat content 
diets for 11 days. 0% and 85% [low-fat, 
high-carbohydrate (LFHC) diet], 41% 
and 44% [intermediate-fat, intermediate-
carbohydrate (IFIC) diet], and 83% and 
2% [high-fat, low-carbohydrate (HFLC) 
diet]  
A high-fat, low-carbohydrate intake reduces the ability of insulin to suppress 
endogenous glucose production and alters the relation between oxidative and 
non-oxidative glucose disposal in a way that favours storage of glucose. 
Westerbacka et al. 2005 2 weeks of isoenergetic high fat diet 
(56%) in 10 overweight/obese healthy 
females 
Liver fat at baseline averaged 10 +/- 7%. It increased by 35 +/- 21% during the 
high-fat diet. Fasting serum insulin increased during the high-fat diet. Serum 
lipids, free fatty acids, and intraabdominal and subcutaneous fat mass were 
unchanged. 
Le et al. 2006 4 weeks of overfeeding in lean healthy 
male subjects with 18% excess energy 
per day of carbohydrate (fructose) 
Increased TAG, VLDL-TAG and fasting glycaemia. Unchanged hepatic, 
adipose and whole-body insulin sensitivity 
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Kechagias et al. 2008 4 weeks of high energy overfeeding of 
carbohydrate, fat and protein in the form 
of convenience food in young healthy 
individuals 
Increased weight, serum ALT and hepatic triglyceride content. Maximal 
ALT/baseline ratio correlated with carbohydrate intake during the second 
week. HDL cholesterol increased 
Le et al. 2009 7 days of overfeeding (+35% energy 
excess) of carbohydrate (fructose) in 
healthy controls and offspring of T2DM  
Increased VLDL-TAGs, IHCLs, IMCLs in healthy controls and offspring of 
T2DM, IHCL higher in offspring of T2DM 
Ngo Sock et al. 2010 7 days of overfeeding carbohydrate 
(fructose and sucrose)  in healthy young 
males 
High fructose and sucrose diets increased VLDL-TAGS and IHCL. IMCL 
increased on the high glucose diet 
Sobrecases et al. 2010 7 days of high fructose (+35%), high fat 
(+30%) or high fructose high 
carbohydrate diets on liver fat 
Hyperenergetic diets increased IHCL, highest with combination high fat and 
carbohydrate followed by high fat and high carb. VLDL concentration 
increased post overfeeding with fructose, decreased with fat and remained 
unchanged with the combination of high fructose and fat.  
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Silbernagel et al. 2011 
4 weeks of overfeeding with 150g 
excess carbohydrate (fructose vs. 
glucose) in lean healthy male and female 
subjects 
Increased TAG in fructose group; but liver, visceral, subcutaneous abdominal 
fat and IMCL unchanged 
Van Herpen et al. 2011 3 weeks high fat isoenergetic diet 
(15%protein, 30% CHO and 55% fat) 
for 3 weeks in overweight men. 
IHL increased by 17%, IMCL and peripheral insulin sensitivity unaffected, 
reduced metabolic inflexibility. Plasma parameters insulin, free fatty acids, 
high-sensitivity C-reactive protein, and liver enzymes and body weight were 
unaffected by diet. 
Brons et al. 2011 5 days high energy (+60% energy)high-
fat (+50%) in healthy men 
Hepatic glucose production and fasting glucose levels increased significantly in 
response to overfeeding. Peripheral insulin action, muscle mitochondrial 
function, and general and specific oxidative phosphorylation gene expression 
were unaffected. 
Sevastianova et al. 2012 3 week high energy carbohydrate 
feeding (1000kcal/day, 98% energy ) in 
healthy overweight subjects 
Liver fat increased by 27% above baseline of 9.2% with significant increase in 
DNL.  
44 
 
Yu et al. 2013 10 wk overfeeding of sucrose or high 
fructose corn syrup equivalent to 
25
th
,50
th
 and 90
th
 percentile in 138 
subjects 
Weight and total energy intake increased. There was no difference in waist 
circumference, fat mass, liver or muscle fat. There was an increase in 
triglycerides but not cholesterol levels. 
Johnston et al. 2013 Effects of 2 weeks of isoenergetic vs. 
hyperenergetic fructose vs. glucose on 
liver TAG, insulin sensitivity and liver 
biochemistry  
No difference between high-fructose and high-glucose diets on liver 
triacylglycerol or biochemistry in healthy overweight men. 
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1.9 Carbohydrate and fat overfeeding diets 
Studies comparing carbohydrate vs. fat overfeeding are scarce. When healthy men with 
normal body mass index were fed either a hyperenergetic (30-35% excess energy from 
fructose or fat) or 65% excess energy from fructose and fat) for a period of 4-7 days, 
intrahepatocellular lipid (using 
1
H MRS imaging) increased with all diets, but more so with 
fat overfeeding (+86% compared to fructose, +16%). Interestingly subjects were only overfed 
fat for 4 days compared to a week in the fructose group. Fasting glycaemia remained 
unchanged whilst serum insulin tended to increase in all groups. Hepatic glucose production 
remained unchanged (Sobrecases et al. 2010).   
Another pertinent study examined the effect of subjects overfed isoenergetic amounts (+50% 
above energy requirements) of fat or carbohydrate on energy expenditure for 2 weeks. The 
study showed that carbohydrate overfeeding produced progressive increases in carbohydrate 
oxidation and total energy expenditure resulting in 75-85% excess of energy being stored, 
whilst fat overfeeding had minimal effects on fat oxidation and total energy expenditure 
resulting in greater fat storage of 90-95% excess energy (Horton et al. 1995). This suggests 
that fat overfeeding results in greater fat accumulation than carbohydrate excess. This is in 
concert with other studies showing a similar result (Flatt et al. 1985, Acheson et al. 1988, 
Schutz et al. 1989, Bennett et al. 1992).  
In summary, a number of mechanisms have been implicated in association with development 
of insulin resistance, from well-established Randle’s fatty-acid glucose cycle to relatively 
recent hypotheses concerning accumulation of lipid metabolites and partially oxidised lipid 
by-products that may interfere with insulin signalling pathway. Intravenous lipid infusion has 
been shown to induce insulin resistance, providing an ideal condition for investigating 
insulin-resistant states without the influence of confounding co-existent factors.  High fat 
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diets appear to modulate insulin sensitivity depending on the type of fatty acids and 
composition ingested that may be as important as lowering total fat consumed. It would 
appear that certain fatty acids are more likely to undergo oxidation in skeletal muscle and 
lipid metabolites such as ceramide and DAG can exert a negative effect on insulin sensitivity. 
High carbohydrate diets seem to increase hepatic triglycerides particularly in overweight and 
obese humans but do not appear to have an effect on insulin resistance, probably influenced 
by the timescale and small numbers investigated in these trials.   
Another significant association with development of insulin resistance is that of ageing and 
shall be discussed in the next section.   
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1.10 Ageing and insulin resistance 
  
Ageing- related insulin resistance deserves particular attention given the rising ageing 
population and its association with diabetes and the metabolic syndrome. 
 
Figure 1.7: Global diabetes prevalence by age and sex for year 2000. Figure taken from 
Wild, S et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 
2030. Diabetes Care 2004; 27(5): 1047-1053. 
A report published in 2004 estimated diabetes prevalence for all age-groups to rise by 1.6% 
and the number of people with diabetes projected to more than double in 2030. A striking 
observation from this study was that the increase in the number of people > 65 years has 
become the major contributor to global demographic change in diabetes prevalence (Wild, 
Roglic et al. 2004). 
An inevitable consequence of ageing and undeniably the most significant contributor to 
development of T2DM, cardiovascular disease and metabolic syndrome seems to be an 
increasing risk of the development of insulin resistance. Impaired glucose tolerance and 
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development of T2DM is more common in older persons, moreover the Third National 
Health and Nutrition Examination Survey (NHANES III) found that the prevalence of 
impaired glucose tolerance, impaired fasting glucose and diabetes mellitus increases with 
advancing age; T2DM was evident in >20% while impaired glucose tolerance was found in 
another 20% of those between 60 and 74 years of age (Harris, Flegal et al. 1998).  It is well 
established that when methods of assessing insulin sensitivity was compared in old and 
young, there appears to be a clear negative correlation of insulin sensitivity and increasing 
age. Table 1.2 presents studies supporting these observations. A comprehensive review by 
Davidson in the 1970s reported at least 60 papers using the oral glucose tolerance method and 
demonstrated a progressive deterioration in oral glucose tolerance as the population aged 
(Davidson 1979). 
Table 1.2: Studies supporting an association between age and decline in insulin sensitivity 
utilising various methods of assessing glucose uptake. 
Authors Study Method Results 
DeFronzo R 
1979 
19 young 
subjects (26±1 
year) vs 17 
older subjects 
(64±2 yrs) 
Hyperinsulinaemic 
euglycaemic clamp 
Amount of glucose infused (M) 
to maintain euglycaemia was 
significantly higher in young 
than older subjects. M (amount 
of glucose)/I (insulin 
concentration) (x 100) ratio was 
higher in young vs older subjects. 
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Refaie et al. 
2006 
40 healthy non-
obese older men 
(mean age 65 
+/-4.8 years vs 
30 young and 
40 T2DM 
subjects 
IV GTT 
Insulin sensitivity 
index 
Lower fasting insulin, insulin 
sensitivity index,insulin 
resistance index,HOMA-IR, 
QUICKI, second phase insulin 
response,fractional insulin 
clearance in old vs young 
Amati et al. 
2009 
7 endurance 
trained young 
athletes vs 12 
older athletes vs 
11 young 
normal weight 
vs 10 normal 
weight older vs 
15 young obese 
vs  15 older 
obese 
 
Hyperinsulinaemic 
euglycaemic clamp 
Higher glucose disposal rates 
regardless of age in athletes 
followed by normal weight and 
obese individuals 
Karakelides et 
al. 2010 
12 young lean, 
12 young obese, 
12 elderly lean 
vs 12 elderly 
obese 
Hyperinsulinaemic 
euglycaemic clamp 
Lower insulin sensitivity in older 
people thought to be secondary to 
age-related increase in obesity 
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The effect of age on insulin secretion remains a matter of debate, likely due to differing 
methods of assessing glucose disposal in the elderly and generally few studies that focus on 
insulin sensitivity in this age group.  There’s the pertinent question of whether it is ‘age’ per 
se or other factors associated with ageing that ultimately affects insulin sensitivity. It is well 
established that ageing is associated with glucose intolerance and increasing insulin 
resistance (Davidson 1979, DeFronzo 1981, Morley 2008). Both fasting and post-prandial 
glucose concentrations are generally higher in the elderly leading to compensatory 
hyperinsulinaemia. The mechanisms underlying age and reduced insulin sensitivity are not 
completely understood, although factors associated with ageing may likely contribute to 
impairing glucose tolerance in the older population.  Insulin resistance may not be a direct 
consequence of aging per se but due to obesity (Kelley, Goodpaster et al. 1999) and physical 
inactivity. (Amati, Dube et al. 2009) Early studies seem to point to a post-receptor defect in 
target insulin function (Rowe, Minaker et al. 1983). In recent years several causes that have 
been implicated include changes in body composition such as increasing fat mass (Schutz, 
Kyle et al. 2002),(Amati, Dube et al. 2009), together with accelerated decline in skeletal 
mass and strength (Baumgartner, Wayne et al. 2004), and accumulation of lipid in muscle 
(IMCL) (Goodpaster, He et al. 2001). In addition an increasing sedentary lifestyle seen in the 
elderly attenuates muscle use, leading to atrophy and promotes weight gain (Stenholm, Harris 
et al. 2008), in line with sarcopenia (Zamboni, Mazzali et al. 2008). Other metabolic 
perturbations in ageing include abdominal obesity, unrestrained hepatic gluconeogenesis, 
adipose lipogenesis, defective glycogen synthesis and glucose uptake in skeletal muscle 
(Morley 2008). An increase in pro-inflammatory cytokines derived from age-associated 
accrual of visceral fat and increasing senescent cells are also known to interfere with insulin 
action (Sepe, Tchkonia et al. 2011). As part of the normal biology of ageing, lipid 
accumulates in muscle. Compared to younger individuals IMCL content is increased by up to 
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40% in older people, as seen on 
1
H NMR  (Petersen, Befroy et al. 2003). Mitochondrial 
activity and oxidative phosphorylation was reduced in elderly insulin resistant individuals. In 
particular intermediate lipid and metabolites associated with IMCL such as ceramides, DAG 
and acyl-coA cause insulin resistance by activating key proteins that antagonise insulin-
responsive and signalling pathways (Savage, Petersen et al. 2007), therefore accumulation of 
lipid in ageing is correlated with skeletal muscle insulin resistance (Dube, Amati et al. 2008) 
Lipid accumulation also arise from a reduction in mitochondrial quantity and function (Hoeks 
and Schrauwen 2012) resulting in decreased fatty acid oxidation rate (Petersen et al. 2003). 
The association between impaired mitochondrial function and how it might affect insulin-
signalling is complex and is thought to involve incomplete beta-oxidation of fatty acid 
substrates in liver and muscle.  
 
Figure 1.8: Factors contributing to insulin resistance in ageing. IR=Insulin resistance, 
IMCL=intramyocellular lipid 
 
IR in 
ageing 
Body 
composition
Visceral 
adiposity 
Muscle/IMCL 
Diet & 
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inactivity 
Mitochondrial 
dysfunction 
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The factors contributing to insulin resistance in ageing are most probably multifactorial and 
changes seen to accompany ageing have to be considered as playing an influential role.   
1.10.1 Visceral adiposity 
A common feature of ageing is increased visceral fat (sum of fat depots within visceral 
cavity) (Folsom et al. 1993), a risk factor for insulin resistance and correlates strongly with 
insulin sensitivity in human and animal models (Atzmon et al. 2002). Putative mechanisms 
underlying visceral fat and its association with insulin resistance include  increased portal 
release of FFAs (Muzumdar et al. 2008) and/or abnormal expression and secretion of fat-
derived peptides such as leptin, ACRP30, and inflammatory cytokines eg TNF-α. Surgical 
removal of visceral fat in a young rat model improved hepatic insulin action, and was 
reproduced in older rat models (Muzumdar et al. 2008). In animal models at least, selective 
intra-abdominal depots (perinephric and epididymal) appear to modulate insulin action and 
glucose tolerance.  
1.10.2 Sarcopenic obesity 
An inevitable consequence of advancing age is the decline in muscle mass and strength 
(Morley et al. 2001) and this appears to accelerate from around the fourth decade at a rate of 
just under 1% per year (Zamboni et al. 2008, Stenholm 2008). Muscle strength appears to 
decline three times faster than mass, which suggests changes within muscle associated with 
age or physical inactivity: accumulation of fat, structural proteins and mitochondrial 
dysfunction (reduction in mitochondrial numbers, morphology change, oxidative damage, 
reduced oxidative capacity and increased DNA mutations and oxidative stress and damage 
(Jensen et al. 2001).  
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1.10.3 Mitochondrial content 
The reduction in mitochondrial content and activity with ageing (Hoeks and Schrauwen 
2012) may contribute to the development of insulin resistance through the observation that 
muscle of older healthy people contained increased muscle fat and a reduction in 
mitochondrial oxidative phosphorylation activity.   Non-invasive magnetic spectroscopy 
demonstrate a 40% reduction in resting muscle mitochondrial tricarboxylic acid (TCA) cycle 
flux and ATP synthesis rate in lean insulin-resistant elderly subjects (Petersen et al. 2003). 
However there is emerging evidence to suggest that although mitochondrial dysfunction and 
insulin resistance occurs concurrently, this association may occur coincidentally or through a 
common factor such as physical inactivity (Lanza et al. 2009). 
1.10.4 Intramyocellular lipid 
A strong association has been demonstrated between ageing, IMCL accumulation in muscle 
and skeletal muscle insulin resistance. Indeed whilst the physiological role of IMCL was once 
a topic of interest solely associated with exercise physiology, it has become increasingly 
important since the finding of an association with insulin resistance was found. This 
association and the mechanisms underpinning IMCL and insulin resistance have been 
touched upon earlier. In relation to ageing, IMCL is increased by up to 40% in the elderly as 
seen on 
1
H NMR spectroscopy (Petersen et al. 2003). They tended to have larger IMCL 
droplets, fewer mitochondria and lower proportion of IMCL in contact with mitochondria. 
These are likely to contribute to reduction in mitochondrial function and lipid metabolism, 
and thus reduced fatty acid oxidation rates (Crane et al. 2010). The underlying cause for the 
accumulation of IMCL in ageing is not completely understood. It may be because use of 
muscle (as discussed above) declines with age, however muscle loss and strength are also 
seen in highly-trained older athletes (Faulkner et al. 2007). It could be because there is an 
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imbalance between lipid supply and proportional fatty oxidation. Despite the accumulation of 
lipid in muscle of highly–trained endurance athletes, insulin sensitivity was not affected, 
raising the possibility that capacity of lipid oxidation metabolism is one of the major 
mediators in the development of insulin resistance.  
1.10.5 Physical inactivity 
Ageing is often associated with a decline in habitual physical activity and adopting a more 
sedentary behaviour. In early old age (65-75 years of age), a modest increase in activity may 
be observed in an attempt to improve health and fill the time resulting from retirement. By 
middle old age (75-85 years) most would develop some physical disability and by late old 
age (85 years and above), many would be become physically dependent.  However inter-
individual variances in functional capacity occur at any given chronological age (Shephard et 
al. 1998).  Limiting factors include maximal oxygen consumption, fatigability, muscle loss 
and strength, metabolic and hormonal responses, risks of exercise and motivation. Maximal 
oxygen uptake declines by about 5ml per kg per min per decade from 25 to 65 years, with 
possible acceleration thereafter. It is uncertain whether this is an inevitable consequence of 
the ageing process per se or reduced physical activity that occurs with advancing age. Age-
related decline in aerobic capacity may be caused by decrease in maximal heart rate, stroke 
volume and arterio-venous difference.  Increase accumulation of fat mass, IMCL, reduction 
in physical activity therefore increases the risk of development of insulin resistance.  
1.11 Mechanisms of insulin resistance in ageing 
The exact underlying mechanisms of insulin resistance in ageing are mostly unknown. Early 
studies described receptor and post-receptor perturbations in insulin action (Rowe et al. 1983, 
Lonnroth and Smith 1986). Despite the maximally-stimulatory effect of insulin concentration, 
glucose disposal was reduced in the elderly, confirmed with hyperinsulinaemic euglycaemic 
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clamps (1200 mU/m
2
/min) causing a rightward shift in the insulin-action dose-response curve 
(Fink and Kolterman 1983).  
Molecular mechanisms underlying insulin resistance in ageing was studied at the level of the 
insulin signalling cascade in rats in response to in-vivo insulin infusion (Ropelle et al. 2013). 
White adipose tissue of aged rats showed altered subcellular distribution of insulin receptors 
and IRS-1 and a reduction in insulin-stimulated IR tyrosine phosphorylation. Activation of 
Akt and GLUT-4 translocation to the plasma membrane was impaired. Muscle from rats also 
exhibited a defect in GLUT-4 trafficking; however insulin signalling at IR and Akt was 
increased. No difference was seen in liver, indicating that IR in adipose tissue precedes 
development of insulin resistance in liver and skeletal muscle. 
Of the molecular mechanisms implicated in the development of insulin resistance in the 
elderly, one of the more robust mechanistic evidence associated with negative regulation of 
insulin action appears to be stimuli that activate inflammatory serine/threonine kinases eg c-
Jun NH2-terminal kinase and inhibitor of κb kinase.  These stimuli include over-nutrition 
(particularly lipids), oxidative and endoplasmic reticulum stress (Samuel and Schulman 2012, 
Evans et al. 2012, Hotamisligil 2003, 2010) and are linked to reduced mitochondrial content 
and/or function predisposing to accumulation of IMCL.  IMCL appears to be increased in 
ageing (see below) that in turn promotes production of toxic lipids as discussed earlier.  
Ageing has also been associated with increased nitric oxide production as a result of 
inducible nitric oxide synthase (iNOS). iNOS is increased in macrophages and inflammatory 
cells, stimulated by proinflammatory cytokines and has been implicated in insulin resistance 
in the context of obesity (Kaneki et al. 2007). Recent research (Ropelle et al. 2013) report 
that ageing mice exhibited increased iNOS expression and S-nitrosation of the insulin 
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receptor IRS-1 and Akt/PKB leading to insulin resistance. More studies should be conducted 
to substantiate similar findings in humans.  
1.12   Improving insulin sensitivity 
 
Diet and lifestyle is one of several factors that can entirely reduce or even prevent the 
development of diabetes. Several randomised controlled population studies can attest to this, 
including the Da Qing Study, Finnish Diabetes Prevention Study and U.S. Diabetes 
Prevention Program.  
The Da Qing Study was conducted in a province of China involving 6 years of active 
intervention, where diabetes risk was reduced by 31, 46, and 42% in the diet-only, exercise-
only, and diet-plus-exercise groups, respectively, compared with the control group (Pan, Li et 
al. 1997). The intervention proved effective in the long-run assuming the intervention was 
adhered to as in a subsequent 14-year follow-up study, the intervention groups had a 51% 
lower risk of diabetes during the active intervention period compared to control, and a 43% 
lower risk over a 20-year follow-up. (Li, Zhang et al. 2008) 
In both the Finnish Diabetes Prevention Study (Lindstrom et al. 2003) and the U.S. Diabetes 
Prevention Program (DPP), lifestyle intervention significantly reduced diabetes incidence by 
58% (Knowler, Barrett-Connor et al. 2002). 
 
1.11.1 Diet 
As weight gain and adiposity are strongly associated with insulin resistance (McAuley and 
Mann 2006) most dietary plans proposed in improving insulin sensitivity focus on promoting 
weight loss and remain one of the main principles in managing people with T2DM. 
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The American Diabetes Association (ADA, 2011) published nutritional recommendations for 
treatment of individuals with T2DM and subjects at high risk of developing diabetes that 
include: 
1) Weight loss of at least 7% in overweight/obese individuals 
2) Restriction of intake of saturated fats to < 7% of energy intake 
3) Cholesterol intake of <200mg/day including reduction of trans-fat intake 
4) High-fibre intake of > 14g/1000kcal  
5) Protein intake is no longer restricted, providing 15-20% of energy as long as renal function 
is normal. 
Various dietary concepts on modification of macronutrients have been used and are discussed 
below. It has to be borne in mind that some of these studies are short-term and warrant a 
longer period of study under controlled settings to appreciate meaningful outcomes and 
adherence to diets. The latter is key to maintaining weight loss, but often difficult to achieve 
and depends on the practicality, sustainability and palatability of the diets proposed and 
motivation of the individual.  
 
1.11.1.1 Low-energy diets 
Energy-restricted dietary intakes have been proven to reverse pancreatic cell failure and 
hepatic insulin resistance associated with T2DM (Lim et al. 2011). Short term very low 
calorie diet (VLCD) has also been shown to cause a significant reduction in IMCL and an 
increase in insulin sensitivity in the absence of substantial changes in total body fat in people 
with and without T2DM (Lara-Castro et al. 2008).    
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1.11.1.2 Low-fat diets  
Short-term low-fat intervention diets appear to lead to weight loss in overweight individuals 
(Astrup, Grunwald et al. 2000); however these diets appear to have no more an advantage 
than other energy-restricted diets in maintaining weight loss in the long-term. Low-
carbohydrate non-energy restricted diets appear to be at least effective as low-fat non-energy 
restricted diets in promoting weight loss for up to a year. Furthermore adherence to a low-fat 
diet particularly in insulin-resistant individuals is difficult and particularly challenging 
(McClain, Otten et al. 2013).  
 
1.11.1.3 High fibre diets 
The beneficial effects of diets high in fibre is well-known and is regarded an important 
recommendation in nutritional guidelines. Fibre slows gastric emptying and absorption of 
dietary fat and carbohydrate contents attributed to the viscous water soluble types of dietary 
fibre (Weickert and Pfeiffer 2008). However data on fibre’s effects are inconclusive, with 
some only showing moderate effects on weight loss (Howarth, Saltzman et al. 2001). 
Of the different fibres guar gum has received the most attention but its effect on insulin 
resistance is equivocal, varying amongst different populations. No effect was seen in obese 
individuals but a reduction in insulin levels was seen in T2DM patients.  
 
1.11.1.4 Low glycaemic index (GI) diets 
Glycaemic index (GI) is a measure of the ability of carbohydrate in a particular food to raise 
glucose levels defined by the incremental area under the glycaemic response curve (AUC) 
(Wolever, Mehling et al. 2008). Low-GI and/or low-glucose load diets may reduce the risk of 
metabolic syndrome, T2DM, cardiovascular disease and chronic inflammation. In contrast, 
carbohydrates high in GI lead to increases of postprandial glucose and insulin concentrations 
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that may compromise metabolic flexibility (Brand-Miller, McMillan-Price et al. 2009; Isken, 
Klaus et al. 2010). Overweight or obese subjects on short duration low glycaemic index (GI) 
diets lost more weight and have better improvement in lipid profiles than controls receiving 
other diets (Thomas, Elliott et al. 2007). However other findings have been inconclusive, 
most likely due to small study samples and short duration of these studies.  In one of the 
largest intervention studies published to date, weight regain at 1 year was only marginally 
lower with a reduction of the GI (Larsen, Dalskov et al. 2010). In a meta-analysis, 2 servings 
per day of whole-grain intake were associated with a 21% decrease in insulin resistance risk. 
It is likely that diet only will not entirely prevent development of diabetes, but could work in 
conjunction with other factors such as exercise, as will be discussed in more detail in the next 
subsection.  
 
1.11.1.5 Micronutrients 
Evidence has shown that micronutrients such as magnesium (Hua et al. 1995, Lima et al. 
1998), zinc (Chen et al. 1991, Singh et al. 1998), chromium (Thomas and Groper 1996, 
Anderson et al. 1997), L-carnitine (Heller et al. 1986, Mingrone et al. 1999) and fish oils 
(Bathena et al. 1991) can positively influence insulin sensitivity, however results are often 
equivocal and require larger, well-designed human studies. The amino acid L-carnitine will 
be discussed in greater detail as a possible contributor to insulin sensitivity (Chapter 5).    
1.11.2 Exercise  
It has become well established that physical activity and exercise training are effective means 
of increasing insulin action in muscle of insulin resistant individuals and have been proven to 
reduce the risk of development of diabetes. As previously described, the Da Qing IGT and 
Diabetes Study demonstrated that exercise intervention (20 min of mild or moderate, 10 min 
of strenuous, or 5 min of very strenuous exercise one to two times a day) reduced the 
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incidence of diabetes by 46% in people classified as having impaired glucose tolerance (IGT) 
more than diet and exercise (42%) and diet alone (31%) (Pan, Li et al. 1997).  
Briefly, in the early stages of exercise and with increasing exercise intensity, fuel for muscles 
is provided for predominantly by glycogen. When this becomes depleted blood glucose and 
free fatty acids from adipose tissue become the primary source for fuel utilisation (Bergman, 
Butterfield et al. 1999). Intramuscular lipid stores are mostly used during longer duration 
activities (Borghouts, Wagenmakers et al. 2002). 
Exercise training induces improvements in insulin action by: 
(1) up-regulation of GLUT4 expression and facilitation of insulin signal transduction 
(2) chronic activation of AMPK 
(3) promoting mitochondrial biogenesis and increasing lipid oxidation and turnover thereby 
preventing the accumulation of deleterious lipid species. 
 
1.11.2.1 Chronic exercise 
 
Although a single bout of exercise has been shown to improve insulin sensitivity in 
previously sedentary adults (Devlin, Hirshman et al. 1987) and increase glucose uptake by up 
to 40% (Perseghin, Price et al. 1996), these effects only last for 48-72 hours post-exercise 
(King, Baldus et al. 1995). Regular long-term exercise has been shown to exert chronic 
effects on insulin sensitivity. Aerobic exercise at all intensities over a period of weeks has 
been shown to improve insulin sensitivity, enhance the responsiveness of skeletal muscle to 
insulin with increased expression and/or activity of proteins involved in glucose metabolism, 
insulin signalling and fat oxidation capacity. Endurance exercise induced an adaptive increase 
in the GLUT-4 protein concentrations, activities of both glycogen synthase and hexokinase, 
the enzyme that phosphorylates glucose of the glucose transporter in skeletal muscle 
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(Holloszy 2005).  Despite the presence of increased intramuscular triglycerides (IMTG) in 
highly-trained athletes, the observation of a paradoxical increase in insulin responsiveness 
may be reconciled by the muscles ability to increase lipid turnover (increased uptake, 
transport, utilisation and oxidation). Following 12 weeks of endurance training, ageing 
human skeletal muscle that contained higher IMCL content showed improvements in 
mitochondrial biogenesis and electron transport chain activity (Menshikova, Ritov et al. 
2006). The same improvements were seen in Bruce et al.’s study but involved obese subjects 
and IMTG content remained relatively unchanged (Bruce, Thrush et al. 2006). This would 
imply that improved fatty acid oxidation and improvement in insulin sensitivity may be 
driven by greater FFA delivery and uptake and reductions in deleterious lipid metabolites 
from a greater lipid flux. Bruce et al. also showed that following endurance training in obese 
individuals fatty acid metabolites were also reduced.  
Another type of exercise, resistance training, enhances whole-body glucose disposal capacity 
by increasing muscle mass and strength and even a single resistance exercise training session 
can improve insulin sensitivity for up to 24 hours after cessation of exercise (Koopman et al. 
2005). These benefits are possibly partly attributed to reductions in IMTG stores. In  
randomised controlled trials (RCTs), resistance or aerobic training for 10 - 16 weeks in men 
with newly diagnosed or established T2DM improved insulin action, blood glucose control 
and HbA1c values and resulted in significant losses in visceral fat and improved fat oxidation 
(Ibanez et al. 2005; Bweir S et al. 2009).     
Exercise training may improve insulin sensitivity indirectly through its effect on lipids.  
Goodpaster et al. 2003 postulated that the strongest predictor of insulin sensitivity in obesity 
following endurance training is enhanced whole-body fat oxidation. Increased oxidative 
capacity following exercise training is associated with increased CPT-1 activity and 
decreased ceramides and DAG in muscle of obese individuals (Bruce et al. 2006). 
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Collectively this suggests that exercise training may improve insulin sensitivity by increased 
lipid oxidation, therefore preventing accumulation of lipids that may interfere with insulin 
signalling pathways. Four weeks of exercise training was shown to attenuate effects of a 
high-fat diet on muscle lipid storage and was associated with increased palmitate oxidation 
and elevated PGC-1 expression (Lessard et al. 2007). Despite the ‘metabolic inflexibility’ 
and reduced fatty acid oxidation at rest commonly seen in insulin-resistant individuals, they 
have been shown to readily utilise lipids during exercise. Obese sedentary individuals with 
abdominal adiposity were shown to have increased fatty acid oxidation rates during 
submaximal exercise compared to lean sedentary exercised controls (Goodpaster et al. 1999). 
Thus it would appear that the molecular/insulin signalling events that accompany contraction 
during exercise can override metabolic flexibility and predispose to increased fat oxidation.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
CHAPTER 2: METHODS 
2.1 Common Methods 
Methods common to all studies undertaken are described as follows. 
2.1.1 Ethical approval 
Ethical approval for studies carried out and described in this thesis was obtained from the 
University of Nottingham Medical School Research Ethics Committee.  
Study 1 Comparing skeletal muscle lipid, fat metabolism and insulin sensitivity in older vs. 
young healthy men- medical ethics approval number E13102011BMS 
Study 2 Investigating the effects of lipid on amino acid and insulin sensitivity- medical ethics 
approval number F131020122BMS 
Study 3 Investigating the effects of hyperenergetic high fat vs high carbohydrate diet on liver 
fat and insulin sensitivity- medical ethics approval number B14022013BMS 
Study 4 Investigating the effects of carnitine on improving skeletal muscle insulin sensitivity 
in healthy ageing - medical ethics approval number E13102011BMS 
All volunteers who participated in these studies were informed of risks associated with 
experimental procedures before obtaining informed written consent. All studies were 
performed in accordance with the Declaration of Helsinki of the World Medical Association 
(World Medical 2013). 
2.1.2 Pre-screening procedure 
Volunteers were medically screened and completed a health questionnaire, blood screen of 
full blood count, urea and electrolytes, liver function tests (including Hepatitis B and C viral 
screen and ferritin for Study 3), coagulation, lipid profile, thyroid function test and 
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electrocardiograph (ECG). Subjects were excluded if they had a history of diabetes, 
cardiovascular, metabolic or respiratory disease.  Those who did not meet inclusion criteria 
were excluded from further participation.  
2.1.3 Randomisation of volunteers 
Randomisation of volunteers in these studies was done using randomisation codes generated 
electronically (www.randomisation.org). Studies 1, 2 and 3 were partially blinded 
randomised trials whilst study 4 was a double-blinded randomised trial. The intervention or 
placebo groups for study 4 were revealed once data collection was complete. Magnetic 
resonance imaging (MRI) operators involved with scanning the volunteer’s liver and 
investigators analysing liver fat in study 3 were blinded to the groups receiving either high 
carbohydrate or fat diets.  
2.1.4 Blood sample collections 
Blood samples at screening were taken via venepuncture into the appropriate Vacutainer 
blood collection tubes. In all studies arterialised venous blood were obtained by inserting a 
cannula (Venflon, Ohmeda, Sweden) retrograde into a vein of the dorsum of the hand, 
warmed in a device with static air heated at 55
0
C. The heated hand technique has been proven 
under experimental conditions to provide a safe and practical approach to an otherwise 
difficult and less feasible way of sampling blood from arteries (Gallen, Macdonald 1990). In 
previous studies blood chemistry values of pH, pCO2, pO2 and O2 saturations of blood 
sampled from a heated hand vein were consistently similar to that in the arterial range (Liu et 
al. 1992).  For purposes of sampling in metabolic studies, compared to true arterial blood, 
‘arterialised’ or heated venous blood sampling provided no significant differences in 
concentrations of glucose, non-esterified fatty acids, insulin, glucagon and several amino 
acids (Morris, Ueda et al. 1997). With pertinence to the sampling of blood during the 
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hyperinsulinaemic  euglycaemic clamp mean glucose concentrations in ‘arterialised’ venous 
blood and arterial blood have been shown to produce a difference of only 0.1 mmol/L under 
basal and hyperinsulinaemic conditions (Liu et al. 1992).  
A critique of using the hand-heated device in studies presented in this thesis is that the 
temperature of the environment in the device was not routinely measured during the studies 
and it can only be assumed that the temperature remained constant (50-55°C) from study to 
study to avoid inter-visit variability. Other perturbations that contribute to this include the 
volunteers having their hands out of the device during toilet breaks. Hand-warming has been 
shown to effectively arterialise venous blood and gives significantly higher insulin sensitivity 
values but induces systemic haemodynamic effects that may affect measurements of insulin 
sensitivity (Morris, Ueda et al. 1997).     
 
Figure 2.1: A subject having his left hand warmed in the hand heated device during the 
hyperinsulinaemic euglycaemic clamp. 
2.1.5. Blood samples analyses 
Blood obtained for plasma analyses was spun at 3.3G at 4°C for 10 minutes. Plasma was 
divided into aliquots and frozen at -80°C until analysis. Serum samples were left to clot for at 
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least 30 minutes before being spun and frozen also at -80°C. The following assays were 
performed by technicians at the High Performance Liquid Chromatography (HPLC) 
laboratory of the Metabolic Physiology Group, School of Life Sciences, University of 
Nottingham: serum insulin, non-esterified fatty acid (NEFA), lactate, adrenaline and 
noradrenaline (studies 2 and 3) and glucagon, C-peptide, β- hydroxybutyrate, leptin and 
cytokines (Study 2).  
Measurements of plasma to determine enrichment and isotope ratios of tracers [6,6-
2
H2]  
glucose (Study 3), 2-Deoxy-D-Glucose (2DG) and [U-
13
C] Palmitate (Studies 1 and 4) were 
analysed by researchers and technicians at the Human Physiology Labs at Derby Medical 
School, University of Nottingham. 
In all studies utilising the hyperinsulinemic euglycaemic clamp, arterialised blood glucose 
concentrations were measured using the Yellow Springs Instrument  2300 Stat Analyser 
(YSI; YSI Inc, Yellow Springs, Ohio, USA) every 5 minutes. The YSI uses steady-state 
measurement methodology whereby the membrane-based immobilised glucose oxidase 
catalyses the oxidation of glucose to gluconic acid and hydrogen peroxide (Chua and Tan 
1976). The difference between the sample generated plateau current and the initial baseline 
current is proportional to the glucose concentration (YSI STAT 2300 Laboratory manual 5-
4).The YSI 2300 STAT uses an aqueous rather than a serum or plasma –based standard. On 
injection of a test sample into the YSI, the following reactions take place: 
1                   g  
1) D-Glucose + oxygen   (glucose oxidase) gluconolactone + H202 oxidase 
2) The H202 sensitive electrode oxidizes a constant portion of the H202 at the platinum 
anode: H202          2H
+
 + 2e
-
 + 02. 
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3) The circuit is completed by a silver cathode at which oxygen is reduced to water: 4H + 02  
2H20 + 4e
- 
The YSI was found to have good intra and interbatch precision with a coefficient variation of 
1.2% or less for glucose concentrations of 0.94 to 3.98g/litre (5.2 – 22.1mmol/L) and 5.8% or 
less for glucose concentrations of 0.29 to 2.91 g/litre (1.6-16.2 mmol/L) respectively. It is 
simple to use, analyses are quick and requires only small samples (Chua and Tan 1978). 
Determination of glucose using the YSI correlates well with Beckman’s Glucose Analyser     
(r=0.997) and the Haemacue device (r= 0.979).   
2.1.6 Radioimmunoassay 
The radioimmunoassay method as described by Yalow and Berson 1968 was used to 
determine serum insulin and glucagon. This technique involves making a known quantity of 
antigen radioactive by labelling it with it with gamma-radioactive isotopes of iodine, such as 
125
-I, attached to tyrosine.  
2.1.7 Serum Insulin assays 
Serum insulin aliquots were frozen at a minimum of -20
◦
C and measured using a solid-phase 
125
I radioimmunoassay using standard insulin kits.  
2.1.8 Non-esterified fatty acid assays 
FFA was measured using an automated immunoassay analyser and commercially available 
kit. Tubes used to collect blood were pre-filled with 7.5ul per ml plasma of ethylene glycol 
tetraacetic acid (EGTA)-Gluthathione, a preservative to prevent degradation of FFAs during 
storage. 10uL of Tetrahydrolipstatin (THL) was added to vials to inhibit in vitro lipolysis and 
prevent falsely high plasma FFA readings, thus increasing accuracy of determining plasma 
FFA concentrations (Krebs M et al. 2000).   
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2.1.9 Glucagon assays 
Blood samples for glucagon were collected into tubes containing aprotinin, a protein bovine 
pancreatic trypsin inhibitor used for rapidly-degraded proteins and stored in glass tubes at -
80°C until analysis. Total glucagon concentrations were determined using solid-phase 
125
I 
radioimmunoassays as described above.  
2.1.10 β-Hydroxybutyrate (β-OHB) assays 
Serum βOHB and lactate were measured using an automated immunoassay analyser and 
commercially available kits.  
2.1.11 Hyperinsulinaemic euglycaemic clamp  
The glucose clamp technique as described by DeFronzo et al. (DeFronzo, Tobin et al. 1979) 
remains the gold standard method of directly determining metabolic insulin sensitivity in 
vivo, particularly when the assessment of insulin sensitivity is of primary interest and 
feasibility is not an issue.  Under steady conditions it has a coefficient 
variation/reproducibility of 0.1 and a discriminant ratio of 6.4 (measure of reproducibility and 
ability to distinguish individual results) (Mather et al. 2001). To assess an individual’s 
glucose disposal, a hyperinsulinaemic state is induced via intravenous infusion of insulin 
based on body surface area is achieved resulting in increased skeletal muscle and adipose 
tissue glucose disposal and suppressed hepatic glucose production. 20% glucose is infused at 
variable rates aiming to achieve euglycaemia (an arbitrary predetermined level of glycaemia 
within normal range of glycaemia, 4.5mmol/L was chosen for studies presented in this 
thesis). The glucose infusion rate (GIR) is thus equal to glucose disposal rate (M) under the 
assumption that hyperinsulinaemia is sufficient to completely suppress hepatic glucose 
production and there is no net-change in glucose concentrations under steady state conditions. 
69 
 
The method has been shown to be reproducible in subjects at high (insulin infusion rate 
40mU/m
2
/min; concentration 100µunits/ml) (De Fronzo, Tobin et al. 1979), mid-(60-
70µunits/ml) (Soop et al., 2000) and low (insulin infusion rate 20 mU/m
2
/min; concentration 
38µunits/ml) (Kingston, Livingston et al. 1986) physiological ranges of hyperinsulinaemia. 
M is typically normalised to body weight or fat free-mass. Lean body mass was determined 
from Dual energy x-ray absorpmetry (DEXA) (apart from Study 2 where fat-free mass was 
determined via skin calipers and Bioelectric Impedance Analysis (BIA) were used in 
estimating glucose disposal rates of volunteers in these studies. The validity of insulin 
sensitivity utilising the glucose clamp technique depends on steady state conditions being 
achieved. A more reliable approach of determining accurate values for glucose disposal rates 
is to take a period of at least 30 minutes, more than 1 hour post insulin start during which the 
coefficient of variation for blood glucose, plasma insulin and GIR is < 5% (KatzA et al. 
2000).  
Under ideal settings insulin infusion rates should be matched to the population studied, thus 
multiple infusion rates are adjusted according to an individual’s insulin resistant or insulin 
sensitive state in a stepwise fashion.  Although desirable, this approach is time-consuming 
and not feasible for both the operator and subjects (Muniyappa et al. 2008). Another 
significant advantage of the clamp is the ability to simultaneously measure and distinguish 
hepatic glucose production and peripheral (mostly skeletal muscle) insulin 
resistance/sensitivity, lipolysis and protein metabolism using radiolabelled tracers. The use of 
glucose tracers also proves useful at lower insulin infusion rates or in studies in insulin-
resistant individuals so appropriate corrections can be made to glucose disposal.   
Radiolabelled glucose tracers can also be used simultaneously during the clamp to quantify 
hepatic glucose production and whole body disposal, 2DG in Studies 1 and 3, deuterated 
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glucose in Study 2. Other isotope tracers such as phenylalanine may also be used to assess 
metabolism of glycerol or protein metabolism during the clamp.  
A small but important limitation of this method is that it is laborious and time consuming, so 
may not be feasible for large population or epidemiological studies. It also requires trained 
personnel who are able to deal with complications related to the clamp. These are generally 
infrequent, indeed the commonest issue encountered during studies in this thesis was the 
cannula ceased working temporarily thus several blood glucose samplings were missed.  
The clamp should also only be considered if the primary objective is to assess insulin 
sensitivity, as it is costly.  Consideration should also be given to the assumption that levels 
achieved during steady state are supraphysiological and this may reverse the normal 
peripheral to portal gradient, so it may not accurately reflect insulin action and glucose 
dynamics under normal physiological conditions (Muniyappa et al. 2008). 
The studies presented in this thesis utilised the hyperinsulinaemic euglycaemic clamp for a 
number of reasons: 
1) Assessment of insulin sensitivity was the primary or one of the primary objectives of   
each study.  
2) Gold standard technique of assessing insulin sensitivity 
3) Could be used simultaneously with phenylalanine, 2DG and [6,6
2
H2] glucose tracers. 
4) Relatively small group of volunteers undergoing glucose clamp and availability of 
trained personnel to run the clamp. 
Compared to other methods of quantifying insulin sensitivity such as the insulin suppression 
test, oral glucose tolerance test and Homeostatic Model of Assessment of Insulin Resistance 
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(HOMA-IR), where only fasting plasma insulin and glucose are required, running an insulin 
clamp is labour intensive, costly and requires an experienced operator to manage technical 
difficulties.  
2.1.12 Other direct and indirect measures of assessing insulin sensitivity 
Table 2.1 Summary of the advantages and disadvantages of other methods of assessing 
insulin sensitivity. 
Test Method Advantages Disadvantages 
Insulin 
suppression 
test 
Somatostatin/ octeotride 
is infused to suppress 
endogenous secretion of 
insulin and glucagon. 
Insulin and glucose are 
infused simultaneously 
for 180mins 
Highly reproducible 
test 
Applied to larger 
populations 
Not as labour 
intensive or costly as 
the clamp 
Used to determine 
skeletal muscle insulin 
sensitivity but does not 
specifically reflect 
hepatic insulin 
sensitivity 
Oral Glucose 
Tolerance 
Test 
75g glucose load 
Blood glucose and 
insulin every 30 mins for 
120 mins 
Mimics glucose and 
insulin dynamics of 
physiological 
conditions, (more so 
than the 
hyperinsulinaemic 
euglycaemic clamp)  
Does not assess insulin 
sensitivity per se 
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Minimal 
model 
Analysis of 
frequently 
sampled 
intravenous 
glucose 
tolerance test 
5 min infusion of insulin 
(4mU/kg/min) 20 mins 
after the IV bolus of 
glucose. Glucose and 
insulin blood samples 
taken at 1, 2, 10 mins 
then 20 min intervals 
until 180 mins. Data 
entered into a minimal 
model of analysis 
programme generates an 
index of insulin 
sensitivity (SI). 
Advantages over the 
clamp: less labour 
intensive, steady-state 
and continuous 
infusion of insulin and 
glucose not required. 
Coefficient of 
variation of SI as good 
as clamp 
 
Oversimplifies 
physiological glucose 
homeostasis. Estimates 
of SI are less reliable in 
individuals with 
impaired insulin 
secretion or significant 
insulin resistance 
Simple 
indices of 
insulin 
resistance 
1/Fasting insulin 
Glucose/Insulin ratio 
HOMA-IR, QUICKI 
Simple, inexpensive 
and minimally 
invasive, can be used 
in large 
epidemiological 
studies.  It is 
appropriate to be 
considered where 
insulin sensitivity is 
not the primary 
outcome, direct 
Poor correlations with 
clamp, less predictive of 
insulin sensitivity in 
glucose 
intolerance/diabetes 
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measurement of 
insulin sensitivity is 
not required or 
unfeasible to obtain. 
   
2.1.13 Indirect calorimetry 
 
Figure 2.2: Indirect calorimetry during the hyperinsulinaemic euglycaemic clamp. A plastic 
hood is placed over the subject’s head and connected to the GEM machine that measures VO2 
and VCO2 which is then used to measure energy expenditure. 
One of two ways (the other being direct calorimetry) and by far the most practical of 
measuring energy expenditure in humans is indirect calorimetry. This approach allows 
measurement of whole-body consumption of oxygen and production of carbon dioxide using 
a calorimeter with built-in on-stream analysers. A plastic hood is placed over the subject so 
air drawn through this canopy by a pump is collected and analysed. For resting studies 
presented in this thesis, indirect calorimetry was used using the Gas Exchange Machine) 
GEM (GEMNutrition Ltd, Cheshire, UK). 
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Indirect calorimetry quantifies resting energy expenditure (REE) or Basal Metabolic Rate 
(BMR), thus total energy expenditure (TEE) can be calculated using the following equation 
(Levine JA 2005): 
TEE = (REE + diet induced thermogenesis)* activity factor 
The REE or BMR is energy expended at complete rest in a post-absorptive state accounting 
for approximately 60% of TEE in sedentary adults. 
Thermic effect of food describes energy derived from digestion, absorption, and storage of 
food and nutrients; accounting for around 10% of TEE. 
The activity factor can account for up to 100% of TEE depending on the degree of activities 
of daily living and fidgeting.  
Indirect calorimetry by gas exchange measurement can accurately predict energy expenditure 
and poses minimal burden on subjects and costs. 
When VCO2 and VO2 values are obtained via breathing under the canopy or mask of the gas 
exchange machine, substrate oxidation rates are measured. Frayn’s equation (Frayn 1983) for 
calculating substrate utilisation includes calculations for urinary nitrogen excretion, and as 
opposed to the equations below assumes the accumulation and excretion of metabolic 
intermediaries or end products through the form of ketogenesis, lipogenesis, gluconeogenesis 
or lactate. For studies utilising indirect calorimetry in this thesis, the non-protein equations of 
Peronnet and Massicotte (Peronnet and Massicotte 1991) were used, as urine was not 
routinely collected for measurement of nitrogen excretion.    
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Carbohydrate oxidation:  4.585 * VCO2 – 3.226 * VO2   
Fat oxidation:   1.695 * VO2 – 1.701 * VCO2 
Where VO2 and VCO2 are expressed in litres per min (L/min) oxidation rate in grams per 
minute (g/min).  
There are few requirements to be observed during use of the indirect calorimetry method. 
These include an air-tight canopy to provide constant flow of air to provide oxygen and 
carbon dioxide within a reasonable range, sensitive, stable O2 and CO2 analysers for 
continuous sampling of expired air, a calibration routine using standard gas mixtures and a 
system to trap or condense out the moisture of the expired air line feeding into sensors.  
During the course of each study the indirect calorimeter was calibrated several times to 
correct for any drift in analyser sensitivity. This method can be used concomitantly with other 
research methods such as hyperinsulinaemic euglycaemic clamping and tracer methodology. 
Indeed indirect calorimetry was carried out during infusion of the tracers 2- deoxy-D-glucose, 
[6,6-
2
H2] glucose and 
13
C6 palmitate. It is important to take into account that indirect 
calorimetry estimates whole-body rates of substrate oxidation whilst most tracer techniques 
calculate blood or plasma turnover rates.   
However achieving perfect conditions during indirect calorimetry measurements can be 
challenging, and certain conditions can contribute to errors in data acquisition. Clearly 
operator expertise and volunteer compliance help to minimise errors.  Restlessness, hyper or 
hypoventilation and other perturbations may impinge on the assumed VO2 and VCO2 data 
derived from metabolic events.  
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2.1.14 Muscle Biopsies 
Bergstrom’s percutaneous muscle biopsy technique provides a simple and reproducible 
method of obtaining muscle samples (Bergstrom 1975).  When handled correctly and 
appropriately, this method of sampling is quick, relatively atraumatic and well-tolerated. It 
also avoids the use of general anaesthesia, reduces scarring and the need for repeated biopsies 
(Goldberger, Henry et al. 1978; Edwards, Young et al. 1980; Edwards, Round et al. 1983), 
With suction applied to the biopsy needle whilst doing biopsies, the reliability of obtaining 
adequate amounts and size of tissue is increased. (Greig, Askanazi et al. 1985; Tarnopolsky, 
Pearce et al. 2011).  Muscle tissue is obtained 10-15cm above the patella on the vastus 
lateralis or quadriceps which is the preferred site of biopsy (other than gastrocnemius (calf 
muscle), deltoid and biceps (arms).  
Briefly once the volunteer has consented to the procedure, the location where muscle is to be 
obtained is identified and marked. The vastus lateralis muscle is located by measuring a spot 
16cm above the patella bone, then 4-5 cm lateral. The volunteer is asked to tense the thigh to 
confirm the site. After the area is cleaned with betadine solution, 1 ml of 1% Lidocaine is 
injected just under the skin. A further 5-10mls of Lidocaine is injected intramuscularly, 
carefully avoiding blood vessels. After 1minute a scalpel is introduced into the anaesthetised 
area making a 2 cm incision after which firm pressure using gauze is applied immediately to 
the incision site. After about 2-3 minutes, a size 5 or 6 Bergstrom needle (size corresponds to 
diameter size of the window at the tip of the needle) is inserted into the incision, a further 
firm pressure is applied with the needle until a ‘give’ is felt. This corresponds to cutting 
through the tough fascia layer of muscle. The introducer needle is released and pushed into 
the needle holder a few times to ‘snip’ muscle, whilst suction connected to the top of the 
needle is applied to improve yield of the sample. The needle is then taken out completely and 
77 
 
pressure is applied once more to the site to stop further bleeding. The site is secured with 
steristrips and bandage.   
    
Figure 2.3: Bergstrom muscle biopsy kit and incision site over vastus lateralis. 
 Of the over 350 muscle biopsies performed for the studies presented here, three subjects 
experienced haematomas/bruising, 3 temporary loss of sensation over biopsy sites, and 3 
older volunteers experienced vasovagal syncope secondary to biopsy-induced pain. It could 
be contended that ultrasound-guided muscle biopsies should be used to avoid or minimise the 
risks of complications, however this is not used routinely and may not be practical 
particularly when biopsies are required immediately post-exercise. The use of ultrasound 
helps avoid major vessels but cannot avoid the possibility of biopsy induced pain.  
 Other methods of obtaining muscle samples include the open and bard needle biopsy 
methods (Dubowitz 2013). An advantage of the open biopsy method is that clamping the 
specimen prevents contraction of the biopsy fibres, but requires a larger incision and is 
slightly more invasive.  Increased amounts of local anaesthesia may be required for obese and 
particularly anxious subjects and the wound is usually sutured closed. The bard biopsy 
technique uses the same preparation method as the Bergstrom biopsy technique but instead of 
the Bergstrom needle the bard needle is inserted into the incision site and repeated cuts are 
made using the retracting needle. An advantage of this technique is that repeated biopsies can 
be made that is relatively less invasive and traumatic. However only a small piece of muscle 
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is obtained each time and precise measurements of depth for needle insertion may be under or 
overestimated. At the David Greenfield MRC/ARUK research unit of the medical school 
University of Nottingham, the use of ultrasound prior to bard biopsies has minimised the 
risks of hitting a blood vessel and has proven invaluable in estimating depth of muscle, 
especially in overweight subjects. 
A limitation of the percutaneous muscle biopsy technique is the potential delay in freezing 
muscle tissue specimens that can lead to inaccuracy of muscle metabolite analyses and 
variation in assays caused by non-muscle contaminants. Nevertheless this delay is not 
thought to largely influence most analytical methods. (Bergstrom 1975). 
The muscle sample taken is frozen immediately to prevent degradation as this may affect 
biochemical studies. A problem of direct immersion of material into liquid nitrogen is that it 
allows gaseous nitrogen to coat the specimen, slowing the cooling process. To avoid this, 
liquid isopentane or propane is used to freeze the material which is subsequently immersed in 
liquid nitrogen to -160°C (Dubowitz 2013). Isopentane was used to freeze all muscle biopsy 
specimens in studies apart from visit 1 in Study 3 where fresh muscle specimens were 
required to prepare mitochondrial extracts for subsequent processing. Liquid nitrogen is 
preferred for long term storage of the specimen until ready for sectioning (Dubowitz 2013). 
If IMCL content is the only determinant required from muscle then a less invasive method of 
analysing muscle is through using 
1
H Nuclear Magnetic Resonance (
1
HNMR) Spectroscopy 
(Petersen et al. 2003).   
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2.1.15 Stable Isotopes 
2.1.15.1 Steele’s Equation 
 
Figure 2.4: Steele’s single compartment model 
Explained in its simplest terms, Steele’s single compartment model is analogous to a bathtub 
where water enters through a tap (endogenous glucose production, EGP) and leaves via the 
drain (glucose disappearance) Rd. The water level in the bathtub (glucose level in the single 
compartment) rises when water from the tap exceeds the water being drained (EGP>Rd), falls 
when Rd>EGP or remains in steady state when EGP=Rd. Steady state occurs during fasting 
or during the clamp when peripheral glucose concentrations remain constant. The tracer 
dilution technique is commonly used to measure endogenous glucose production where 
unlabelled glucose dilutes the tracer. Referring again to the bathtub analogy, when a dye 
(tracer) is added to the water in the bathtub it becomes uniformly distributed, such that when 
the water drains (Rd), it will not change the resultant dye concentration in the bathtub. 
However water coming from the faucet which has no dye will dilute the concentration over 
time (Vella and Rizza 2007).   
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Assuming the single compartment model can be applied to humans, where tracer and glucose 
are uniformly distributed this model can be used to measure endogenous glucose production.  
Assuming the tracer is infused at a constant rate, equilibrium is achieved when tracer and 
trace are cleared at the same rate. At this point, the concentration of the tracer and tracee 
reflects the rate of infusion and disappearance respectively (Steele et al. 1956, 1959). 
Ra   =     F            x        Tracee 
          Tracer 
 
Enrichment = Tracee     +     tracee 
                        Tracer  
APE (Atom per excess) =          tracer         x  100                                  
                                            tracer + tracee 
 
Under most experimental conditions, where there is a sudden perturbation to steady state of 
the pool such as an insulin infusion, the tracer is diluted further by ‘cold’ glucose. To account 
for changes to tracer and tracee concentrations, the equation can be modified to take into 
consideration changes over time and multiple pools, rapidly and slower- equilibrating pools 
(Wall et al. 1957). These 2 pools can be further simplified to a single compartment separated 
into two by a pool fraction of the total extracellular glucose pool. The non-steady state Steel 
equation is therefore modified to two different time points: 
 
81 
 
(pv x [(glucose1 + glucose2)/2]      x    SA2   -  SA1 )     X     (            1____      )     
    1         T2  -  T1            [(SA1 + SA2)/2] 
p = pool fraction, V = total extracellular pool, SA= concentration of tracer enrichments at 
times T1 and T2.  
Applying the concept above, the rate of appearance (Ra) and disappearance (Rd) of palmitate 
(Study 3) was calculated using the single pool non-steady state Steele equations (Steele 1959) 
that were adapted for stable isotope methodology(Wolfe and Jahoor 1990). 
Ra =  F – V[(C2 + C1)/2][(E2-E1)/(t2-t1)] 
                      (E2 + E1)/2 
            Rd = Ra – V (C2 – C1 /t2 – t1) 
Where F is the infusion rate (µmol kg
-1
 min
-1
), V is the distribution volume for palmitate or 
glucose (40 and 160ml kg
-1
) respectively, C1 and C2 are the palmitate and glucose 
concentrations (mmol
-1
) at times 1(t1) and 2 (t2), respectively, and E1 and E2 are the plasma 
palmitate or glucose enrichments (tracer to tracee ratio TTR) respectively at t1 and t2 
respectively. 
 
2.1.15.2 Determination of hepatic insulin sensitivity 
The labelled euglycemic–hyperinsulinemic clamp is the most frequently used method for 
measuring hepatic insulin sensitivity in response to glucose and insulin infusions. 
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Among the stable-isotope glucose tracers, [6,6-
2
H2]glucose appears to be the most suitable 
because apart from being safe and non-recycling, it is also considered to give the best 
estimate of true endogenous glucose production. 
        
Figure 2.5: Monocompartment model (based on Steele’s monocompartmental model and 
modified from Choukem and Gautier 2008). V: volume of compartment; Ra: hepatic glucose 
production rate; Ra*: tracer infusion rate; C: plasma glucose concentration; C*: plasma tracer 
concentration; Rd: rate of glucose disappearance; Rd*: rate of tracer disappearance 
Basal hepatic glucose production rate corresponds to the hepatic response to physiological 
plasma insulin, under clamp conditions HGP measured is an estimate of the hepatic response 
to supraphysiological insulin concentrations (residual HGP). Under non-steady state 
conditions created by insulin and glucose concentrations, a one-compartment model with 
constant volume (V) is used (Fig. 3) to facilitate calculation of residual HGP. Steel’s equation 
is the most widely used, although a more complex (Radziuk et al. 1978) and more recent 
model (Bluck and Clapperton 2005) that accounts for the error in Steele’s equation has also 
been proposed.  
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 Assuming basal HGP rate is equal to the liver’s response to plasma insulin, under steady-
state conditions, the glucose rate of appearance (Ra) equals its rate of disappearance (Rd); 
and the ratio of plasma tracer/tracee (C*/C), which corresponds to tracer enrichment (ε), is 
equal to the ratio of tracer infusion rate/glucose rate of appearance (Ra*/Ra). Thus, ε 
=Ra*/Ra (Ra=Ra*/ε). As Ra corresponds to the HGP rate in steady-state,  
HGP = Ra*/ε  
Although the isotope dilution method remains the best in determining hepatic insulin 
sensitivity in vivo and by far the safest and most practical compared to the arteriovenous-
difference method and use of radioactive-isotope tracers, a number of limitations make it less 
than perfect. The liver is not the only glucose-producing organ during fasting conditions. The 
kidney’s relative contribution to endogenous glucose production in the post- absorptive state 
is estimated to range from 5% to 28% (Cherrington et al. 1998, Gerich et al. 2001, Diraison 
et al. 2003). The monocompartmental model and the assumptions that constitute the basic 
principles of tracer methodology may also be subject to error. Another inconsistency is the 
computation of HGP rate using Steele’s equation, which often generates negative values of 
HGP during the euglycemic clamp; this is perhaps due to an error in the equation itself. These 
negative values have been seen in studies (Choukem et al. 2008) and are assumed to 
correspond to zero, that is, complete suppression of HGP.  
2.1.15.3 Palmitate tracer as a FFA tracer 
FFAs are avidly bound to albumin and are insoluble in aqueous media. The stable isotope 
method described by Woolfe in the 1970s utilises palmitate labelled with 
13
C or 
2
H and 
provides a precise and sensitive method of FFA tracer kinetics. For Study 3, 63.6mg of 
13
U 
palmitate was made up in 5mls of water. Because palmitate in its diluted form precipitates at 
room temperature, the palmitate was made up in warm water at 55°C and the syringe 
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containing the tracer was warmed again on a hot plate just before mixing with human 
albumin solution. 100mls of 4.5% human albumin solution was heated in a bath at 55°C. 
Once the palmitate became dilute it was injected sterilely into the bottle of albumin (as 
palmitate will bind to albumin and this mimics biological processing) and allowed to cool to 
room temperature before infusing. 
                      
gure 2.6a and b: Palm itate solution is  injected in to a 100mls  bott le of Human Al bumin S olution 4. 5% war med to 55°C, then left t o cool at roo m temperatu re before i nfus ing into  the human subject.  
 
Figure 2.6a and b: Palmitate solution is injected into a 100mls bottle of Human Albumin 
Solution 4.5% warmed to 55°C, then left to cool at room temperature before infusing into the 
human subject.  
 
The sample tracer is extracted from plasma after addition of a stable isotope internal standard 
to allow quantification of concentration, purified by thin layer chromatography and 
derivatised to their methyl esters. Isotopic enrichment of palmitate is then determined by gas 
chromatography mass spectrometry (GCMS). This method is superior to older methods of 
tracing FFAs, such as calorimetry and enzymatic assays. It provides an accurate way of 
identifying low individual and total FFA concentrations observed during an insulin infusion 
and is specific in determining tracer enrichment. However relatively large amounts of tracer 
and albumin were required to allow detection. Infusion rates can now be reduced with the 
introduction of combustion isotope ratio mass spectrometry where 
13
CO2 is measured. Of the 
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FFA tracers, palmitate, oleate and linoleate provide estimates of total FFA flux that are within 
15% of actual values. Continuous palmitate infusion allows determination of regional kinetics 
in tissues. FFA oxidation can be estimated using FFA carbon tracers 
13
 C and 
14
 C. A 
correction for CO2 fixation is often done to prevent inaccuracy (Sidossis et al. 1995).  
2.1.15.4 Sodium bicarbonate  
0.006375mg/kg of sodium bicarbonate was dissolved in 10mls of 0.9% saline and injected 
intravenously to prime the bicarbonate pool, to allow isotopic equilibrium of the palmitate. 
The main advantage of a primer is to achieve plateau in a shorter period of time, making 
infusions for volunteers feasible and cuts isotope costs and time of running studies. However 
some argue that the normal physiology of the tracer may be altered by priming due to rapid 
intake of tracer and that priming produces an artificial plateau (Wolfe and Chinkes 2005).  
2.1.15.5 Breath samples enriched with 
13
CO2 
For Study 3 breath samples were collected into a bag and then transferred into a vacutainer. 
Briefly the subject is asked to form a tight seal with their mouth over the rubber tubing 
connected to the bag, blowing comfortably into the bag. Before removing the tube from their 
mouths the tube is clamped, and then connected to a 3 way tap. One end is connected to the 
vacutainer (BD) where expired air is injected into evacuated tubes for determination of 
13
CO2/
12
CO2 ratio. As described by Siddossis et al. expired air is passed through a water trap 
followed by condensation in a liquid nitrogen trap to allow isolation of CO2 and evacuation 
of other gases. 
13
CO2/
12
CO2 is then determined by isotope ratio mass spectrometry (IRMS).  
The ratio is expressed in units of tracer to tracee ratio (TTR), defined as: 
TTR = (
13
C/
12
C)sa -   (
13
C/
12
C)ref – [(
13
C/
12
C)bk   -  (
13
C/
12
C)ref] 
Where sa = sample, ref = reference gas and bk = baseline sample 
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Figure 2.7: Breath bag and 3 way-tap to collect breath samples for 
13
CO2 analysis 
2.1.15.7 [6, 6-
2
H2] glucose quantification 
50 µl of plasma was mixed with 10µl of internal standard (methyl glucopyranose 50µg/ml). 
Addition of the internal standard results in a characteristic spectrum where the peak of 
interest is divided by the internal standard peak to account for losses. 300µl of cold absolute 
ethanol was then added to the mixture to deproteinise it. This mixture was spun down and the 
supernatant removed. A tenth of the supernatant was evaporated under N2 at 90
o
C to form a 
dried solid residue. 50µl of pyridine and hydroxylamine (25mg/ml) was added to this solid 
residue to form an oxime group. This was then incubated at 70
o
C for 45 minutes and allowed 
to cool slightly. 50µl of Trimethylsilyl-N-Trimethylsilyl Trifluoroacetimidate (BSTFA, 1% 
TMCS) was added and it was incubated at 70
o
C again for 45 minutes.  
The resultant mixture was then injected in a gas chromatography mass spectrometer at 240
o
C 
for up to 240 minutes. An enrichment curve was generated by making up 0.5%-5% 
deuterated glucose standards.  By this method, internal standard peaks, unlabelled glucose 
peaks and deuterated glucose peaks are generated.  
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2.1.15. 8  2-Deoxy-D-glucose (2DG) plasma concentrations 
100uL of plasma was aliquoted and mixed with 10ul of fluorodeoxyglucose (FDG) standard. 
1 ml of 100% ice cold ethanol is added to each tube and placed in ice/fridge for 20mins then 
spun for 2 mins at 10000rpm. The supernatant is dried completely in the techne
®
 block at 
90°C for 10mins. 100uL of oxime (20mg hydroxylamine HCL per 1ml pyridine) is added to 
each tube, vortex-mixed and incubated at 75°C for 30 mins in the oven. After cooling at room 
temperature, 70uL of BSTFA is mixed and incubated for 30 mins at 70°C in an oven in fume 
hood. Around 90uL is transferred into autosampler vials and capped. 
These were run on GCMS, and the first major doublet peak area (2DG) and second major 
doublet peak area of FDG standard (elutes closely after second 2DG peak) are recorded.  
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Figure 2.8: The trace shows 4 peaks, the lower shows 2, which are both glucose derivatives. 
The mass spectrum shows the major fragments in the glucose-oxime-TMS derivative. 
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Figure 2.9: The chromatograms show the 3 masses monitored. The 319 mass is used for 
quantitation and is the major fragment where there are to labelled atoms (no deuterium). The 
tracer 
2
H2, 2 deuteriums are replaced in the glucose molecule, so mass 319 + 2 =321 is looked 
at and quantified.  The 323 mass represents the internal standard, added to quantify glucose. 
When added to plasma the ratio between glucose is fixed, so a standard glucose curve (of 
known concentrations & containing the same amount of internal standard) is generated. 
Diagram courtesy of Dr K Smith, School of Medicine, University of Nottingham, UK. 
2.1.15.9 Determining skeletal muscle protein synthesis rate  
The tracer L-[ring-
2
H5 ]-phenylalanine was utilised in Study 2 to determine the fractional rate 
of mixed muscle protein synthesis (FSR). An amino acid bolus (which excluded 
phenylalanine and tyrosine) was fed via nasogastric tube in the same study due to palability 
issues. Arterialised blood samples were obtained into evacuated-heparinised tubes 
(Vacutainer) and chilled on ice.  
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After deproteinisation on ice with dry 5-sulfosalicylic acid and derivatisation with tert-butyl 
dimethylsilyl (TBDMS) as described (Gorissen, Burd et al. 2014), plasma was analysed for 
phenylalanine and leucine concentrations and enrichment by GCMS.   
Muscle protein synthesis rate was calculated by dividing the increment in enrichment in L-
[ring-
2
H5 ]-phenylalanine by the enrichment of the precursor. Plasma and muscle free L-[ring-
2
H5 ]-phenylalanine enrichments were used to provide an estimate of the lower and higher 
boundaries of true FSR respectively. Thus the formula used was: 
FSR (% hr 
-1) = [∆Ep/Eprecursor x t] x 100 
Where ∆Ep is the delta increment of protein bound L-[ring-2H5]-phenylalanine during 
incorporation periods, Eprecursor is the enrichment of the precursor used during the time 
period for amino acid incorporation determination, and t denotes the time duration (hour) 
between biopsies. The equation is multiplied by 100 to express FSR as percentage per hour.  
As the administered amino acid drink in Study 2 did not contain phenylalanine, whole body 
protein breakdown during the basal and fed periods could be determined from the rate of 
appearance of phenylalanine using the single-pool equation Ra=F/Ess where F is the infusion 
rate (µmol/kg min) and Ess is the steady state plasma phenylalanine enrichments (TTR) 
during the final hour of the basal and fed period.  
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2.2 Methods specific to studies 
The following methods are specific to the studies presented in this thesis 
2.2.1 Energy Predictions 
Whilst indirect calorimetry is one of the most accurate in estimating basal metabolic rate 
(BMR), where this is unavailable or not feasible, BMR could be obtained by using equations 
based on anthropometric measurements. The FAO/WHO/UNU 1985 recommended the use of 
age and gender-specific equations based on weight and height or weight alone to predict 
BMR in all populations. These have been modified and widely adopted (Schofield et al. 
1985), until recent times when it was observed that Schofield equations were inaccurate in 
predicting BMR in certain populations (Piers and Shetty 1993; Henry and Rees 1998). 
Specifically the inclusion of data from a population where the majority were Italian male 
military cadets and miners tended to result in overestimation of BMR in other populations. A 
challenging issue that persists is which predictive equation is most suitable for use in 
overweight and obesity.  The issue lies with the lower metabolic rate of adipose tissue 
compared to lean tissue. Resting energy expenditure (REE) thus increases in a non-linear 
fashion with weight, and tends to over-estimate energy requirements in overweight and obese 
(Horgan and Stubbs 2003). Thus the Schofield equation is inappropriate for use in this group 
(Frankenfield 2005). 
Based on comparisons made between the most commonly used predictive equations in 
clinical practice of Harris and Benedict (1919), FAO/WHO/UNU weight or weight and 
height equations (1985), Mifflin –St Jeor (1990) and Owen (1986, 1987), the Mifflin-St Jeor 
was found to be the most reliable, predicting resting metabolic rate (RMR) within 10% of 
measured in more nonobese and obese individuals than any other equation, and also had the 
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narrowest error range (Frankenfield 2005). However errors existed when applied to 
individuals and generalized to certain age and ethnic groups.     
The current modified Schofield or Henry’s/Oxford equation excludes Italian data and is 
currently accepted for use in most populations (Henry and Hayter 1999, Henry 2005). The 
new predictive formula includes height in addition to weight, and has been proven to be more 
accurate than the Schofield equation in an overweight or obese setting (Ramirez-Zea 2005; 
Weijs 2008) and showing a smaller deviation compared with REE determined with indirect 
calorimetry in adults with BMI within the normal range (Razalee et al. 2008).  
Henry/Oxford prediction equations for BMR using height and weight: 
 18 - 30 years:  REE = 14.4 x W + 313 x H + 113  
30 - 60 years:   REE = 11.4 x W + 541 x H – 137 
Henry/Oxford prediction equations for BMR using weight alone: 
18-30 years:                REE=16.0 X W + 545 
30-60 years:       REE=14.2 X W - 593 
Where W is weight in kilograms, H is height in meters, and REE is kcal/day 
Although both equations incorporating weight and height and just weight alone could be 
used, the equation used for estimating energy requirements in study 2 used body weight as 
the only independent variable. Body weight, an easily and accurately acquired variable has 
been considered the best single predictor of BMR (Schofield 1985, Henry 1991). Regression 
equations with body weight and combination of body weight and height yielded similar R
2
 
values (Razalee 2010).  Based on regression equations from the 1985 FAO/WHO/UNU 
Expert Consultation on Energy and Protein Requirements, including height as a second 
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predictor after weight, did not contribute significantly further to the equations for both 
genders, apart from those under three and above sixty years of age (Schofield 1985).     
Once the predicted BMR has been estimated, total energy expenditure (TEE) is determined 
by factoring in the physical activity of the subject. Subjects’ physical activity was assessed 
using the self-completed short version of the International Physical Activity Questionnaire 
(IPAQ) (Hagstromer, Oja et al. 2006) at screening. The IPAQ was developed in the late 
1990s by a multi-national group, supported by WHO and has been shown to correlate with 
objective evidence of physical exercise (Mader, Martin et al. 2006).  It assesses physical 
activity levels during the preceding seven days and generates a low (1.5), moderate (1.6) or 
high (1.8) activity score.  
2.2.2 Determination of energy and macronutrient intake 
For study 3 subjects completed 3 day food records of two weekdays and one weekend day 
before embarking on their study diet. ‘Microdiet’ software (Downlee Systems Ltd., Salford, 
UK) is a nutrient analysis software package that incorporates UK based nutrient data with the 
ability to edit and add additional foodstuffs not within the database. Nutrient content of 
foodstuffs could be added based on the nutritional information from food labels and 
published values. The Microdiet software was also used to design the food plans (isoenergetic 
with 50-55% CHO, 30-35% Fat and 13-15% Protein) for one week and 25% excess energy of 
either CHO or Fat for the following two weeks. Subjects were provided with and delivered 
commercially prepared food.    
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2.2.3 Methods of determining exercise capacity and performance 
2.2.3.1 Incremental shuttle walk test 
Baseline incremental shuttle walk test (ISWT) outcomes were compared between older lean 
and overweight volunteers in Study 1. Older volunteers performed the ISWT at the start and 
after the 6 month intervention for Study 4. Briefly this test involves shuttling between 2 cones 
10 metres apart in time increments paced to a series of bleep signals until they are no longer 
able to keep up or exhibited symptoms limiting their performance. It provokes a symptom 
limited maximal performance that allows direct comparison of a patient’s performance 
originally developed to evaluate functional capacity in patients with chronic progressive 
obstructive disease.(Singh et al. 1992) and later validated for use in other chronic diseases 
(ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories). It 
is proven to be a feasible measure of functional capacity in older people and correlates well 
with other markers of disability (Dyer et al. 2002).  
2.2.3.2 VO2 max testing 
VO2 max testing was determined using an electronic-braked cycle ergometer (Lode 
Excalibur, Groningen, The Netherlands) during an incremental exhaustive exercise test to 
determine rate of VO2 max measured using an online gas analysis system. This allowed 
further determination of the corresponding workload at 50% VO2 max at which older subjects 
cycled to. Most data describing maximal oxygen uptake and requirements for achieving this 
have been developed using young healthy subjects. There is no single standardised or 
protocol of determining the maximum aerobic function in elderly people. Cycle ergometer 
and treadmill tests are considered the commonest method of exercise stress tests. Of the two, 
the treadmill has more diagnostic sensitivity and presents a more familiar and functional 
exercise modality ie walking (Lear, Brozic et al. 1999), but this may present a problem for 
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some elderly patients with balance problems or arthritis. VO2 max values achieved with cycle 
ergometer are generally 11% (range 8-15%) lower than those with the treadmill due primarily 
to smaller volume of exercising muscle mass (Hermansen and Saltin 1969). VO2 max tends 
to decline with age, at around 1% each year after the 3
rd
 decade of life (Astrand 1960). This 
may be associated with the decline in cardiorespiratory function and muscular function with 
advancing age. The difficulty of directly measuring VO2 max in the elderly stems from the 
physical limitations or chronic medical conditions in older people but also other factors such 
as muscle fatigue, perceived exhaustion, subject motivation and the clinicians willingness to 
continue exercising until exhaustion, particularly in elderly subjects who are at higher risk of 
coronary artery disease and arrhythmias.(Astrand 1976) Current literature indicates 
variability in protocols used to achieve VO2 max and was mostly developed for use in young 
subjects. The requirements seen in literature include:- 
1) Respiratory Exchange Ratio (RER)>1.0 (Cress, Thomas et al. 1991, Hollenberg, Ngo 
et al. 1998) or >1.1 (Shephard, Allen et al. 1968) 
2) Peak exercise heart rate of at least 85% of age-predicted maximum (Borg 1982)or 
heart rate within 10 beats per minute of age-predicted maximum (Howley, Bassett et 
al. 1995) 
3) Borg’s perceived exertion scale >15 
No single protocol for exercising elderly subjects exists. Table 2.2 current protocols used in 
various studies on VO2 max.  A protocol for VO2 max tests for elderly subjects (65-75 years) 
in this study was proposed based on current protocols used in exercising young healthy 
subjects but  modified to take into account the physical limitations, early fatigability, 
increased risk of arrhythmias and coronary heart disease. Of relevance is the study by 
Thomas et al. (Thomas, Cunningham 1987) who compared three different VO2max testing 
protocols across the same group of elderly subjects and suggested that a continuous ramp-like 
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protocol with small increases in both speed and grade was the most appropriate for healthy 
older men. The protocol however had limited generalisation to the greater population of older 
adults due to the exclusion of women. A longitudinal study performed on 375 healthy women 
(48.6±16 yrs) and 435 men ( 51.9±16 yrs) from the Baltimore Longitudinal  Study of Aging 
(BLSA) using treadmill testing considered achievement of maximal exercise to have been 
achieved when volunteers heart rate reached > 85% of predicted and appeared fatigue, and 
could not have carried on for at least another minute (Fleg and Lakatta 1988).  
Therefore the requirements for ensuring VO2 max has been achieved for this study were 
similar to that used for testing younger subjects and based on protocols seen in other studies 
involving elderly subjects  ie RER>1.1 or HR> 85% of predicted maximal heart rate (HR) for 
age or Borg scale > 15. Modifications from that used in younger volunteers included a short 
familiarisation period (10 mins) of cycling at 40W. Power output then increased by 20 W 
every 3 mins, until 12 mins where it was increased every 20 W/min per minute until 
exhaustion. Subjects were attached to the heart rate (3 lead) monitor and the test was stopped 
if the volunteer exhibited chest pain, increasing dizziness, deceleration of heart rate, more 
than 2 ventricular ectopics on the ECG screen ie > 2 ectopics per 10 seconds. 
It has been suggested that VO2 peak data may provide sufficient information in determining 
maximum aerobic capacity in elderly people or perhaps redefining the maximum HR to be 
achieved during the max test. 
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Table 2.2: Protocols to determine VO2 max in older subjects seen in literature and of that used in study 4. 
Authors Subjects Protocol 
Jones et al., 
1985  
• 100 healthy subjects (50 male and 50 female), 
selected to provide an even distribution of age 
(15–71 y) and height 
• Initial power setting 16.3 W 
• 10 men and 10 women between 55 and 71 y 
• Power increased by 16.3 W/min until a symptom-limited power 
output reached 
Poehlman & 
Danforth, 1991  
• 19 older adults (13 men, 6 women) (64 ± 1.6 y) • Initial workload for women: 25 W at 50 rpm 
• Initial workload for men: 50 W at 50 rpm 
• Initial workload sustained for 3 min 
• Increased by 25 W every 2 min until exhaustion or until subjects 
unable to maintain 50 rpm 
Fairbarn et al., 
1994  
• 231 men and women equally divided within 
decades between 20 and 80 y (no breakdown of 
specific ages within decades provided) 
• Initial power ouput at 16 or 32 W 
• Power increased by 16 W/min until subject reached symptom-
limited maximal power output 
Cress & Meyer, 
2003  
• Men and women (N = 192; 76 ± 7 y) from 
single-family community dwellings or retirement 
communities with multiple levels of care  
• Familiarization period 
• Ramped test 
• Power output increased at a rate of 8–16 W/min 
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Pruchnic et al. 
2004 
 
13 healthy (67.3 ± 0.7 yr old) volunteers (8 
women and 5 men) 
 
Initial workload of 0-25W for first 2 mins then increment of 10-
25W every 2 mins until volutional exhaustion and until one of 
established criteria reached based on the American College of 
Sports Nutrition  
Study 4 of 
present thesis 
23 healthy men (mean 69 years) Initial workload 40W,increased by 20 W every 3 mins for first 12 
mins,then 20w every min until subjects unable to maintain 60 
rpm and until one of RER>1.2 or HR>85%predicted or Perceived 
Borg Score> 15 
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2.2.4 Methods of determining body composition 
2.2.4.1 Anthropometric assessments 
Skinfold measurements and bioelectric impedance analysis (BIA) were used to assess body 
composition in study 3. 
Skinfold measurement is used to assess subcutaneous fat thickness at various regions of the 
body. It is traditionally used to assess the degree of fatness and specifically the size of 
subcutaneous fat depots  The primary limitation is that most callipers have an upper 
measurement limit of 45 -55 mm, so this would not be ideal in very overweight or obese 
subjects (Duren, Sherwood et al. 2008). The mean of skinfold thickness measurements are 
calculated, per cent body fat is then calculated from the means of each four skin fold 
thickness measurements (biceps, triceps, subscapular and suprailiac) following the method of 
Durnin and Womersley (Durnin and Womersley 1974). Body fat percentage is estimated 
from the Siri formula (Siri1961), by dividing 495 by the body density (ε) calculated from the 
mean skinfold thickness measurements, minus 450 and multiplying by 100: 
Body fat = (495/ε skinfold measurement -450) x 100.  
2.2.4.2 Bioelectric Impedance Analysis 
This method produces estimates of total body water (TBW), fat-free mass (FFM), and fat 
mass by measuring resistance of the body as a conductor to a very small alternating electrical 
current (Lukaski, Johnson et al. 1985; Chumlea and Guo 1994). The impedance index 
[stature squared divided by resistance (S
2
/R) at a frequency] is proportional to the volume of 
total water and is an independent variable in regression equations to predict body 
composition (Baumgartner RN et al. 1990). BIAs use these equations to describe statistical 
associations for a specific population therefore these are useful only for subjects that closely 
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match the reference population in body size and shape. BIA’s ability to predict the degree of 
fat in obese subjects can be difficult to interpret because these individuals have a greater 
proportion of body mass and body water accounted for by the trunk, the hydration of FFM is 
lower in the obese, and the ratio of extracellular to intracellular water is increased in the 
obese.(Gray, Bray et al. 1989). BIA’s advantages are its portability, ease of use, relatively 
low cost and safety. The validity of BIA is influenced by gender, age, disease state, race and 
ethnicity (Rush, Chandu et al. 2006) and level of fatness (where TBW and relative ECW are 
greater in obesity compared with normal-weight individuals). Single-frequency BIA has 
better agreement than multifrequency BIA compared to DEXA  as a criterion measure for fat 
mass and FFM estimates in overweight and obese men.(Pateyjohns, Brinkworth et al. 2006) 
2.2.4.3 Dual energy x-ray absorptiometry (DEXA) 
Dual energy x-ray absorptiometry (DEXA) scan (Lunar Prodigy, GE Healthcare) was used to 
measure body composition of volunteers in studies 1, 2 and 4. Study 3 utilised the methods of 
Bioelectric Impedance Analysis (BIA) and skinfold anthropometric measurements. Originally 
developed by Mazess et al. (Mazess, Peppler et al. 1981) to precisely measure total bone 
mineral content, DEXA is today widely and commonly used to measure fat and lean body 
mass. Commercially available DEXA scanners manufactured by Lunar, Norland and Hologic 
generate two low energy x-rays levels to distinguish total body adipose and soft tissue, bone 
mineral content and density. Calculations are based on the assumptions on levels of 
hydration, potassium and tissue density and vary between manufacturers. The method is 
based on the energy dependence of the attenuation coefficients for photon absorption of bone 
mineral (containing high atomic number of calcium) and soft tissue (contain low atomic 
number elements of carbon, hydrogen and oxygen) (Mazess, Barden et al. 1990) An x-ray 
tube behind a filter converts the polychromatic x ray beam into one with two main energy 
peaks. The attenuation of non-bone tissue was previously assumed to be constant but is now 
101 
 
measured therefore limiting errors in estimation of composition (Roubenoff, Kehayias et al. 
1993).  
The ratio of soft tissue attenuation (RST) at the two energy levels is measured. The subject’s 
ratio of lean mass and fat (RL and RF) are known from theoretical calculations and human 
experiments. Thus the proportion of fat (alpha) and lean (beta) mass in each pixel can be 
determined: 
RST (40Kv) = α (Rf) + β (RL)          (1) 
RST (70Kv) = α (Rf) + β (RL)          (2) 
In its’ primary role of assessing bone mineral density, DEXA has a confidence value (CV) of 
~ 1 %.( Mazess, Barden et al.1990)  
Physical limitations include body weight, length, thickness and width of the subject. Indeed 
others have found that DEXA is unreliable in assessing body composition in obesity. 
Nevertheless DEXA is considered quick, convenient, non-invasive and exposes volunteers to 
a low radiation of <5mrem. This method can be applied to populations requiring minimal 
cooperation. It can also be performed by operators with minimal training.   
Wang et al. (1992) described changes in body composition with growth, ageing and illness. 
When assessing composition, it has to be assumed that the hydration of lean body mass is 
uniform and fixed at 0.73ml/g (Roubenoff and Kehayias 1991). This may not hold true in 
elderly or hospitalised ill patients (Heymsfield and Waki 1991) and will clearly also affect 
analyses using the bioelectric impedance and underwater weighing method in these groups. 
Abnormal hydration affects the subjects RL (ratio of lean mass) leading to deviation from the 
RL in the equations 1 and 2, leading to an error in the amount of lean tissue contributing to 
total body tissue. DEXA measurements of bone are sensitive to the anteroposterior thickness 
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of the body so there may be a difference in thin and obese subjects. Bias can thus emerge 
from following body composition during weight-reduction studies or growth in adolescents. 
(Roubenoff et al.1993). 
Particular regions such as the thorax and arms (where bone forms the greatest proportion of 
total mass) could lead to errors in soft tissue measurements. Pixels can sometimes miss small 
areas of bone and be included as lean tissue as the average absorption of coefficient for x-rays 
is closest to lean tissue than is bone, leading to possible overestimation of lean mass. It has 
also been shown that DEXA instruments from different manufacturers produce different 
measurements, and lack cross-validation using a standard phantom (Roubenoff et al. 1993).  
For studies presented here, at least three trained technicians have carried out DEXA scans  
using the same DEXA scanner (Lunar Prodigy). Ideally the same operator should carry out 
both scans (at the beginning and end of the study) to minimise inter-operator variability. To 
attempt to minimise this inconsistency, the regions scanned were re-measured by one single 
operator at the end of the study.   
Despite its limitations, considering the advantages, relative precision and practicality of 
DEXA compared to MRI/CT scanning and other indirect methods such as BIA and skinfold 
measurement, DEXA scanning appears to be the most useful in determining body 
composition.   
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Figure 2.10a and b: DEXA scanner and MRI scanner used to determine body composition in 
Studies 1, 2, 4 and hepatic and muscle triglyceride in study 3 respectively. 
 
2.4.4.4 Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectrometry 
(MRS) 
For study 3 magnetic resonance imaging and spectroscopy was employed at the beginning 
and end of the 2 weeks of overfeeding either fat or carbohydrate to quantify the effect of both 
diets on liver fat. 
The basic principles of MR scanning depend on a nucleus with non-zero spin such as 
1
H, 
13
C 
and 
19 
F. As 
1
H is the most naturally abundant element it produces the most intense MR 
signals and is thus the most frequently analysed element for MR and spectroscopy assessment 
(van der Graaf 2010).  
The MRI process consists of five major elements (van der Graff 2010): 
1) Magnet 
2) Gradient systems 
3) Radiofrequency (RF) coil system 
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4) Receiver 
5) Computer 
The magnet aligns the nuclei in low (parallel) and high (anti-parallel) energy states. A strong 
magnetic field is required and should be uniform over the area of interest; a shim system 
maintains this uniformity. The field uniformity can be altered using a magnetic field gradient 
(GZr) which varies linearly with position r to spatially encode the NMR signal. Gradients are 
generated by passing currents through arranged coils of wire placed surrounding the subject 
imaged.  
To generate an NMR signal, an RF field flips the magnetisation away from its equilibrium 
state using an RF transmitter that is responsible for pulse shape, duration, power and timing. 
Each spin produces a sinusoidal signal at a frequency dependent on the local magnetic field. 
An RF coil detects the signal from the spins by coupling the nuclei to an external circuitry. 
Either a volume or surface coil can be used, with the former being the most efficient. 
The RF signal is ‘received’ by a receiver system, where it is first amplified with a low-noise 
amplifier which is then transmitted to form an image on a remote computer. The computer 
system then retrieves images using a form of Fourier transform (FT). The fast FT can be used 
for two to three dimensional images.     
As smaller metabolite signals other than water or fat are often required in MRS, a magnetic 
field of sufficient strength is required, generally 1.5 Tesla (T) or higher. Clinical MR systems 
with field strengths of 3T have improved signal-to-noise ratio (SNR) in MR spectra, enabling 
acquisition of spectra from smaller volumes (van der Graff 2010).  
Liver fat content was quantified using H –MRS with a 3.0 Tesla (T) scanner (Philips Medical 
Systems) in Study 2. At 3T the chemical shift between water and the dominant fat peak 
corresponding to a frequency difference of -434 Hz. This oscillation period is half that of 
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1.5T and the corresponding IP and OP echo times at 3T are halved.  A spectroscopy 
localisation technique with time of repetition of 3000ms, echo time of 30ms, and 16 
acquisitions was used to obtain liver spectra. Measurements of abdominal subcutaneous and 
intraabdominal adipose tissue volume were obtained from 16T1-weighed axial magnetic 
resonance imagesby using selective fat excitation ranging from 8cm below and above the 
L4/L5 lumbar intervetebral disc. Adipose tissue volume and liver fat content were analysed 
by 2 different investigators using MRI software.     
MRS is considered the most accurate non-invasive means of measuring liver fat content 
showing good correlations with histological samples (Longo et al. 1993, Thomsen et al. 
1994, Szczepaniak et al. 1999). This method separates the liver signal into its water and fat 
components and calculates a signal fat-fraction. MRS is particularly recommended for 
assessment of small lipid fractions in liver as sensitivity to low signal intensities from fat is 
higher, and signals from water and fat are better distinguished.  Resonance frequencies as 
depicted by MR correspond to protons in water and dominant protein signals in fat. When 
signal intensities at frequencies corresponding to water and fat are quantified the signal-fat 
fraction is calculated (Mitchell et al. 1991, Fishbein et al. 1997, Hussain et al. 2005). 
Fat-signal fraction η is calculated as the signal from fat protons divided by combined signal 
from fat and water protons in the liver   
η = F / W+F 
F = fat signal  
W =Water signal 
It is assumed that the fat signal fraction reflects fat concentrations if the signals from W and F 
are corrected for confounding factors. 
106 
 
In particular 
1
H MRS directly measures the protons in the fatty acids of the triglycerides, 
providing a quantitative assessment of hepatic triglyceride. 
MRS carried out in this study used the Dixon method (Mitchell et al. 1991), the in phase and 
out of phase (IOP) imaging acquired in-phase images when signal from water and fat add, 
and out of phase images when signal from water and fat subtract.  
Sagittal, coronal and axial slices through the right lobe of the liver were acquired and a single 
voxel measuring 3x3x3cm
3
 was manually placed in liver parenchyma using multiplanar 
localising images. For reliable spectra from liver parenchyma to be recorded, voxels are 
carefully placed to avoid artificial signal contributions from intrahepatic blood vessels, large 
bile ducts, lateral margin of the liver and surrounding adipose tissue.  Shimming (placing a 
box within area of the liver to be scanned) is performed to achieve a homogenous magnetic 
field across the voxel and to avoid non-uniformity of fat suppression (See figure 2.11). A 
spectroscopic sequence is then performed.  
 
Figure 2.11: Placement of volume shim for optimum fat suppression in liver imaging: 
Increased phase shifts between fat and water occur creating image artifacts so complete fat 
suppression is required to eliminate this. This can be eliminated using a frequency selective 
fat suppression pulse (SPIR/SPAIR) with volume shimming. Air or soft tissue interfaces can 
create non-uniformity of fat suppression; therefore air within the vowel can be minimised by 
proper placement of volume shim box as above.  
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Figure 2.12. MRI scout images in the transverse (left) and sagittal (right) plane used for 
voxel placement of STEAM localized MRS (red box). 
 The two main methods used for single-voxel spectroscopy are point resolved spectroscopy 
(PRESS) (Ordridge et al. 1985) or stimulated-echo acquisition mode (STEAM) (Frahm et al. 
1989). PRESS uses a 90-180-180 pulse sequence with long echo time, allowing for better 
visualisation of metabolites with long T1 relaxation times. The STEAM method on the other 
hand consists of a shorter echo time and lower signal yield compared to PRESS. 
The magnitude-based approach is perhaps the most commonly used MR approach for liver 
fat assessment currently. Two gradient echos are acquired, one at an echo time (TE) in which 
the water peak and dominant fat peak are out of phase and one at a TE in which two peaks are 
‘in’ phase. The TEs corresponding to in phase and out of phase (IOP) depend on the field 
strength. The MRI signal strength used in this study was 3 Tesla (3T).  
MRS fat quantification techniques are shown to be safe, non-invasive and have high intra-
individual reproducibility in repeated measurements. However it relies on overall volume 
fraction of lipids in liver parenchyma whereas quantification from liver biopsies is taken from 
percentage of hepatocytes that show distinct fat droplets. There may thus be a difference in 
reported percentage values of steatosis between 
1
H MRS and histological analysis. 
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There is not as yet a clinically-defined cut-off value for normal vs abnormal levels of hepatic 
fat. A large MR spectroscopy study involving over 2000 participants of the Dallas Heart 
Study defined a 95
th
 percentile cut-off of 5.56% fat-fraction as abnormal based on a subset of 
345 patients with no identifiable risk factors for hepatic steatosis (Szczepaniak, Nurenberg et 
al. 2005). Indeed cut-off values may be modified slightly in the future when fat fractions are 
related to histological samples or clinical outcomes. Nevertheless based on current fat 
fraction cut-off values derived from the study above (~5%) the accuracy (bias) and precision 
(standard deviation) of a quantitative fat content biomarker must be smaller than 5-6% to 
provide a reliable diagnosis (Reeder, Cruite et al. 2011). 
The MRI scanner may also not be suitable for people suffering claustrophobia, having orbital 
metallic implants, pacemakers or metallic heart valves. Although metallic implants generally 
do not pose safety risks, spinal fusion metallic plants or knee implants for example may 
distort images and affect quality of liver fat quantification. 
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Figure 2.13: Single voxel MR spectrum of vegetable oil at 3.0T demonstrates the spectral 
complexity of fat. Triglycerides such as those in human liver fat have at least 6 identifiable 
peaks at clinical field strengths, similar to those shown in this figure. Methods such as IOP 
imaging and chemical shift based water-fat separation methods that model fat as a single 
NMR peak at -434Hz (-217Hz at 1.5T) will inaccurately estimate the concentration of fat 
within tissue if all peaks are not included in signal measurements. The frequencies that are 
shown present the chemical shifts of the different peaks at 3.0T relative to water (Reeder et 
al. 2011). 
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Figure 2.14. STEAM localized 
1
H MRS with water suppression (TE=20ms) at 3T acquired 
from a 20x20x20mm voxel within the right lobe of the liver of one subject (9 averages in one 
breath hold). The spectrum shows high resolution of multiple fat peaks allowing easy peak 
fitting quantification. Diagram courtesy of Dr Stephen Bawding, School of Physics,  
University of Nottingham. 
2.2.4.5 Other methods for quantifying liver fat 
Liver biopsy and direct histological analysis of tissue samples are currently the gold standard 
for quantifying intrahepatic lipid content. However this method is invasive, relatively 
expensive compared to imaging methods and presents risks in otherwise healthy subjects 
(Bravo et al. 2001) so may be inappropriate for use in research or longitudinal studies. 
Biopsy is also subject to sampling variability as it evaluates a small portion (0.05cm
3
) of the 
liver (800-1000cm
3
) (Ratziu, Charlotte et al. 2005) and the distribution of fat throughout liver 
may be non-uniform.   In this respect MRI/MRS provide a non-invasive means of measuring 
liver fat content. Compared with ultrasound and CT, it is capable of detecting small amounts 
of intrahepatic lipid content. Longo et al. 1993 described how H-MRS of liver parenchyma 
was well-correlated with data from CT studies and liver biopsies.  
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Ultrasound is one of the most common modalities of imaging to evaluate hepatic steatosis; it 
is non-invasive, costs less, and easily available. Liver fat content is evaluated indirectly based 
on qualitative sonographic features such as liver echogenicity, echotexture, vessel visibility 
and beam attenuation. The use of ultrasound is operator and machine-dependent and thus has 
limited repeatability and reproducibility. It would be an inappropriate tool to use in the 
HFHC study (Chapter 4), as the use of ultrasound in overweight or obese subjects is 
challenging due to impaired beam penetration and limited liver visualisation. The positive 
predictive value for detection of hepatic steatosis is only 62-77% (Graif, Yanuka et al. 2000; 
Saadeh, Younossi et al. 2002). 
Unlike ultrasound, CT evaluates hepatic steatosis indirectly based on hepatic X-ray 
attenuation that can be measured objectively and with high precision (Saadeh et al. 2002, 
(Kodama, Ng et al. 2007). Other factors such as iron, copper, glycogen and fibrosis and 
oedema can affect CT attenuation values resulting in errors in fat quantification and low 
sensitivity for mild to moderate steatosis. CT also relies on ionising radiation that will be 
appropriate for use in children or repeated monitoring of liver fat in adults (Fazel, Krumholz 
et al. 2009). The inherent variability in attenuation values across CT scanners manufactured 
by different vendors also exists (Birnbaum, Hindman et al. 2007).  
2.2.4.6 Proton magnetic resonance spectroscopy (
1
H MRS) of muscle 
Besides liver, MRS of muscle was also determined. Within muscle, triglyceride is stored 
either intra (IMCL) or extra-myocellular (EMCL). The main proton signal from muscle is 
from water. Following water suppression the main peak seen on sprectroscopy is lipid, and 
EMCL and IMCL are closely opposed but can be separately identified. Unlike the liver, 
movement due to respiration is not an issue, so subjects are not required to carry out breath-
holds during scanning. The reproducibility using this method for identifying IMCL is 
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acceptable with a coefficient of variation of 13% using 1.5 T scanner (Torriani, Thomas et al. 
2005).  
2.2.5 Skeletal muscle biopsy samples 
The following methods were used for studies 1, 3 and 4. 
2.2.5.1 Determining total muscle carnitine content 
Muscle samples obtained by biopsy were immediately frozen in isopentane then stored in 
liquid nitrogen. Muscle was then dissected free of visible blood and connective tissue, 
pulverised and used for the determination of free-, acetyl- and long-chain acyl-carnitine 
content (Cederblad et al. 1990). Total muscle carnitine was calculated as the sum of these 
carnitine moieties. Long-chain acyl-CoA content was determined from the same extract as 
long-chain acylcarnitine using a modified version of the radioenzymatic method of Cederblad 
et al. (1990). 
Freeze-dried powdered muscle was extracted with 0.5mM perchloric acid in 1mM Na2 
EDTA and neutralised with 2.1M KHCO3. 
2.2.5.2 Acetyl-coA assay 
Using a standard assay kit (Sigma-Aldrich), free CoA was quenched then Acetyl CoA is 
converted to CoA. The CoA was reacted to form NADH which interacts with PicoProbe to 
generate fluorescence (Ex=535/Em=587 nm). Briefly, tissue samples for measurement were 
deproteinised using perchloric acid/KOH protocol. The homogenate was spun at 10000g and 
neutralised with KHO3 and put on ice for 5 minutes. Acetyl CoA standard curves were 
generated by diluting Acetyl CoA Standards whilst background free CoASH and succ-CoA in 
samples were corrected for by adding 10µl of CoASH Quencher to each standard, sample and 
background samples to quench free CoA. 2µl of Quench remover (ie NEM) was then added 
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and incubated for 5 mins at room temperature. CoA conversion was carried out by making up 
50µl of reaction mix for all the wells, and incubated at 37°C for 10 minutes. Fluorescence 
using Ex/Em =535/589nm with a plate reader was carried out. Background values and correct 
Acetyl-CoA values for each sample were determined and a standard curve was plotted where 
Acetyl-CoA amounts in the sample wells were obtained.  
Acetyl CoA concentrations in the test samples: 
C = Ay/Sv (pmol/μl; or nmol/ml; or μM) 
Where: Ay is the amount of Acetyl CoA (pmol) in the sample from the standard curve. 
Sv is the sample volume (μl) added to the sample well. 
2.2.5.3 Determination of 2DG in muscle 
 Frozen muscle (30–40 mg) was powdered under liquid nitrogen, and transferred to 70% 
ethanol. The sample was vortex mixed and then centrifuged at 5,000g for 10 min. The 
resultant supernatant was used for 2-deoxyglucose-6-phosphate (2DG6P) analysis using a 
commercial kit (Cosmo Bio Ltd, Tokyo). 2DG accumulates in muscle as 2DG6P and is 
oxidised by the introduction of glucose-6 phosphate dehydrogenase (G6PDH), resulting in 
NADPH where it was quantified at 420 nm using a recycling amplification enzymatic-
photometric system (Saito K and Minokoshi Y et al. 2011).  
2.2.5.4 Electron Microscopy of muscle 
Muscle samples were first fixed in 1% osmium tetroxide, then dehydrated in ethanol and 
embedded in Spurr’s resin (25ml Araldite CY212 resin, 15ml Agar 100 resin, 55ml DDSA, 
2ml Dibutylphthalate and 1.5ml DMP 30). Thin sections were cut using an ultramicrotome, 
placed on Cu/Pd grids and stained for 5 min in uranyl acetate followed by 2 min in lead 
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acetate. Longitudinal images were visualized using a transmission electron microscope at a 
magnification of x4200. Approximately 40 micrographs from at least four different muscle 
fibres were taken at random and sequentially by an operator blinded to subject age, with 
around half of the images containing a SSL region. Images were analysed in a blinded 
manner described by Crane et al. 2009 using ImageJ (NIH) to determine percentage IMCL 
per fibre area, lipid droplet size, total number of lipid droplets per square micrometer of 
tissue and percentage IMCL area density. 
2.2.5.5 Lipid metabolites 
Quantification of intramuscular DAGs and ceramides was performed using high-performance 
liquid chromatography (HPLC) tandem mass spectroscopy. Tissue homogenates were 
fortified with internal standards and extracted into a one-phase neutral organic solvent 
system, evaporated and reconstituted in methanol. Quantitative analysis was performed in a 
positive multiple-reaction-monitoring mode, based on calibration curves generated by adding 
to an artificial matrix known amounts of target analytes, synthetic standards and an equal 
amount of internal standard. DAG and ceramide levels were normalized to total protein 
levels. For skeletal muscle DAG and ceramide analyses, 50 ng internal standard (1,3[d5]-15:0 
DAG) was added to 5 mg freeze-dried muscle powder, total muscle lipids were extracted in 
CHCl3:MeOH:H2O (26) and the most abundant DAG (diC16:0, C16:0/C18:1, diC18:1) and 
ceramide (C16:0, C18:0, C18:1, C20:0, C24:1, C24:0) species were quantified using 
LCMS/MS. (Blachnio-Zabielska A et al. 2012, Blachnio-Zabielska A et al. 2013). Briefly, 
chromatographic separation was performed on a C8 MOS-1 Hypersil column (2.1 x 100 mm; 
3.0 µm, Thermo Scientific) at a flow rate of 0.2 ml/min, using a binary gradient (90-99% 
solvent B; 0-20 mins) with 1.5 mM ammonium formate, 0.1% formic acid in water as solvent 
A and 2 mM ammonium formate, 0.15% formic acid in methanol as solvent B. DAG and 
ceramides were monitored in positive electrospray ionisation mode (Quattro Ultima triple 
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quad) as their [M+NH4]
+
 and [M-H2O]
+ 
adducts, respectively. Peak areas (MassLynx 4.0, 
Micromass Ltd, UK) normalised to the internal standard were converted to absolute 
concentrations using standard curves constructed for each species undergoing the full 
extraction procedure.  
 
2.2.5.6 Skeletal muscle oxidative capacity 
Freeze-dried muscle was dissected free of visible blood and connective tissue, pulverised and 
used for the determination of muscle free carnitine, acetylcarnitine and long-chain 
acylcarnitine using the radioenzymatic method described previously by Cederblad (1990). 
Approximately 20 mg of wet muscle tissue was used to determine maximal CPT1 activity 
using the forward radioisotope assay (McGarry JDM et al. 1983). Briefly, muscle was 
homogenised in 50 mm Tris/HCl buffer (pH 7.5) and immediately used to determine 
malonyl-CoA (10 μm)-sensitive [14C]palmitoylcarnitine production from 100 μm palmitoyl-
CoA, 1 mm L-carnitine and 0.05 μCi l-[14C]carnitine, which was normalised to total protein 
content using the Bradford assay.  
Muscle phosphocreatine (PCr), lactate and glycogen were determined on freeze-dried muscle 
using the spectrophotometric method of Harris (1974). Muscle total creatine content was 
calculated as the sum of free creatine and PCr. In addition, maximal citrate synthase activity 
was determined spectrophotometrically on whole muscle homogenates based on the methods 
of Opie & Newsholme (Opie et al. 1967) and Zammit & Newsholme (1976) and expressed as 
mmol/min/ (kg wet muscle). 
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CHAPTER 3: STUDY 1 
Comparing skeletal muscle lipid content, fat metabolism and insulin sensitivity in older 
vs. young healthy men  
This chapter presents data comparing skeletal muscle lipid and metabolism at rest and during 
light-intensity exercise in healthy older and young men. The same older individuals 
participated in a further study to examine the effects of carnitine supplementation on skeletal 
muscle metabolism and insulin sensitivity, the results of which are presented in Chapter 6. 
3.1 Introduction 
 
It is established that insulin resistance increases with age but the proposed factors implicated 
in the decline of insulin sensitivity in ageing remains equivocal. Whilst it has been proposed 
that age influences insulin sensitivity independent of changes in body composition and 
physical activity (Shimokata et al. 1991), there is a growing body of evidence to suggest that 
increasing insulin resistance is closely related to increased adiposity (visceral fat) and 
sarcopenia (reduced muscle mass, strength and function), both closely associated with ageing 
(Evans and Campbell. 1993, Ferrannini et al. 1996, Imbeault et al. 2003). Age-related decline 
in glucose tolerance in population studies were also shown to be closely correlated with 
leisure-time activity (Wang et al. 1989).  When age-related variables such as adiposity, 
dietary habits and physical activity were controlled for, the degree of correlation were 
reduced (Zavaroni et al. 1986, Zamboni et al. 1997), suggesting that elevation of glucose and 
insulin levels in ageing may be due to environmental factors. Moreover it has been shown 
that insulin resistance is not an obligatory finding in ageing as healthy centenarians have been 
demonstrated to have preserved insulin action compared to aged subjects (Barbieri et al. 
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2011). Thus ageing per se does not always appear to cause insulin resistance (Kohrt et al. 
1993, Amati et al. 2009, Karakelides et al. 2010). 
Elevated triglyceride levels in muscle consistently correlate with models of insulin resistance. 
Increased IMCL has been found in patients with T2DM (Falholt et al. 1988) and in cross-
sectional studies of healthy humans, insulin resistance correlates most closely with IMCL 
compared to percentage body fat, BMI or age (Stein et al. 1997). Moreover, lipid metabolites 
associated with IMCL such as acyl-coA, diacylglycerol (DAG) and ceramide could cause 
insulin resistance in skeletal muscle by activating key proteins that antagonise insulin-
responsive metabolic and signalling pathways (Savage et al. 2007). Compared to young, 
IMCL content is increased by up to 40% in older people as seen on 
1
H Nuclear Magnetic 
Resonance (
1
HNMR) spectroscopy (Petersen et al. 2007). As alluded to in the introduction 
chapter of this thesis, the accumulation of IMCL may be caused by the mismatch between 
lipid supply and reduction in proportional fat oxidation in ageing (Nair 2005) and not 
necessarily associated with insulin resistance. Indeed, studies on the causal relationship 
between skeletal muscle lipid accumulation and insulin resistance are inconclusive. 
Goodpaster’s  proposal of the ‘athlete’s paradox’ described highly-trained endurance athletes 
who possessed high muscle oxidative capacity and increased insulin sensitivity despite 
increased muscle lipid content (Goodpaster et al. 2001). He speculated that it was not the 
accumulation of lipid in muscle per se but an individual’s muscle’s capacity for lipid 
oxidation that influenced development of insulin resistance.  Indeed inhibition of 
mitochondrial carnitine-palmitoyl-transferase-1 (CPT-1) fatty acid oxidation by R –isomer of 
ethyl-2- [6-(4-chlorophenoxy) hexyl]-oxirane-2-carboxylate (etoximir) in rats elicited a 
reduction in whole-body insulin-mediated glucose disposal and endogenous glucose 
production (Dobbins et al. 2001), indicating the importance of fatty acid oxidation (or lack 
thereof) in the development of insulin resistance. Factors implicated in diminished fat 
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capacity in the elderly include increased fat mass (Nagy et al. 1996, Toth et al. 1996, 
Levadoux et al. 2011), reduction in skeletal muscle oxidative enzyme activity (Houmard et 
al. 1985, Petersen et al. 2007) and reduction in physical activity levels (Sial et al. 1996). Fat 
oxidation rates during sleep and over a 24- hour period of free activity were lower in older 
compared to young individuals regardless of activity levels (Levadoux et al. 2011). 
Moderate-intensity exercise in older people has been shown to elicit a 35% lower fat 
oxidation rate compared to younger subjects exercising at the same absolute and relative 
intensities, presumably caused by altered skeletal muscle metabolism in ageing as whole 
body lipolysis and plasma FFA availability were not-rate limiting (Sial et al. 1996).  
With regards to exercise metabolism, other than impaired fatty acid metabolism the few 
studies investigating the effects of exercise in older individuals showed modified lactate and 
glycogen kinetics following exercise, but these studies were carried out in highly trained or 
master athletes and were investigated at maximal oxygen uptake (VO2 max) (Masse-Biron et 
al. 1992).  The changes seen in the ability of ageing skeletal muscle to respond to exercise 
may be due to loss of muscle mass, decreased muscle oxidative enzyme activity and 
capillarisation or reduced physical activity and training with ageing (Rofers and Evans 1993).  
Why there is an age-related decline in fat oxidation resulting in IMCL accumulation and 
insulin resistance cannot be entirely explained by a decline in physical activity or availability 
of free fatty acid during exercise. Animal studies show that the rate of fatty acid oxidation in 
perfused working hearts was lower in aged compared to young (Abu-Erreish et al. 1977). As 
an inverse relationship exists between insulin sensitivity and triglyceride accumulation in 
muscle (Johannesen et al. 2012), the capacity of fat oxidation in aged muscle may be of 
critical importance to development of metabolic disease in ageing.  
IMCL-derived fatty acid oxidation during exercise and how this affects lipid content and 
glucose uptake in muscle in older people have also not been investigated in detail. Moreover, 
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distinct pools of IMCL droplets within the intermyofibrillar (IMF) and subsarcolemmal 
(SSL) regions of the muscle cell have been identified (Nielsen et al. 2010; Crane et al. 2010, 
Chomentowski et al. 2011  Jonkers et al. 2012;), but their contribution to IMCL oxidation 
and utilisation during exercise has not been elucidated. A 3-fold higher volume of lipid 
droplets in the SSL region has been identified in people with T2DM compared to obese and 
high-endurance athletes (Nielsen et al. 2010). SSL lipid droplet accumulation in particular 
have been implicated in the development of insulin resistance, perhaps as a result of lipid 
droplet metabolites on insulin action, due to its proximity to muscle fibre nuclei and 
signalling pathways of the sarcolemma via DAG and ceramides (Coen and Goodpaster 2012). 
Moreover, change in the number of lipid droplets post-exercise in SSL and IMF differ but 
have only been investigated in healthy middle-aged sedentary normal-weight, (Malenfant et 
al. 2001a and b, He et al. 2004; Li et al. 2014) overweight (Malenfant et al. 2001, Li et al. 
2014), T2DM (Nielsen et al. 2010) and endurance-trained older subjects (van Loon et al. 
2003).   
As body composition and physical activity changes with age it is important to 
examine if and how these factors, rather than inherent ageing per se, affect insulin sensitivity, 
skeletal muscle substrate metabolism and utilisation in healthy older vs. healthy young men. 
Moreover, no studies to date have characterised skeletal muscle fat metabolism during 
exercise in older healthy people with skeletal muscle insulin sensitivity. This study compared 
body composition, substrate metabolism and skeletal muscle lipid accumulation during rest 
and light-intensity exercise and insulin sensitivity in older and young healthy men with the 
premise that these parameters are influenced by body composition, rather than ageing. It was 
also hypothesised that lipid accumulation in ageing is caused by impaired IMCL oxidation 
during exercise.  
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3.2 Methods 
3.2.1 Human Participants 
Seven old lean (69.7±0.9 years, body mass 70.3±2.4 kg), 7 old overweight (68.6±0.8 years, 
body mass 86.3±1.8 kg) and 7 young (21.1±0.9 years, body mass 74.4±4.0 kg) healthy males 
were recruited to the study. All participants underwent medical screening, blood testing and 
gave informed consent as described in the common methods section (Chapter 2). Subjects 
were excluded if they smoked, had diabetes or other metabolic disorders, cardiovascular 
disease, blood disorders or abnormal blood tests. 
3.2.2 Pre-experimental tests  
The incremental maximal oxygen consumption (VO2 max) test was performed prior to the 
experimental visits to determine the workload or intensity equivalent to 50%VO2 max that the 
participants were required to cycle at during the exercise visits. This low intensity exercise 
model was chosen as fat oxidation would be expected to be maximal (Romijn et al. 1993, 
Achten 2004), where in vivo mitochondrial function would be challenged and could be 
assessed, and previous studies have suggested age-related differences (Sial et al. 1996). 
Participants attended for two experimental visits separated by at least a week, as described 
below.  
3.2.3 Experimental Visits 
The first experimental visit involved a resting 3-hour hyperinsulinaemic euglycaemic clamp 
with infusion of 2DG, a glucose analogue to determine skeletal muscle insulin sensitivity; 
whereas the following visit involved the fatty acid tracer, [U-
13
C] palmitate infusion and 
exercising at 50% of VO2 max for one hour to measure fat oxidation and metabolism in 
muscle during light-intensity exercise. 
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3.2.3.1 Hyperinsulinaemic euglycaemic clamp visit 
Participants arrived at the David Greenfield MRC/ARUK Centre for Musculoskeletal 
Ageing Research laboratory at 0800 after an overnight fast. A DEXA scan (Lunar Prodigy, 
GE Healthcare, US) was performed to assess body composition. They then rested semi-
supine on a bed while cannulae were inserted retrograde into a superficial vein on the back 
of the hand for arterialised blood sampling and forearm veins for insulin, glucose and 2DG 
infusions. The hand was placed in a hand-heated box throughout the experiment to allow for 
arterialised blood sampling. A 3-hour hyperinsulinaemic euglycaemic clamp at 60 mU m
-2
 
min
-1
 was carried out to assess insulin sensitivity. 2DG was infused at a rate of 6mg kg
-1
h
-1
 
at the same time. Blood glucose concentrations during the clamp were determined at 5 min 
intervals using an autoanalyser (Yellow Springs Instrument YSI, US). Arterialised venous 
blood was also obtained at t= 0 and every 30 min throughout the clamp and centrifuged at 
1000g at 4°C for 10 min, and stored at -80
◦
C until subsequent analysis for serum insulin and 
plasma 2DG. Indirect calorimetry was performed before and during steady state of the 
hyperinsulinaemic euglycaemic clamp (2 hours after start of clamp) using a GEM (Gas 
Exchange Measurement, GEMNutrition Ltd, Cheshire, UK) ventilated hood system. Samples 
for serum insulin were placed in aliquots and frozen at a minimum of -20
◦
C and measured 
using a solid-phase 
125
I radioimmunoassay using standard insulin kits (Milipore Human 
Insulin Assay; Merck Millipore). Muscle biopsy samples using the technique described by 
Bergstrom were obtained from the vastus lateralis muscle of each subject at rest before and 
immediately after the clamp to determine incorporation of muscle 2DG. 2DG is a glucose 
analogue and is regarded a robust surrogate marker of glucose uptake by muscle 
(Yamamoto et al. 2009). Post-absorptively, total muscle 2DG accumulates in a linear 
fashion, and exercise, a known stimulus of skeletal muscle glucose uptake, significantly 
and consistently increases muscle 2DG uptake.   The linear accumulation of 2DG 
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suggests that 2DG is neither stimulating (through a “mass effect”) nor inhibiting 
(through hexokinase inhibition) its own uptake. It closely resembles glucose in the 
characteristics of its transport but is metabolised only to the 6-phosphate derivative, 
2DG6P. It is therefore effectively trapped within skeletal muscle where its concentration 
(and that of 2DG) can be determined as a function of glucose uptake, assuming 2DG 
uptake to be representative of all hexose uptake.  
 
3.2.3.2 Exercise Visit 
At least a week after the resting study visit, participants reported to the laboratory and rested 
semi-supine on a bed while a cannula was inserted retrograde into a superficial vein for 
arterialised blood sampling and the other into a forearm vein for infusion of 
[U-
13
C] palmitate (99% enriched (Cambridge Isotope Laboratories, Andover, MA, USA) at a 
concentration of 0.19mg kg
-1
 h 
-1 
for 2 hours. Breath samples were collected via one-way 
valve bags and introduced into breath tubes (BD Biosciences) for subsequent 
13
CO2 
enrichment analysis before the start of the infusion and every hour of the resting period. 
Plasma samples for palmitate tracer and FFAs were collected hourly during resting. At the 
end of the second hour, percutaneous biopsy sampling from the vastus lateralis muscle was 
performed before participants went on to cycle on the ergometer at 50% VO2 max equivalent 
workload. The [U-
13
C] palmitate concentration was increased to 0.28 mg kg
-1
 hr
-1
 at the onset of 
exercise for 1 hour. Blood plasma for FFAs, palmitate tracer and breath samples for 
13
CO2 were obtained every 10 minutes. During the last 10 minutes of exercise, indirect 
calorimetry was determined (Quark CPET system, Cosmed, Italy). A muscle biopsy was 
again taken at the end of the 1 hour exercise. 
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Figure 3.1: Schematic diagram on the experimental visits. Protocol A –Resting visit and 
Protocol B- Exercise visit  
 
3.2.4 Sample collection and analysis 
All DEXA scans were analysed by a single operator to avoid inter-operator variability. The 
scans were analysed for trunk, leg and arm composition using standardised regions 
conforming to specifications.  Blood samples were collected in tubes containing 
ethylenediaminetetraacetic acid (EDTA) and centrifuged at 1000g at 4°C for 10 min. Plasma 
aliquots were subsequently stored at -80
◦
C until analysis. Blood serum and plasma were 
collected at baseline and every 30 minutes during the clamp, allowed to clot and then 
centrifuged (1400 RCF at 4
◦
C for 10 mins) for subsequent storage at -80°C until use for 
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determination of insulin concentrations and 2DG glucose tracer respectively. Muscle samples 
were snapped frozen in isopentane and stored in liquid nitrogen, and subsequently analysed 
for 2DG content.  
3.2.5 Palmitate tracer analysis 
Palmitate tracer is extracted from plasma after addition of a stable isotope internal standard to 
allow quantification of concentration, purified by thin layer chromatography and derivatised 
to their methyl esters. Isotopic enrichment of palmitate is then determined by gas 
chromatography mass spectrometry (GCMS). This method is superior to older methods of 
tracing FFAs, such as calorimetry and enzymatic assays. It provides an accurate way of 
identifying individual and total FFA concentrations observed during an insulin infusion and is 
specific in determining tracer enrichment. Relatively large amounts of tracer and albumin 
were previously required to allow detection. Infusion rates can now be reduced with the 
introduction of combustion isotope ratio mass spectrometry where 
13
CO2 is measured. Of the 
FFA tracers, palmitate, oleate and linoleate provide estimates of total FFA flux that are within 
15% of actual values. Continuous palmitate infusion allows determination of regional kinetics 
in tissues.  
  
3.2.6 Electron Microscopy analysis 
Lipid and mitochondrial analyses were determined using a computerised image analysis 
system (Image-J), by an operator blinded to subject and age following criteria set to 
identifying lipid and mitochondria (Crane et al. 2013).  Lipid droplets and mitochondrial 
fragments were circled and converted to actual size using a calibration grid. Skeletal muscle 
samples were first fixed in 1% osmium tetroxide, then dehydrated in ethanol and embedded 
in Spurr’s resin. Thin sections were cut using an ultramicrotome, placed on copper/palladium 
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(Cu/Pd) grids and stained for 5 minutes in uranyl acetate followed by 2 minutes in lead 
acetate. 40 longitudinal images were visualised using a transmission electron microscope at a 
magnification of x4200. Two micrographs from four different muscle fibres were taken at 
random and sequentially by an operator blinded to subject age. Images were taken from the 
SSL region adjacent to the nucleus with most of the image containing the intermyofibrillar 
area. The images were photographed using a 1-s exposure time and digitised using a white 
light illuminator. Values are reported as mean individual IMCL or mitochondrial size, total 
number of IMCL droplets or mitochondria per square micron of tissue and percentage IMCL 
or mitochondrial area density.  
 
Figure 3.2: Electron micrograph (x4200) of a vastus lateralis muscle cell depicting IMF and 
SSL lipid droplets. 
3.2.7 Insulin sensitivity and skeletal muscle 2DG uptake  
Insulin sensitivity was measured as the rate of insulin-stimulated glucose disposal (Rd) 
during a 3hour hyperinsulinaemic (60mU m
-2
min
-1
) euglycaemic clamp at the same time as 
infusion of the stable tracer isotope 2DG. The Matsuda’s insulin sensitivity index was also 
SSL 
IMF 
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determined from steady state of plasma glucose and serum insulin.  Frozen muscle (30–40 
mg) was powdered under liquid nitrogen, and transferred to 70% ethanol. The sample was 
vortex mixed and then centrifuged at 5000g for 10 minutes. The resultant supernatant was 
used for 2DG/2DG6P analyses using a 2DG uptake measurement kit (Cosmo Bio Ltd, 
Tokyo). Briefly 2DG accumulates in muscle as 2DG6P and is oxidised by the introduction of 
glucose-6 phosphate dehydrogenase (G6PDH), resulting in NADPH where it was quantified 
at 420 nm using a recycling amplification enzymatic-photometric system (Saito K and 
Minokoshi Y et al. 2011).  For determination of plasma 2DG, 100uL of plasma was aliquoted 
and mixed with a standard 10ul of fluorodeoxyglucose (FDG). 1 ml of 100% ice cold ethanol 
is added to each tube and placed in ice/fridge for 20mins then spun for 2 minutes at 10000 
rpm. The supernatant is dried completely in the Techne
®
 block heater at 90
◦
C for 10minutes. 
100uL of oxime (20mg hydroxylamine HCL per 1ml pyridine) is added to each tube, vortex-
mixed and incubated at 75
◦
C for 30 minutes in the oven. After cooling at room temperature, 
70uL of BSTFA is mixed and incubated for 30 minutes at 70
◦
C. The samples were then run 
on gas chromatography mass spectroscopy (GCMS), and the first major doublet peak area 
(2DG) and second major doublet peak area of FDG standard (elutes closely after second 2DG 
peak) are recorded.  
3.2.8 Analysis of lipid metabolites DAG and ceramide 
Quantification of intramuscular DAGs and ceramides was performed using high-performance 
liquid chromatography (HPLC) tandem mass spectroscopy. Tissue homogenates were 
fortified with internal standards and extracted into a one-phase neutral organic solvent 
system, evaporated and reconstituted in methanol. Quantitative analysis was performed in a 
positive multiple-reaction-monitoring mode, based on calibration curves generated by adding 
to an artificial matrix known amounts of target analytes, synthetic standards and an equal 
amount of internal standard. DAG and ceramide levels were normalized to total protein 
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levels. For skeletal muscle DAG and ceramide analyses, 50 ng internal standard (1,3[d5]-15:0 
DAG) was added to 5 mg freeze-dried muscle powder, total muscle lipids were extracted in 
CHCl3:MeOH:H2O (Folch et al. 1957) and the most abundant DAG (diC16:0, C16:0/C18:1, 
diC18:1) and ceramide (C16:0, C18:0, C18:1, C20:0, C24:1, C24:0) species were quantified 
using LCMS/MS (Blachnio-Zabielska et al. 2012,2013). Briefly, chromatographic separation 
was performed on a MOS-1 Hypersil  C8 column (2.1 x 100 mm; 3 µm); Thermo Scientific  
at a flow rate of 0.2 ml/min, using a binary gradient (90-99% solvent B; 0-20 mins) with 1.5 
mM ammonium formate, 0.1% formic acid in water as solvent A and 2 mM ammonium 
formate, 0.15% formic acid in methanol as solvent B. DAG and ceramides were monitored in 
positive electrospray ionisation mode (Quattro Ultima triple quad) as their [M+NH4]
+
 and 
[M-H2O]
+ 
adducts, respectively. Peak areas (MassLynx 4.0, Micromass Ltd, UK) normalised 
to the internal standard were converted to absolute concentrations using standard curves 
constructed for each species undergoing the full extraction procedure.  
 
3.2.9 Determination of skeletal muscle metabolites 
 
Freeze-dried muscle was dissected free of visible blood and connective tissue, pulverised and 
used for the determination of  muscle free carnitine, acetylcarnitine and long-chain 
acylcarnitine using the radioenzymatic method described previously by Cederblad (Cederblad 
et al. 1990). Approximately 20 mg of wet muscle tissue was used to determine maximal 
CPT-1 activity using the forward radioisotope assay (McGarry et al. 1983). Briefly, muscle 
was homogenised in 50 mm Tris/HCl buffer (pH 7.5) and immediately used to determine 
malonyl-CoA (10 μm)-sensitive [14C] palmitoylcarnitine production from 100 μm palmitoyl-
CoA, 1 mm L-carnitine and 0.05 μCi l-[14C]carnitine, which was normalised to total protein 
content using the Bradford assay.  
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Muscle phosphocreatine (Pcr), lactate and glycogen were determined on freeze-dried muscle 
using the spectrophotometric method of Harris (Harris et al. 1974). Muscle total creatine 
content was calculated as the sum of free creatine and PCr. In addition, maximal citrate 
synthase activity was determined spectrophotometrically on whole muscle homogenates 
based on the methods of Opie & Newsholme (1967) and  Zammit & Newsholme (1976) and 
expressed as mmol min
−1
 (kg wet muscle)
−1
. 
3.2.10 Calculations 
Total fat and carbohydrate oxidation rates were calculated using the non-protein respiratory 
quotient (Frayn 1983) and described in detail in the common methods section of this 
thesis. 
Fat oxidation rate =1.695 x VO2 + 1.701 x VCO2 g/min 
Carbohydrate oxidation rate = 4.585 x VCO2 -3.226 x VO2 g/min 
EE = 15.9 x VO2 + 5.2 x VCO2 J/min 
 
Where VO2 and VCO2 are expressed as litres per min and oxidation rates as grams per 
minute. 
Breath and plasma enrichments are expressed as the tracer/tracee ratio (TTR);  
TTR = (
13
C/
12
C)sa - (
13
C/
12
C)bk 
where sa denotes the sample and bk the background value. 
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The rate of appearance (Ra) and rate of disappearance (Rd) of palmitate was calculated using 
the single-pool non steady- state Steele equations (1959) adapted for stable isotope 
methodology as described by Wolfe & Jahoor 1990. 
Ra = F – V [(C2 + C1)/2][(E2 – E1)/(t2-t1)] 
(E2 + E1)/2 
Rd = Ra –V(C2-C1) 
t2-t1 
 
where F denotes the infusion rate (μmol kg-1 min-1), V is the distribution volume for palmitate 
(40 ml kg
-1
), C1 and C2 are the palmitate concentration (mmol l
-1
) at times 1 (t1) and 2 (t2), 
respectively, and E1 and E2 are the plasma palmitate enrichments (TTR) at times t1 and t2, 
respectively. 
13
CO2 production (Pr
13
CO2; mol min
-1
) from the infused palmitate tracer was 
calculated as: 
Pr
13
CO2 = (TTRCO2
 
X VCO2)/(k) 
where TTRCO2 is the breath 
13
C/
12
C ratio at a given time point, k is the volume of 1 mol of 
CO2 (22.4 l mol
-1
). 
Plasma palmitate oxidation (Rox; mol min
-1
) can subsequently be calculated as: 
Rox palmitate = Rd palmitate x (Pr
13
CO2/F x 16) 
where Rd palmitate is the rate of disappearance of palmitate (mol min
-1
), F is the palmitate 
infusion rate (mol min 
-1
) and 16 is the number of carbon atoms in palmitate. Total plasma 
FFA oxidation was calculated by dividing palmitate oxidation rate by the fractional 
contribution of plasma palmitate to total plasma FFA concentration. 
The contribution of plasma FFA oxidation to total fat oxidation was determined by assuming 
that the molecular mass of triglyceride is 860gmol
-1
 and every TG molecule contains three 
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fatty acids. The contribution of other fat sources was hence calculated by subtracting plasma 
FFA oxidation from total fat oxidation. 
Insulin sensitivity during the clamp was calculated using the equation 
SIClamp = M/(G × ΔI) 
where M is normalized for G (steady-state blood glucose concentration;mmol
-1) and ΔI 
(difference between fasting and steady-state plasma insulin concentrations, mUl-1). 
 
5.2.11 Power Calculations 
The repeated measures coefficient of variation for the insulin clamp technique is 10%; 
therefore a 15-20% difference in insulin sensitivity should be able to be detected in 7 
participants. Therefore the aim was to recruit 10 volunteers for each group (older lean, older 
overweight and young lean) to allow for a 30% dropout. Both older lean and overweight 
volunteers were subsequently investigated for the effects of carnitine on muscle metabolism 
and insulin sensitivity (Chapter 6).   
3.2.12 Statistical analysis 
Values presented in text, tables and figures are expressed as mean ± the standard error of 
mean (s.e.m). Analyses were performed using the statistical program (GraphPad Prism 6.0, 
GraphPad Software Inc, USA) to detect differences between the three groups at rest using a 
one-way ANOVA and within and between groups during exercise using a two-way ANOVA 
(time and treatment factors). When a significant effect was observed, Tukey’s and Sidak’s 
post-hoc test was performed, respectively, to identify individual differences. Statistical 
significance was set at P<0.05. 
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3.3 Results 
3.3.1 Participant Characteristics 
10 participants for each group were initially recruited (20 older and 10 young); however there 
were a total of 6 and 3 drop-outs from the older and young groups respectively, due to several 
reasons (Appendix 1).  Table 3.1 shows characteristics of study participants.  Body mass, 
body mass index (BMI) and lean body mass (LBM) were not different in older lean and 
young groups at baseline. When total body fat mass was divided into regions, older 
overweight (OO) had higher mean BMI and body mass, greater trunk, arm and leg fat mass 
compared with older lean (OL) and young lean (YL) participants (Figure 3.1). HOMA-IR 
was also greater in OO than OL (P<0.001). Both OO and OL were well-matched in terms of 
age and both absolute (ml/min) and relative (ml/kg LBM/min) VO2max. OO and OL 
achieved lower absolute and relative VO2max and corresponding 50%VO2max workloads 
compared to YL. Self-reported habitual physical activities were similar between the young 
and older lean participants and lower in older overweight compared to older lean (P<0.001).   
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Table 3.1: Characteristics of Participants 
 Young lean Old lean Old overweight 
n 7 7 7 
Age (y) 21.5 ± 1.0 69.7 ± 0.9
+++
 68.6 ± 0.8
***
 
Statin use (n) 0 3 4 
Body mass (kg) 71.8±3.6 70.3±2.4 86.3±1.8***,††† 
BMI (kg/m
2
) 22.4 ± 0.7 24.0 ± 0.6 29.0 ± 0.7
***,†††
 
Fat free mass (kg) 55.9 ± 3.2 51.3 ± 1.5 55.6 ± 1.9 
Arm lean mass (kg) 7.6 ± 0.4 6.7 ± 0.3 7.4 ± 0.3 
Leg lean mass (kg) 21.8 ± 0.4 18.3 ± 0.6 19.6 ± 0.7 
Trunk fat mass (kg) 4.6 ± 0.8 7.2 ± 1.1 16.0 ± 0.8
***,†††
 
Arm fat (kg) 0.9 ± 0.1 1.5 ± 0.2 2.6 ± 0.3
***,†††
 
Leg fat (kg) 4.7 ± 0.4 4.9 ± 0.4 7.4 ± 0.6
†
 
Fasting glucose (mmol/L) 4.5±0.1 4.7±0.1 5.0±0.1* 
Fasting insulin (mIU/L) 10.6±1.4 7.4±1.6 12.6±1.2† 
HOMA IR 2.14 ± 0.32 1.60 ± 0.36 2.81 ± 0.25
†††
 
VO2max (l/min) 3.19 ± 0.19 2.26 ± 0.15
+++
 2.19 ± 0.13
***
 
VO2max (ml/kg LBM/min) 57.4 ± 2.4 43.8 ± 1.9
+++
 39.9 ± 1.5
***
 
Workload at 50% VO2max 
(W) 
93.0 ± 5.9 55.9 ± 5.8
+++
 46.3 ± 6.7
***
 
Heart rate at 50% VO2max 
(beats/min) 
137 ± 2 102 ± 7
+++
 102 ± 6
***
 
Physical activity frequency 
(occasions/week)  
3.5 ± 0.5  5.1 ±  1.2 1.8 ± 0.7
†††
 
Incremental shuttle walk test 
(ISWT) (m) 
 622.9±16.1 498.6±23.2††† 
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One-Way ANOVA with Tukey post-hoc test apart from unpaired t-test for ISWT 
All values (n=7) are means ± standard error of mean (SEM).*P<0.05, ***P<0.001, Old overweight 
different to corresponding Young lean value. 
†
P<0.05, 
†††
P<0.001, Old overweight different to 
corresponding Old lean value. 
+++
P<0.001, Old lean different to corresponding Young lean value. 
 
 
 
Figure 3.3: Insulin sensitivity index of young lean (n=7), old lean (n=7) and old overweight 
(n=7). 
+
P<0.05 different to Old lean value, **P<0.01 different toYoung lean value.    
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Figure 3.4: Steady state glucose disposal rates during the resting hyperinsulinaemic 60mu m
-
2
min
-1
 euglycaemic clamp in Young lean (n=7), Old lean (n=7) and Old overweight (n=7) 
participants. *P<0.05 different to Young lean value. 
 
Figure 3.5: Steady state serum insulin concentrations during the hyperinsulinaemic 60mu m
-
2
min
-1
 euglycaemic clamp in Young lean (n=7), Old lean (n=7) and Old overweight (n=7) 
participants. 
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Figure 3.6: 2DG6P uptake in skeletal muscle during steady state of the hyperinsulinaemic 
60mum
-2
min
-1
 euglycaemic clamp in Young lean (n=7), Old lean (n=7) and Old overweight 
(n=7) participants. **P<0.01 different to Young lean value. 
 
 
 
Figure 3.7: Plasma 2DG during the resting 3hr hyperinsulinaemic 60mu m
-2
min
-1
 
euglycaemic clamp in young lean (n=7), old lean (n=7) and old overweight (n=7) 
participants. *P<0.05, ** P<0.01, Old overweight different to corresponding Young lean 
value. 
+
P<0.05, 
++
P<0.01, Old overweight different to corresponding Old lean value.  
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Figure 3.8: Resting energy expenditure pre and post insulin during the 3 hr 
hyperinsulinaemic 60mu m
-2
min
-1
 euglycaemic clamp in Young lean (n=7), Old lean (n=7) 
and Old overweight (n=7) participants. *P<0.05, Old overweight different to corresponding 
Young lean value. ^P<0.05, ^^P<0.01, different to corresponding pre-insulin values.  
 
Figure 3.9: Relative contribution of carbohydrate (COX) and fat (FOX) oxidation rates to 
total resting energy expenditure during the 3 hr hyperinsulinaemic 60mu m
-2
min
-1
 
euglycaemic clamp in Young lean (n=7), Old lean (n=7) and Old overweight (n=7). 
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3.3.2 Insulin sensitivity 
Fasting glucose was greater in OO (5.0±0.1 mmol/L; P<0.05) than YL (4.5±0.1 mmol/L; 
P<0.05), with a trend of this being greater than OL (4.7±0.1 mmol/L; P=0.07), Table 3.1.  
Whilst there was no difference in fasting insulin concentrations between OO (12.6±1.2 
mIU/L) and YL (10.6±1.4 mIU/L), OO had greater fasting insulin concentration than OL 
(7.4±1.6 mIU/L; P<0.05), Table 3.1. 
Matsuda’s Insulin Sensitivity Index (SI) was similar between YL (0.13±0.01) and OL 
(0.11±0.01; P<0.05) and both groups in turn have greater SI than OO (0.07±0.01; P<0.01 in 
YL, P<0.05 in OL); Figure 3.3.  
Insulin sensitivity as determined from glucose disposal rates via the 3 hr hyperinsulinaemic 
60mU m
-2
min
-1
 euglycemic clamp at rest in OO was lower than OL and YL (41.6 ± 5.3 µmol 
kg lbm
-1
 min
-1
 vs. 57.8 ± 5.9 µmol kg lbm
-1
min
-1
; P<0.05 and 65.2 ± 5.6 µmol kg lbm
-1
min
-1
, 
P<0.01; respectively), Figure 3.4. 
Steady-state mean serum insulin levels during the clamp did not differ between groups; 
Figure 3.5. The accumulation of 2DG6P in skeletal muscle was greater by two-fold in YL 
compared with OO during the glucose clamp (91.2 vs. 38.2 µmol kg
-1
 wet muscle; P<0.01) 
but not different in OL; Figure 3.6 
Steady –state mean plasma 2DG concentrations during the 3 hr insulin clamp were greater in 
OO compared to OL and YL (72.6 ± 2.2 vs. 50.0 ± 1.9 and 48.8 ± 2.2 µmolL
-1
; P<0.05) 
respectively; Figure 3.7. 
Insulin stimulated energy expenditure increased at rest from 94.0 to 105.0 J kg lbm
-1
min
-1
 
(P<0.05) and from 90.5 to 102.4 J kg lbm
-1
min
-1
 (P<0.01) in YL and OL respectively, but not 
in OO; Figure 3.8.  However there was no difference in the relative contribution of 
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carbohydrate (COX) and fat (FOX) oxidation rates to total resting energy expenditure during 
the 3 hr hyperinsulinaemic 60mu m
-2
min
-1
 euglycaemic clamp; Figure 3.9. 
3.3.3 Muscle Phenotype  
3.3.3.1 IMCL volume and droplets in the SSL and IMF regions  
At rest the percentage area of SSL region of skeletal muscle covered by lipid droplets in OO 
was almost 3-fold greater compared with YL (4.29 ± 1.23% vs. 1.43 ± 0.19%; P<0.05) and 
there was a tendency for a 2- fold greater percentage area covered by lipid in OO than OL 
(4.29 ± 1.23 vs. 1.99 ± 0.45%; P=0.06) respectively (Figure 3.10). SSL lipid area in OO was 
also greater than YL (P<0.01) and OL (P<0.05) post-exercise, predominantly due to a 25% 
increase in mean SSL lipid size (Figure 3.11). In contrast there was no difference in the 
percentage area of IMF fibre covered by droplets between groups; Figure 3.12. The 
percentage of IMF fibre area covered by lipid droplet during exercise decreased by 40% in 
YL (0.05; Figure 3.13). Average IMF LD size was 45% greater in OO compared to OL and 
YL post-exercise (both P<0.01; Figure 3.14).  
 
3.3.3.2 Post-exercise skeletal muscle lipid content 
Post exercise the percentage area of SSL covered by lipid droplets in OO was almost 3-fold 
compared with YL (5.06 ± 0.96 vs. 1.26 ± 0.27%; P<0.01) respectively and more than 2-fold 
compared with OL (5.06 ± 0.96 vs. 2.05 ± 0.26%; P<0.05); Figure 3.10. This was associated 
with an increase in lipid droplet size in OO (0.40 ± 0.06 to 0.50 ± 0.07 µm
2
; P<0.05) but not 
in OL or YL; Figure 3.11. A decrease in the percentage of IMF area covered by droplets was 
seen after exercise in YL (0.65 ± 0.11 to 0.40 ± 0.09%; P<0.05) but not in OL or OO; Figure 
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3.12. A reduction in droplet number in OO was seen (23.1 ± 3.8 to 16.7 ± 2.7; P<0.05). 
Average droplet size remained unchanged post-exercise across the groups; Figure 3.13.  
 
 
Figure 3.10: SSL lipid droplet % fibre area in young lean (n=7), old lean (n=7) and old 
overweight (n=7) pre and post-exercise. *P<0.05, ** P<0.01, Old overweight different to 
corresponding Young lean value. 
†
P<0.05, Old overweight different to corresponding Old 
lean value. ^P<0.05, different to corresponding pre exercise value. 
140 
 
 
Figure 3.11: Average SSL lipid droplet size per fibre area in young lean (n=7), old lean 
(n=7) and old overweight (n=7) pre and post-exercise. ** P<0.01, Old overweight different to 
corresponding Young lean value. 
†
P<0.05, 
††
P<0.01, Old overweight different to 
corresponding Old lean value.  
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Figure 3.12: Intramyofibrillar lipid droplet percentage fibre area in Young lean (n=7), Old 
lean (n=7) and Old overweight (n=7) pre and post-exercise. ^P<0.05, different to 
corresponding pre exercise value. 
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Figure 3.13: Average intramyofibrillar lipid droplet size per fibre area in Young lean (n=7), 
old lean (n=7) and Old overweight (n=7) pre and post-exercise. *P<0.05 different from 
corresponding values in Young lean and Old lean values. 
3.3.3.3 Skeletal muscle lipid metabolites 
There was no difference in skeletal muscle DAG species apart from diC18:1, which was 
greater in OO compared to OL and YL (42.6 ± 3.3 vs. 29.8 ± 4.2 and 29.4 ± 3.0 ug mg
-1
 
protein; P<0.05) respectively; Figure 3.14. There was also no difference in the skeletal 
muscle ceramide content with the exception of C20:0, which was greater in OO compared to 
YL (0.49 ± 0.03 vs. 0.31 ± 0.02ug mg
-1
 protein; P<0.01); Figure 3.15. DAG and ceramide 
analyses were carried out in only 7 OO vs. 5 OL and YL participants who had sufficient 
muscle samples for analyses.  
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Figure 3.14: DAG species of resting skeletal muscle in Young lean (n=5), Old lean (n=5) and 
Old overweight (n=7). *P<0.05 vs. Young lean, 
† 
P<0.05 vs. Old lean. 
 
Figure 3.15: Ceramide species of resting skeletal muscle in young lean (n=5), old lean (n=5) 
and old overweight (n=7). *P< 0.05 vs. corresponding young lean values. 
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3.3.3.4 Citrate synthase (CS) and CPT-1 activity 
There was a trend of lower CS activity in OO compared to OL (96.8 vs. 125.2 mmol
-1
mg 
protein min
-1
; P=0.08) respectively. There was no difference in CPT-1 activity (1.84 ± 0.19, 
2.05 ± 0.12 and 2.58 ± 0.28 % of CS activity, respectively) between YL, OL and OO, 
respectively; Figures 3.16A and B. 
 
Figures 3.16A and B: Citrate synthase and CPT activity analyses from muscle of Young lean 
(n=7), Old lean (n=7) and Old overweight (n=7).  
 
3.3.4 Exercise fuel metabolism  
There was no difference in the relative contribution of total fat to total energy expenditure 
during exercise at 50% VO2max between OO, OL and YL (40.0 ± 4.6 vs. 42.4 ± 3.1 and 43.9 
± 7%, respectively; Figure 3.17). Other fat oxidation (IMCL) was greater in YL (199.0 ± 
36.4J kg lbm
-1
 min
-1
) compared to OL and OO (76.7±13.9 and 73.8 ± 13.1 J/kg lbm min
-1
; 
P<0.05) respectively. Energy expenditure was greater in YL compared to OL and OO 
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(622.2±37.7 vs. 498.0±32.4 and 439.2±41.1 J kg lbm-1 min-1; P<0.05) respectively. There was no 
difference in the relative contribution of carbohydrate oxidation during exercise at 50% VO2 max 
between groups. The difference between plasma fatty acid rate of disappearance and 
oxidation rates was also not different between OO, OL and YL (8.01 ± 1.62, 7.30 ± 1. 17 and 
4.97 ± 1.02 µmol kg lbm
-1
min
-1
) respectively; Figure 3.18A. Similarly there was no 
difference in palmitate oxidation rates across the groups, 1.34±0.21, 2.16±0.29 and 2.06±0.49 
µmol/kg/min in OO, OL and YL respectively; Figure 3.18B.    
 
3.3.5 Exercise IMCL utilisation   
The relative contribution of IMCL to total fat oxidation in OO and OL was lower than that of 
YL (45.0 ± 7.9 and 38.7 ± 7.7 vs. 71.9 ± 3.3% respectively; P<0.01 Figure 3.17). 
 
Figure 3.17: Total energy expenditure and relative contribution of fat and other fat (IMCL) 
to energy expenditure during 1 hour 50% VO2 max exercise in young lean (n=7), Old lean 
(n=7) and Old overweight (n=7). **P<0.01 vs.corresponding Young lean values (total energy 
expenditure). 
++
 P<0.01 vs. corresponding Young lean values (other fat).   
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Figures 3.18A and B: Plasma FFA rate of disappearance (Rd) and contribution of fat 
oxidation (A) and palmitate oxidation (B) during 1 hr exercise at 50%VO2 max in Young 
lean (n=7), Old lean (n=7) and Old overweight (n=7).  
3.3.6 Exercise systemic metabolism  
From similar baseline concentrations, plasma noradrenaline rose to a similar steady-state in 
OL and OO throughout 1 hr of exercise, and was around 1.5-fold greater than the steady-state 
concentration achieved in YL (both P<0.05 respectively; Figure 3.19). There was no 
difference in plasma adrenaline between groups at baseline, however at steady state OL and 
YL have greater levels than OO (0.79 ± 0.23 and 0.74 ± 0.10 nmol/L vs. 0.58 ± 0.16, P<0.05; 
respectively, Figure 3.20).  
Steady state plasma FFA concentrations were greater in the older group (both OO and OL) 
compared to YL, P<0.05; Figure 3.21. Blood lactate concentrations initially increased in the 
first 10 minutes of exercise (0.71 ± 0.06 to 1.50 ± 0.29, 0.97 ± 0.13 to 2.05 ± 0.31, and 0.87 ± 
0.09 to 1.73 ± 0.28 mmol/L in OL, OO and YL respectively. During steady state, plasma 
lactate concentration in OO was greater than of OL and YL, P<0.05; Figure 3.22). 
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Figure 3.19: Plasma noradrenaline during 1 hr exercise at 50%VO2 max in young lean (n=7), 
old lean (n=7) and old overweight n=7). ** P<0.01, Old overweight different to 
corresponding Young lean value. 
+
P<0.05, 
++
P<0.01, Old lean different to corresponding 
Young lean value. 
 
Figure 3.20: Plasma adrenaline during 1 hr exercise at 50%VO2 max in Young lean (n=7), 
Old lean (n=7) and Old overweight (n=7) 
ф
P<0.05, Old overweight different to corresponding 
Old lean value. *P<0.05, Old overweight different to corresponding Young lean.   
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Figure 3.21: Plasma FFA concentrations during 1 hr exercise at 50%VO2 max in Young lean 
(n=7), Old lean (n=7) and Old overweight (n=7). **P<0.05 in Old lean compared to 
corresponding old overweight values, ^^P<0.05 in Young lean compared to corresponding 
old overweight values. 
 
 
Figure 3.22: Plasma lactate during 1 hr 50%VO2 max exercise in Young lean (n=7), Old lean 
(n=7) and Old overweight (n=7), *P<0.05 Young lean and Old lean compared to 
corresponding Old overweight values.   
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3.3.7 Exercise muscle metabolism 
OO had the lowest resting skeletal muscle glycogen content compared to OL and YL (235.7 
± 22.6 vs. 329.7 ± 29.3 and 316.5 ± 22.9 mmol kgdm
-1
; P<0.05) respectively, Figure 3.23. 
There was a trend of an increase in skeletal muscle glycogen content in YL post exercise 
(231.8 ± 37.8 to 316.5 ± 22.9 mmol kgdm
-1
, P=0.09. There were no differences post-exercise 
in OL and OO (288.6 ± 48.3 to 329.7 ± 29.3 and 228.6 ± 42.0 to 235.7±22.6 mmol kgdm
-1
) 
respectively.  
Skeletal muscle acetylcarnitine content increased in YL and OL post-exercise (YL 1.7 ± 0.4 
to 4.8 ± 1.1; P<0.05, OL 1.0 ± 0.2 to 7.5 ± 1.5 mmol kgdm
-1
; P<0.01, respectively) Figure 
3.24. 
Skeletal muscle Pcr content was lower in OO compared to OL and YL at rest (60.1±5.1 vs. 
75.4 ± 2.4; *P<0.05 and 75.5 ± 2.6 mmol kgdm
-1
; 
†
P<0.05) respectively and this was also 
seen post-exercise (58.9 ± 5.4 vs. 73.7 ± 4.2, *P<0.05 and 77.6 ± 3.7 mmol kgdm
-1
; 
†
P<0.05) 
respectively, Figure 3.25.  
Skeletal muscle lactate content more than doubled in OO (4.6±1.1 to 11.1 ± 1.3 mmol kgdm
-
1
; P<0.05) post-exercise compared to corresponding value pre-exercise, Figure 3.26. 
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Figure 3.23: Skeletal muscle glycogen content pre- and post-exercise at 50%VO2 max in 
young lean (n=7), old lean (n=7) and old overweight (n=7).  
 
Figure 3.24: Skeletal muscle acetylcarnitine content pre and post exercise at 50%VO2 max in 
young lean (n=7), old lean (n=7) and old overweight (n=7). ^P<0.05, ^^^ P<0.001 vs. 
corresponding pre-exercise values.  
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Figure 3.25: Skeletal muscle phosphocreatinine content pre and post exercise at 50% VO2 
max in young lean (n=7), old lean (n=7) and old overweight (n=7). *P<0.05, Old overweight 
different to corresponding Young lean value. †P<0.05, Old overweight different to 
corresponding Old lean value.  
 
Figure 3.26: Skeletal muscle lactate content pre and post exercise at 50% VO2 max in young 
lean (n=7), old lean (n=7) and old overweight (n=7). ^P<0.05 vs. corresponding pre exercise 
value.  
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Table 3.4: Summary of differences between young lean, old lean and old overweight healthy 
males pre-intervention (Week 0). 
 Young lean 
(n=7) 
Old lean 
 (n=7) 
Old overweight  
(n=7) 
Body fat Low Low High 
BMI Low Low High 
VO2 max High Low Low 
Physical activity levels (based 
on  self-reported activity levels) 
Moderate to 
high 
Moderate to high Low to moderate 
EE upon insulin stimulation at 
rest 
Increased Increased Unchanged 
Relative contribution of total fat 
oxidation to EE during light-
intensity exercise 
Similar Similar Similar 
Relative fatty acid oxidation 
rates during light-intensity 
exercise 
 Lower compared to 
young lean  
Lower compared to 
young lean 
IMCL utilisation during exercise  Lower compared to 
young lean 
Lower compared to 
young lean 
SSL Lipid accumulation post-
exercise 
Unchanged Unchanged Increased 
IMF Lipid accumulation post-
exercise 
Decreased Unchanged Unchanged 
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3.4 Discussion  
 
Ageing may be influenced by various factors in its association with a decline in insulin 
sensitivity. This study demonstrated differences in body composition, VO2 max, substrate 
oxidation at rest and exercise, skeletal muscle metabolism and lipid content between the older 
and young groups. Self-reported physical habitual activities were similar between young and 
old lean, but lower in old overweight groups. This study supports the notion that skeletal 
muscle insulin sensitivity is reduced in older people compared to young, with greater insulin 
resistance in the older overweight compared to older and young lean, and is associated with 
reduced IMCL utilisation during light-intensity exercise. This suggests a discordant reduction 
in muscle fat oxidation, as FFA availability and uptake were not limiting, resulting in an 
increase in muscle lipid accumulation particularly in the SSL region of muscle in older 
overweight people.  This is not entirely due to age per se, but associated with accumulation of 
fat mass and possibly activity levels. Skeletal muscle insulin resistance also appears to be 
associated with lipid accumulation in the SSL region. This is the first study to directly 
investigate whether IMCL oxidation is impaired during exercise in older insulin resistant 
individuals, taking into account other factors such as adiposity and physical activity. 
 
3.4.1 Body composition 
When body composition was differentiated into overweight (BMI≥26) and lean (BMI≤25), a 
difference was seen in older individuals and thus they were separated post-hoc into groups of 
older lean and older overweight.  It is well documented that changes in body composition, 
often without concomitant changes in body weight and BMI occur as part of the normal 
biology of aging (St-Onge 2005). Fat mass increases and fat-free mass decreases (Cohn et al. 
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1980, Flynn et al. 1989) in line with features of sarcopenic obesity (Prado et al. 2008) seen in 
ageing. The average male aged 65-70 has 12 kg less lean body mass than at age 25 (Forbes 
and Reina 1970). Over a 2 year follow-up study in older men, there were significant losses in 
leg muscle mass and appendicular skeletal muscle mass, calculated as the sum of arm and leg 
fat-free soft tissue (Zamboni, Zoico et al. 2003). This may be as a result of a general decline 
in physical activity with ageing, however over a three year-period, a mild but significant 
decline in muscle mass and body fat accumulation were seen in healthy old participants 
despite leisure time physical activity (Raguso 2006). Computed tomography of muscles show 
that after the age of 30, there is a decrease in cross-sectional area of the thigh and density 
associated with increased intramuscular fat (Borkan et al. 1983). Although the exact 
underlying cause is not known, it would appear that there may be other mechanisms 
including physical inactivity that promotes accumulation of lipid and/or reduction in fat 
oxidation with ageing. Moreover, this study has shown reduced insulin sensitivity levels in 
older overweight compared to older and young lean subjects. Older overweight subjects also 
reported lower physical activity time per week.  
3.4.2 Maximal oxygen consumption (VO2 max) 
Older partipants recruited to the study achieved lower maximal oxygen consumption (VO2 
max) than young participants during the incremental exhaustive exercise test regardless of 
body composition or physical activity levels. This study demonstrated around a 40% 
difference in mean VO2 max levels between older and young in concert with evidence 
supporting a 10% per decade decline in VO2 max in men and women (Heath et al. 1981) 
irrespective of activity level (Hawkins and Wiswell 2003). This age-related decline may be 
due to adaptations of the body to cardiovascular (reduction in maximal heart rate) and body 
composition changes (lean body mass reduction) (Hawkins and Wiswell 2003) and decrease 
in vigorous physical activity (Rosen, Sorkin et al. 1998).    
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In a longitudinal study based on the Baltimore Longitudinal study in ageing (Flegg and 
Laketta 1988), peak VO2 max decelerated with each increasing decade particularly after the 
age of 70. Although greater levels of habitual physical activity increase the absolute peak 
V̇O2 at any age, this does not appear to prevent the accelerated decline with advancing age. 
Functional capacity as assessed by ISWT in this study revealed a distinct difference between 
older lean and older overweight with shorter distances walked by overweight men. This 
demonstrates that ageing per se does not influence functional capacity as much as adiposity 
or body composition. 
 
3.4.3 Insulin sensitivity  
A modest increase in mean fasting plasma glucose of 1mg/dL (0.1mmol/L) is seen per decade 
(Davidson 1979). Using the hyperinsulinaemic euglycaemic clamp in the present study there 
was a significant difference (p<0.01) in glucose disposal rates between older and young 
participants. A significant difference in fasting insulin sensitivity index was also seen 
between older and young participants (higher fasting glucose but similar fasting serum insulin 
levels). When divided into older overweight, older lean and young lean, insulin sensitivity 
index was lowest in the older overweight, followed by older lean and young lean. Although 
there are numerous studies on ageing and insulin resistance, there are not as many studies 
cited in literature that have primarily evaluated and compared glucose disposal rates in older 
and young healthy volunteers using the hyperinsulinaemic euglycaemic clamp, and even 
fewer have examined the difference on older participants based on body composition. Older 
volunteers were shown to have 30% lower mean glucose disposal rates compared to young 
despite similar serum insulin levels at steady state. In line with the development of sarcopenic 
obesity in ageing, it is unclear if the increasing glucose intolerance in aging is caused by an 
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age-related decline in muscle mass or fat regional distribution, or indeed whether the 
increasing insulin resistance in ageing contributes to functional decline of muscle. The insulin 
infusion or glucose disposal rates were based on lean body mass in all groups. One of the 
more pertinent studies utilising the insulin clamp showed that glucose disposal rates were 
significantly decreased by 30-35% in the elderly group compared with the non-elderly group 
at all steady state plasma glucose concentrations at a fixed insulin concentration
 
(Fukagawa, 
Minaker et al. 1988). However body composition was not analysed in greater detail. The 
authors concluded that the reduced insulin sensitivity was due to a reduction in the maximal 
capacity of glucose utilization with aging. Glucose and protein homeostatic responses to 
different insulin infusion rates during a euglycaemic clamp showed lower glucose disposal 
rates adjusted for lean body mass in elderly men compared to young at all infusion rates apart 
from the highest rate (400mU/m
2
/min)(Krebs and Roden 2005). The effect of non-insulin-
mediated glucose disposal (which is responsible for the majority of basal glucose uptake) was 
examined in old versus young healthy men using a euglycaemic clamp and showed a 
significantly lower glucose disposal in older men at baseline (Meneilly, Elahi et al. 1989) 
This may translate to why fasting glucose increases with age.   
Another plausible cause for the observed reduced glucose disposal rates in older people could 
be explained by skeletal muscle insulin resistance, as this increase with age through the 
accumulation of IMCL and associated metabolites and altered muscle mitochondria. Skeletal 
muscle acts as a pool for insulin-mediated glucose uptake so it would be reasonable to 
hypothesise that perturbations to muscle such as changes seen with ageing would affect 
glucose uptake and thus insulin sensitivity. Indeed skeletal muscle uptake of 2DG was 
greatest in young, followed by old lean and old overweight.  
 
157 
 
3.4.4 Substrate oxidation at rest under fasting and insulin-stimulated conditions 
At rest and under fasting conditions there was no significant difference between older and 
younger volunteers with regards to carbohydrate and fat oxidation rates and respiratory 
exchange ratios (RER). There was a trend towards increased energy expenditure in the 
younger group when expressed per kg lean mass. Upon insulin stimulation, carbohydrate 
oxidation rates increased significantly and a trend towards a rise in RER was seen in younger 
participants. A trend towards an increase in carbohydrate oxidation was seen in the older 
group whilst no changes were seen in fat oxidation rates, RER and energy expenditure.  
The effect of insulin on carbohydrate oxidation at baseline was significant in younger 
participants compared to older participants, with younger individuals achieving a relative 
13% increase in carbohydrate oxidation compared to older individuals. Studies examining 
substrate oxidation in ageing tended to focus on the effects of diet and physical 
activity.(Davy, Horton et al. 2001; Melanson, Donahoo et al. 2007). Of the few pertinent   
studies concerning fat oxidation in the fasting state, some have shown a decline (Calles-
Escandon et al. 1995) and an increase in fat oxidation with ageing (Bonadonna et al. 1994). 
A possible reason for the inconsistencies may lie with the influence of body composition. 
Melanson et al. 1997 observed no significant effects of age per se on fasting fat oxidation, but 
a significant negative effect of body fat was seen when the best-fitting regression multiple 
analysis was applied. Others supporting this observation have shown low basal fat oxidation 
rates in older obese individuals and that oxidation rates are altered with changes in body 
composition (Wohl, Girman et al. 2004). In the post-prandial state, lower fat oxidation rates 
were seen in elderly women following a moderately large meal (Melanson et al. 1998). The 
blunted response of energy expenditure to insulin stimulation observed in older participants 
in this study is in concordance with data seen in that of T2DM (van de Weijer, Sparks et al. 
2013). In insulin resistant individuals, capacity to increase skeletal and whole body glucose 
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oxidation and storage during the clamp is impaired with little or no change in respiratory 
quotient (RQ) (van de weiger 2013, Rowe, Minaker et al. 1983; Kelley and Mandarino 2000).  
The lower mean glucose disposal rates and impaired substrate utilization upon insulin 
stimulation in older overweight participants shown in this study imply that insulin sensitivity 
is impaired in overweight and obese individuals. As skeletal muscle accounts for the majority 
of insulin-mediated disposal of glucose (under hyperinsulinaemic clamp conditions) (De 
Fronzo et al. 2009), perturbations to this tissue may aggravate insulin resistance. 
Mitochondrial abnormalities impair lipid oxidation and consequently increase lipid 
accumulation in  muscle (Boden, Chen et al. 1994). This imbalance further impairs insulin 
signalling and increases lipotoxic intermediates leading to a decline in glucose uptake in 
muscle (Randle et al. 1963, Defronzo 2004, Kashap et al. 2003, Schrauwen et al. 2010). 
Impaired in vivo mitochondrial function has also been shown to be the single most important 
predictor of basal RER, in contrast insulin-stimulated RER was largely influenced by glucose 
disposal rate suggesting that mitochondrial capacity mainly affects basal substrate utilization 
but does not necessarily impact on skeletal muscle to switch substrates.  
 
3.4.5 Skeletal muscle lipid 
Studies of the role of IMCL subcellular fractions and distribution of important muscle 
determinants of insulin sensitivity such as lipid, mitochondria, glycogen and nuclei are 
extremely limited. Post-exercise, the overweight and older lean participants in the present 
study showed a 3-fold and a trend towards a 2-fold accumulation of lipid in the SSL region of 
muscle, respectively. Greater IMCL accumulation in this region in older people during 
exercise has been attributed to a need for rapid energy source in conditions of continuous 
supply of lipid (Skovbo et al. 2008). If unaccompanied by a concomitant rise in fat oxidative 
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capacity, as seen in conditions of insulin resistance this may result in a surplus and thus 
overspill of lipid in muscle. In a pertinent study evaluating lipid content of skeletal muscle in 
ageing, older men exhibited larger number of IMCL droplets in total muscle area, greater 
IMCL content in the SSL region, lower number of mitochondria, and reduced number of lipid 
droplets in contact with mitochondria at rest (Blaak and Wagenmakers 2002). The findings in 
this study also reflect that seen in people with T2DM who showed a 3- fold higher volume of 
lipid in the subsarcolemmal region and similar volume density of IMF lipids in the pre-
training state compared with BMI-matched control subjects and highly endurance-trained 
subjects. Endurance exercise halved lipid content in the SSL region but no differences in IMF 
lipids among groups were found (Nielsen et al. 2010). One of the novel findings of the 
present study is that lipid was found to accumulate to a greater extent in the SSL regions of 
muscle in older people, albeit older overweight during light-intensity exercise and this is 
likely as a result of blunting of IMCL oxidation capacity. Figure 3.8A shows reduced relative 
IMCL (other fat) to total fat oxidation during exercise in older overweight compared to older 
lean and young subjects. This was despite similar self-reported activity levels. Over a period 
of time this may affect skeletal muscle insulin sensitivity as a result of increasing IMCL 
stores (Krssak et al. 1999, Pan et al. 1997).  In healthy young individuals, IMCL depots have 
been shown to decrease in response to acute exercise (Nielsen et al. 2000), but very little is 
known of the effects of exercise on IMCL depots in older individuals. Lipid flux in the SSL 
regions appears to depend on the degree of uptake and oxidation of fat as aerobic training 
decreased SSL content of people with T2DM by almost two-fold, approaching levels 
observed in normal healthy controls (Ritov et al. 2005). Moreover there was a strong inverse 
relationship between pre-training levels of SSL lipid and insulin sensitivity in these subjects. 
Taken together this demonstrates an abnormality of SSL lipid accumulation in T2DM, and 
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this could also be an important factor contributing to the regulation of skeletal muscle insulin 
sensitivity in otherwise healthy older people.  
Compartmentalisation of muscle into distinct regions has further enabled examination of 
physiological differences between IMF and SSL content including the localisation of key 
proteins involved in the insulin signalling pathways and metabolism. Changes in 
mitochondrial content (Ritov et al. 2005, Happelar et al. 2003), GLUT-4 vesicle translocation 
(Lauritzan et al. 2008) and glycogen metabolism (Marchand et al. 2007) appear to be 
location-dependent in response to stimuli such as endurance training (Marchand et al. 2007) 
and diets (Lauritzan et al. 2008). Likewise it could also be that there is a predilection for 
particular lipid intermediates such as DAG or ceramide species to accumulate in the SSL 
region, so causing a deleterious effect on insulin signalling pathways. However studies on the 
effect of lipid metabolites on insulin sensitivity are limited and have yielded inconsistent 
findings and not many have investigated its effect on insulin sensitivity in older people. 
Whilst lipid infusion studies have provided insights into IMCL accumulation and its effect on 
insulin-signalling pathways (Hoy et al. 2009), others have shown that it may not be IMCL 
per se affecting insulin sensitivity but  increased lipid metabolites (DAGs, acyl-coA, 
ceramides) causing insulin resistance (Adamas et al. 2004, Moro et al. 2009, Coen et al. 
2010).  This study did not show a difference in total DAG or ceramide content between old 
and young, pre and post exercise, but DAG species C18:1 and ceramide species C20:0 were 
elevated in the older overweight. The significance of this is uncertain and may not entirely 
explain the difference in insulin-sensitivity in older overweight, older lean and young. In 
contrast to other studies showing either higher total intramyocellular DAG content or low 
ceramide content associated with higher insulin sensitive muscle (Dube et al. 2011), total 
DAG content in the present study was comparable between the groups despite greater glucose 
disposal rates in young subjects. This could be because that only certain DAG moieties are 
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associated with insulin sensitivity or that DAG and ceramide are not the primary 
determinants of lipid metabolites that cause insulin resistance in old muscle. This is in accord 
with other studies where similar ceramide content were seen regardless of differing insulin 
sensitivities of obese, lean and endurance trained subjects. Aerobic capacity did not appear to 
influence muscle ceramide content in these groups (Pan et al. 1997).  
As fatty acid availability or beta-adrenergic stimulation in both older lean and overweight 
subjects were not limiting the reduction in skeletal muscle fat oxidation may be the result of 
an age-related decline in the capacity of skeletal muscle to oxidize fatty acids at the expense 
of lipid being diverted to greater lipid storage in muscle. Factors implicated with this decline 
include diminished content of muscle oxidative enzymes and capacity, possible 
adrenergically-mediated reduced activation of fatty acid transport, increased glycolytic flux 
inhibiting fatty acid transport into mitochondria (van Loon et al. 2005) and reduction in the 
number and skeletal muscle content of mitochondria (Crane et al. 2010, Blaak et al. 2000). 
This may, over time have a deleterious effect on muscle mass and metabolism, leading to a 
progressive decline in muscle metabolite function. These changes may eventually contribute 
to the development of a decline in muscle mass, strength and increase in body fat content in 
line with sarcopenia and skeletal muscle insulin resistance. Endogenous carbohydrate 
oxidation rates during the 50% VO2 max exercise were not dissimilar between the groups. 
However during exercise, there was little muscle glycogen use and a trend towards an 
increase in muscle lactate accumulation post exercise in older overweight subjects. Other 
skeletal muscle metabolites such as muscle total creatine, acetylcarnitine and PCr were 
lowest in the older overweight. Muscle oxidative capacity as measured by citrate synthase 
activity also tended to be lower in muscle of the older overweight, although there was no 
difference in CPT-1 and CPT-2 activity. 
 
162 
 
3.4.6 Substrate oxidation during light-intensity exercise 
No difference in relative contribution of total fat to total energy expenditure during exercise 
at 50% VO2 max was seen between the groups, however the relative contribution of 
intramyocellular to total fat utilisation in older overweight men was lower than that of older 
lean and young men despite increased FFA availability (Figure 3.9) and greater 
catecholamine response compared to young (Figure 3.10A). The relative contribution of 
plasma FFA availability to oxidation was also lower in older individuals. Taken together, this 
suggests that IMCL and plasma oxidation are impaired in older individuals despite greater 
availability.  
The impaired total fat oxidation to energy expenditure in older people are consistent with 
findings of others. These studies did not however compare body composition and IMCL 
oxidation during exercise between participants in detail. Although fatty acid oxidation was 
lower in older compared to young healthy males during exercise performed at a similar 
relative intensity (56% of maximal VO2 max)(Sial and Coggan 1996) the rate of appearance 
(Ra) of FFA was found to be lower in older subjects.  Higher catecholamine concentration 
levels in response to exercise and meals appear to promote FFA availability (Coggan and 
Spina 1997) leading to increased 24 hour fat oxidation (Melanson 2007). Older people appear 
to have a blunted lipolytic response to FFA availability and beta-adrenergic stimulation 
(Blaak 2000), and muscle lipid are insensitive to catecholamines (Galbo et al. 1975). In this 
study, although plasma FFA Rd in older individuals was at a level that was even higher than 
in the young, the relative IMCL utilisation to total fat oxidation during exercise was lower. 
The present finding of reduced fat oxidation between old and young during exercise is in 
concert with Sial et al who examined substrate utilisation during exercise performed at 
absolute and relative intensities (Sial et al. 1996). In line with findings from the present study 
FFA availability and lipolysis were not limiting. In fact greater fatty acid flux was seen in 
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older subjects.This suggests that although fatty acid uptake can be increased, the ability to 
utilise IMCL through some unknown mechanism is impaired with ageing. This could perhaps 
be related to altered skeletal muscle metabolism.  Although no difference was seen in plasma 
fatty acid oxidation, the difference between plasma rate of disappearance and oxidation (rate 
of storage) in older subjects in this study was significant implying greater ectopic fat 
deposition, presumably in muscle; as fat serves as the primary fuel in skeletal muscle 
metabolism during low to moderate intensity exercise (Romijn 1993). It could be that healthy 
individuals muscle appear to possess the ‘flexibility’ or ability to adapt to increased fat 
delivery by  improving fat oxidation or increasing mitochondrial oxidative capacity during 
exercise training, facilitating the oxidation of fat over carbohydrate ,whereas the opposite is 
seen in insulin-resistant states.   
3.4.7 Exercise metabolism 
There is little disagreement with the major metabolic effects observed after endurance 
exercise in older people even at submaximal VO2max. These are slower utilisation of muscle 
glycogen and blood glucose, greater reliance on fat over carbohydrate oxidation and less 
lactate production during exercise at a given intensity. Skeletal muscle metabolic response  to 
exercise appear to decline with age and are thought to be due to a reduction in the number of 
mitochondria , muscle oxidative capacity, increased IMCL , increased fat mass and decline in 
physical exercise with ageing (Holloszy and Coyle 1984). However endurance and resistance 
training appear to minimise these changes. The results of the present study mostly support the 
findings of others, in particular a greater accumulation of muscle lactate and less glycogen 
utilisation during exercise in older healthy men compared to young subjects. In particular 
glycogenolysis was lowest in older overweight participants. Muscle PCr and total creatine 
were also lower in older overweight compared to young subjects.   
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The older overweight participants in this study were noted to have lower CS levels compared 
to older lean, and there was no difference between older lean and young participants. The 
mitochondrial respiratory capacity of skeletal muscle as measured by citrate synthase activity 
have been found by some to be no different in older or young individuals (Orlander et al. 
1978, Larsson et al. 1978, Grimby et al. 1982). In contrast, Essen-Gustavsson and Borges 
1986, Coggan et al. 1993 and Meredith et al. 1989 showed  lower CS activity levels in older 
compared to young individuals. This difference in findings may be because the early 
Scandinavian studies were confounded by physical activity  levels of subjects whereas the 
latter studies were in truly sedentary individuals. Thus it is unclear from these studies if 
ageing per se or the influence of physical activity affects the respiratory capacity of skeletal 
muscle.  
3.4.8 Underlying mechanisms  
Several mechanisms may explain the observed inability of old overweight men to oxidise 
excess FFA Rd.  Individuals predisposed to familial longevity were shown to have lower 
IMCL content and increased peripheral insulin sensitivity regardless of physical activity and 
body composition (Wijsman et al. 2012) and endurance-trained young lean subjects also 
accumulate IMCL (Goodpaster 2001). This suggests that in these individuals, either FFA 
levels were not elevated and/or fatty acid oxidation was not impaired. Whilst mitochondrial 
activity and function were not assessed in Wijsman’s study, muscle oxidative capacity was 
shown to be greater in insulin-sensitive endurance-trained athletes despite higher IMCL 
content (Wijsman 2012).   Compared with young, IMCL content was increased by up to 40%, 
and reduction in mitochondrial oxidative and phosphorylation activity was seen in older 
people through 
1
H Nuclear Magnetic Resonance Spectroscopy (
1
HNMRS)  (Petersen 2003) . 
However, although participants were matched in body composition habitual activity levels 
were not considered. These studies point towards impaired mitochondrial function as a cause 
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of impaired fatty acid oxidation and insulin resistance in older people. Findings elucidated 
from this study show that impairment of  IMCL oxidation and subsequent skeletal muscle 
insulin resistance may be due to perturbations to mitochondrial content and function in 
overweight or obesity as there was a trend towards lower CS, CPT-1, relative contribution of 
fat to total energy expenditure or muscle metabolic response to exercise. Although this may 
explain the difference in older overweight participants in the present study, fatty acid 
oxidation impairment is more likely as a consequence of greater FFA Rd relative to energy 
expenditure. This study has shown greater lipid accumulation in SSL region of older 
overweight as a result of impaired IMCL oxidation, whilst no difference was seen in older 
lean and young. This is in contrast to others (Crane et al. 2010) who have shown greater SSL 
lipid accumulation in older individuals irrespective of body composition, implying that age is 
a predictor of IMCL content. The difference may be because older participants in Cranes’ 
study were not matched for physical activity.   
 
3.4.9 Conclusion 
In conclusion, this study demonstrates that several parameters change with age, such as 
increased truncal fat mass, increased levels of fasting glucose, decreased VO2 max, impaired 
skeletal muscle insulin sensitivity and fat oxidation rates during light-intensity exercise, 
compared to young. However differences in body composition and habitual physical activity 
appear to have a greater  influence on skeletal muscle insulin sensitivity and lipid 
accummulation. Further, lipid droplet accumulation in the subsarcolemmal region of  muscle 
of older overweight could further explain a cause for the development of insulin resistance in 
older insulin resistant people as this is the site of insulin action. The greater FFA availability 
in old (both lean and overweight) and noradrenaline concentrations during exercise suggest 
an exaggerated response that develops with ageing per se.  Future studies should focus further 
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on unraveling the mechanisms involved at the SSL region of muscle in healthy older people 
and compare this with people with diabetes. Certain micronutrients shown to increase fat 
oxidation should be investigated to see if this could improve insulin sensitivity. This will be 
tested and discussed in Chapter 5. Figure 3.11 illustrates the interplay between adiposity, 
reduced physical activity and skeletal mucle insulin resistance and T2DM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: The relationship between impaired IMCL oxidation and adiposity in promoting 
skeletal muscle insulin resistance. 
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Chapter 4: STUDY 2  
Investigating the effects of an acute increase in lipid availability on insulin and amino 
acid stimulated protein metabolism. 
 
4.1 Introduction 
 
Anabolic resistance or the inability of skeletal muscle to synthesise new protein in response 
to anabolic stimuli such as amino acid ingestion or exercise has been implicated in muscle 
loss seen in ageing (Volpi, Mittendorfer et al. 2000; Cuthbertson, Smith et al. 2005), 
sarcopenia (Rasmussen, Fujita et al. 2006), insulin resistance, critical illness (Rennie 2009) 
and lipotoxicity. The issues concerning anabolic resistance have gathered momentum in 
recent years in line with recognition of increasing muscle loss and strength with ageing, and 
its impact on the older population as a main contributor to disability, risk of falls and quality 
of life (Evans 1995; Melton, Khosla et al. 2000). Furthermore as there is a strong association 
between anabolic resistance and insulin resistance, examining the underlying mechanisms 
involved can provide important insights into elucidating the protein and insulin signalling 
pathways affected. 
4.1.1 Insulin stimulated protein metabolism 
Insulin is widely described as a potent stimulus for muscle protein anabolism, indeed 
hyperinsulinaemia can increase muscle protein synthesis particularly when muscle amino 
acid availability is also increased (Bennet, Connacher et al. 1990). However insulin has been 
regarded to have a permissive rather than a modulatory role in MPS, and it is the availability 
of amino acids rather than insulin that appears to regulate rate of protein synthesis 
(Cuthbertson et al. 2005). 
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Insulin induces protein synthesis by activating translational factors and increasing cellular 
ribosomes mediated primarily through phosphoinositide 3-kinase and activation of protein 
kinase B. This allows for overall activation of protein synthesis through its regulation of 
mammalian target of rapamycin (mTOR) and 4E-BP1, both of which are mainly involved in 
synthesis of protein (Proud 2006). mTOR complex 1 also targets and activates kinases such 
as S6K1 that ultimately results in ribosomal biogenesis and translation. This has been 
discussed in detail in chapter 1. 
 
Figure 1 from (Haran, Rivas et al. 2012). Anabolic stimuli (amino acids, growth factors (insulin, 
IGF-1), and exercise (not shown) act through the mTOR and Akt signalling pathways. mTORC1 is 
involved in the phosphorylation and activation of S6K1 and phosphorylation and inactivation of 4E-
BP1, resulting in ribosome biogenesis, increase in translational efficiency, and heightened MPS. The 
energy sensor AMPK inhibits this pathway, and is active when the AMP/ATP ratio is high. Growth 
factor stimulates activation of the PI3K pathway as well as mTORC2; both eventually activate Akt, 
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which can inhibit stress signalling and apoptosis through inactivation of FOXO1/O3 transcription 
factors. Akt also plays a role in carbohydrate metabolism.  
P- phosphorylation, activation or inactivation; PI3k- phosphoinositide 3 kinase; Akt-protein 
kinase B; FOXO- forkhead protein box O; AMPK -AMP-activated kinase; 4E-BP1- eIF4E-
binding protein 1; S6K1- S6 kinase 1 
 
4.1.2 Lipid excess and anabolic resistance 
Diet-induced obesity, a major risk factor in the development of insulin resistance, was found 
to cause reduced skeletal MPS in mice (Anderson, Gilge et al. 2008). There was also an 
association between impaired protein metabolism and reduced post-absorptive protein 
turnover in obese individuals (Guillet, Delcourt et al. 2009). Although there exists 
compelling evidence to link obesity and reduced protein metabolism, the underlying 
mechanisms to explain this association are not clear. Increased activation of mTOR pathway 
and its downstream effectors have been implicated as contributors to insulin resistance 
stemming from obesity (Le Bacquer, Petroulakis et al. 2007).   
Increased basal expression of proinflammatory mediators such as NFκB, TNFα and IL-6 in 
older people (possibly due to increased fat accumulation in ageing) inhibits muscle anabolism 
by interfering with mTOR signalling (Cuthbertson et al. 2005). The same mediators are 
associated with lipid accumulation in non-fatty tissue sites.  
Accumulation of lipids, in particular sphingolipids are well-known to interfere with insulin-
signalling pathways thereby contributing to the development of insulin resistance (Hannun et 
al. 2002; Summers et al. 2005). Similarly lipids such as ceramides cause diminished amino 
acid availability and reduced phosphorylation of translational regulators downstream of 
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mTOR in vitro. Ceramides can activate protein phosphatase 2A which targets and inhibits 
Akt and S6K1 by dephosphorylation (Hannun et al. 2002). 
Other than ceramides, triglycerides are also thought to be detrimental to anabolic signalling in 
skeletal muscle.  Age-induced intramuscular triglyceride infiltration is associated with an 
increase in several lipogenic regulators including sterol regulatory element-binding protein, 
fatty acid synthase, acetyl CoA carboxylase, and stearoyl CoA desaturase. It has been 
demonstrated that AMPK activation and concentration are heightened in aged skeletal 
muscle, even in animals that were subjected to anabolic stimulus in the form of chronic 
muscle overload (Hannun et al. 2002).  This would suggest that intramuscular lipid 
accumulation, especially triglycerides blunts anabolic signalling pathways. 
 
4.1.3 Increasing lipid availability to induce insulin resistance 
The studies described so far have been performed in chronic settings of obesity and insulin 
resistance; however other contributing factors such as physical activity and diet may 
influence anabolic sensitivity to amino acids. Under these conditions it is difficult to 
determine the effects of insulin resistance per se on the mechanisms involved in protein 
turnover. The effect of excess lipid on insulin and amino acid stimulated skeletal muscle 
protein synthesis and the associated signalling pathways in vivo in humans is important but 
not frequently studied.  
Intravenous infusion of a lipid emulsion with heparin is used to elevate free fatty acid 
availability to allow investigation of the acute effects of lipid-induced insulin resistance on 
insulin signalling pathways and its subsequent impairments in glucose uptake, storage and 
oxidation (Boden, Jadali et al. 1991; Chokkalingam et al. 2007). Several studies have shown 
171 
 
that increasing free fatty acid acutely via this method had little effect on muscle protein 
synthesis and actually improved net muscle protein balance by inhibiting protein breakdown 
in a dose dependent manner (Ferrannini, Barrett et al. 1986; Tessari, Nissen et al. 1986; 
Wicklmayr, Rett et al. 1987; Gormsen, Gjedsted et al. 2008; Katsanos, Aarsland et al. 2009). 
In particular the study by Katsanos et al. observed no effect on the normal muscle protein 
synthetic response to ingestion of essential amino acids during a 13.5 hour intravenous lipid 
infusion.  
This present study examined the effect of acutely elevating fatty acid availability to a 
concentration found to induce insulin resistance, on muscle signalling and protein synthetic 
response to amino acid ingestion in the presence of steady-state circulating insulin 
concentration in humans. The study also aimed to elucidate the protein signalling pathway 
involved in altered protein metabolism under these conditions. 
4.2 Methods 
Seven healthy males (23.0 ± 0.8 yrs, body mass 78.5 ± 3.8 kg, BMI 24.5 ± 0.9 kg/m
2
 
participated in the study. 
They presented to the laboratory fasted and abstained from strenuous exercise for the 
previous 48 hours. In a rested supine position,  cannulae were inserted into veins for 
arterialised-venous blood sampling, infusion of insulin, 20% dextrose and [-ring
2
H5] 
phenylalanine (Cambridge Isotopes Limited, Cambridge,MA, USA) and the contralateral 
forearm for infusion of a lipid emulsion (Intralipid; Fresenuis Kabi,Germany) or 0.9% saline. 
On each visit a 7 hour [ring-
2
H5 ]-phenylalanine infusion (0.5/kg/hr) was performed in 
combination with 10% Intralipid (Lipid) or saline (Control) at a rate of 100mls/hr. Heparin 
sodium was also infused at a rate of 600U hr
-1
 to elevate plasma non-esterified fatty acid 
availability. After a 4 hours basal period, a 21 g bolus of amino acids (except phenylalanine 
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and tyrosine; Tyrosidon, SHS International Ltd, UK) was administered in a 440mls solution 
via a nasogastric tube to avoid issues with palatability. This amount of amino acids was 
selected to provide 10 grams of essential amino acids including 2.3 grams of leucine. This 
dose was determined as sufficient to provide a robust stimulation of muscle protein synthesis 
rates in young men under normal conditions (Cuthbertson et al. 2005). At the same time, a 3 
hour hyperinsulinaemic euglycaemic clamp was carried out at a rate of 50mUm
-2
min
-1
 (fed 
period). This rate was chosen as it was previously demonstrated to suppress endogenous 
hepatic glucose production under insulin resistant conditions known to alter substrate 
metabolism (Chokkalingam et al. 2007; Soeters, Sauerwein et al. 2009). The variable glucose 
infusion rate required to maintain euglycaemia was equivalent to peripheral glucose disposal 
and therefore peripheral insulin sensitivity.   
4.2.1 Sample collection and analysis 
Arterialised-venous blood was obtained at t=0, 1.5 hr and every 30 minutes thereafter. 
Plasma was treated with tetrahydrolipostatin (THL) and analysed for NEFA as described in 
the common methods chapter. Plasma separated from EGTA treated blood was analysed for 
insulin concentration by ELISA. After deproteinisation on ice with dry 5-sulfosalicylic acid 
the same plasma was used to analyse phenylalanine and leucine concentrations and 
enrichment by GC-MS after derivatisation with tert-butyl dimethylsilyl (TBDMS) as 
described (Gorissen, Burd et al. 2014). Muscle samples were obtained from the vastus 
lateralis muscle using the Bergstrom needle biopsy technique. Samples were analysed for 
intracellular tissue free phenylalanine enrichments in the similar manner as the plasma 
samples. Amino acids were purified from the remaining pellet as described previously and 
used to determine the phenylalanine enrichments in mixed muscle protein GCMS. Total 
muscle protein homogenates were extracted from another muscle sample portion obtained at 
t= 4 and 7 hr by homogenisation in a HEPES phosphatase buffer in the presence of protease 
173 
 
and phosphatase inhibitors. The total muscle protein content of total and phosphorylated Akt, 
mTOR and 4E-BP1 were determined by western blot analysis and normalised to alpha actin 
to control for loading. A further third sample was analysed for activation status of the 
pyruvate dehydrogenase complex. 
 
4.2.2 Calculations 
Fractional rate of mixed muscle protein synthesis (FSR) was calculated by dividing the 
increment in enrichment in protein bound [ring-
2
H5 ]-phenylalanine by the enrichment of the 
precursor. Plasma and muscle free phenylalanine enrichments were used to provide an 
estimate of the lower and higher boundaries of true FSR respectively. The formula used was: 
                                      FSR  =  ∆Ep     x   t      x  100 
       Eprecursor   
Where ∆Ep is the delta increment of protein bound [2H5] phenylalanine during incorporation 
periods, Eprecursor is the enrichment of the precursor used during the time period for amino 
acid incorporation determination, and t denotes the time duration (hr) between biopsies. The 
equation is multiplied by 100 to express FSR as percentage per hour.  
4.2.3 Statistics 
A two-way ANOVA was performed to detect differences within and between treatment 
groups for all measures described. When a significant effect was observed, a Student’s t-test 
with Bonferroni correction was performed to locate differences. Statistical difference was 
declared at P<0.05. All values presented in texts and figures represent mean ± the standard 
error of mean s.e.m. 
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4.3 Results 
4.3.1 Insulin resistance of glucose metabolism 
Lipid with heparin infusion caused an elevation of steady-state plasma NEFA concentrations 
throughout the basal period compared to Control (P< 0.001; Figure 1A). Plasma NEFA 
concentrations were suppressed (P<0.001) by insulin and amino acid administration to a 
similar degree (delta 0.38±0.01 vs. 0.39±0.01 mmol l
-1
; Figure 1A) such that steady-state 
NEFA concentration remained greater in lipid throughout the fed period (P<0.001; Figure 
1A) where it was maintained at a fasting concentration. Steady state plasma insulin 
concentrations were similar between the two groups during the fed period (104 ± 5 vs 99 ± 3 
mU l
-1
, respectively; Figure 1B). However, despite this similar circulating insulin 
concentration, there was a 19.9 ± 6.2% lower average glucose disposal during the final hour 
of the fed period in Lipid compared to control (**P<0.01; Figure 1C) and a 56±12% lower 
PDCa by the end of the fed period at 7 hrs (*P<0.05;Figure 1D). 
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Figure 1A: Plasma NEFA concentration before (Basal 1.5-4 h) and after (Fed 4-7 h) the 
administration of 21 g of amino acids and a 3 hr euglycaemic hyperinsulinaemic (100 mU/L) 
clamp during 7 hr intravenous infusion of saline (Control; black circles) or 10% Intralipid 
(Lipid; white circles) at a rate of 100 ml/hr. Values represent means ± SEM. 
†††
 P<0.001, 
Lipid significantly different from corresponding Control value. *** P<0.001, Control and 
Lipid during Fed significantly different from corresponding Basal steady-state. 
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Figure 1B: Serum insulin concentration before (Basal 1.5-4 h) and after (Fed 4-7 h) the 
administration of 21 g of amino acids and a 3 hr euglycaemic hyperinsulinaemic (100 
mU/L) clamp during 7 hr intravenous infusion of saline (Control; black squares) or 10% 
Intralipid (Lipid; black circles) at a rate of 100 ml/h. Values represent means ± SEM.  
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Figure 1C: Whole-body glucose disposal after (Fed 4-7 hr) the administration of 21 g of 
amino acids and during the 3 hr euglycaemic hyperinsulinaemic (~100 mU/L) clamp during 7 
hr intravenous infusion of saline (Control; white circles) or 10% Intralipid (Lipid; black 
circles) at a rate of 100 ml/hr. Values represent means ± SEM. ** P<0.01, Lipid significantly 
different from corresponding Control value. 
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Figure 1D:  PDCa before (Basal 1.5-4 h) and after (Fed 4-7 h) the administration of 21 g of 
amino acids and a 3 h euglycaemic hyperinsulinaemic (100 mU/L) clamp during 7 hr 
intravenous infusion of saline (white bars) or 10% Intralipid (Lipid; black bars) at a rate of 
100 ml/hr. Values represent means ± SEM. *P<0.05, Lipid significantly different from 
corresponding Control value.  
 
4.3.2 Amino acid metabolism 
No effect was seen during the basal period following lipid infusion on plasma leucine or 
phenylalanine concentrations compared to control which were both maintained at fasting 
concentrations throughout (Figure 2A and 2B). Similarly plasma phenylalanine enrichments 
remained at the same steady state levels in Lipid and control (Figure 2C) resulting in the 
same phenylalanine Ra (46.6±1.8 vs. 48.2 ±2.7 µmolkg
-1
min
-1
) in lipid and control 
respectively. Insulin and amino acid administration resulted in a similar peak in plasma 
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leucine concentration in Lipid and control after 30 minutes of the fed period (P<0.001; Figure 
2A). However insulin and amino acid administration caused a steady decline in plasma 
phenylalanine concentration during control such that it was 49± 3% lower during the final 
hour of the fed period compared to basal (P<0.001; Figure 2B). The degree of reduction in 
plasma phenylalanine concentration in response to insulin and amino acid administration was 
greater in Lipid (65± 3%; P<0.001) when compared to control, such that the steady-state 
phenylalanine concentrations were lower (P<0.001; Figure 2B). However, this did not result 
in greater enrichment during the final hour of the fed period in lipid compared to control 
(Figure 2C) or a difference in whole body phenylalanine Ra (28.9 ± 1.0 vs. 32.9±1.6 µmol 
kg/min) in lipid and control respectively. 
 
Figure 2A: Plasma leucine before (Basal 1.5-4 hr) and after (AA + Insulin) the 
administration of 21 g of amino acids and a 3 hr euglycaemic hyperinsulinaemic (~100 
mU/L) clamp during 7 hr intravenous infusion of saline (Control) or 10% Intralipid (Lipid) at 
180 
 
a rate of 100 ml/h. Values represent means ± SEM. *** P<0.001, Control and Lipid during 
AA + Insulin significantly different from corresponding basal values. 
 
Figure 2B: Plasma phenylalanine concentration before (Basal 1.5-4 h) and after (AA + 
Insulin) the administration of 21 g of amino acids and a 3 hr euglycaemic hyperinsulinaemic 
(~100 mU/l) clamp during 7 hr intravenous infusion of saline (Control) or 10% Intralipid 
(Lipid) at a rate of 100 ml/h. Values represent means ± SEM. 
+++
 P<0.001, Lipid significantly 
lower corresponding Control value. *** P<0.001, Control and Lipid during AA + Insulin 
significantly different from corresponding basal values. 
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Figure 2C: Plasma phenylalanine enrichment before (Basal 1.5-4 h) and after (AA + Insulin) 
the administration of 21 g of amino acids and a 3 hr euglycaemic hyperinsulinaemic (~100 
mU/l) clamp during 7 hr intravenous infusion of saline (Control) or 10% Intralipid (Lipid) at 
a rate of 100 ml/h. Values represent means ± SEM. *** P<0.001, Control and Lipid during 
AA + Insulin significantly different from corresponding basal values. 
There was no effect of lipid infusion on basal mixed muscle FSR compared to control  
calculated using muscle free (Figure 3A) phenylalanine enrichment as the precursor pool. 
However whereas mixed muscle FSR increased from the basal to fed period in control, it did 
not respond to insulin and amino acid administration in lipid such that it was significantly 
lower than Control (P<0.05; Figure 3A).There were no significant differences between lipid 
and control in the plasma (9.4±0.3 vs 8.6±0.5 mole percent excess (MPE), respectively or 
muscle free (9.4±0.3 vs.8.6±0.5 MPE, respectively) precursor pools following insulin and 
amino acid administration. 
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Figure 3: Skeletal muscle mixed protein fraction synthetic rate (FSR) calculated from 
skeletal muscle [-ring
2
H5]phenylalanine precursor pools before (Basal) and after (AA + 
Insulin) the administration of 21 g of amino acids and a 3 hr euglycaemic hyperinsulinaemic  
(~100 mU/L) clamp during 7 hr intravenous infusion of saline (Control; white bars) or 10% 
Intralipid (Lipid; black bars) at a rate of 100 ml/h. Values represent means ± SEM. 
+
 P<0.05, 
Lipid significantly lower than corresponding Control value. * P<0.05, AA + Insulin 
significantly greater from corresponding basal values. 
4.3.3 Associated signalling pathways 
Lipid infusion did not affect the phosphorylation status of Akt, mTOR or 4E-BP1 compared 
to control during the basal period. Insulin and amino acid administration increased the 
phosphorylation of Akt (P<0.05; Figure 4A), mTOR (P<0.01; Figure 4B) and 4E-BP1 
(P<0.01; Figure 4C) by 1.9, 1.7 and 2.9-fold respectively compared to basal in control. 
However whereas insulin and amino acid administration also increased mTOR 
phosphorylation by 1.5 fold from basal in Lipid (P<0.05; Figure 4B) the 1.8 fold increased in 
Akt phosphorylation was not significantly different (P>0.05; Figure 4A). Furthermore lipid 
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infusion had no effect on 4EBP1 phosphorylation at all such that it was less than half that of 
control at the end of the fed period (P<0.01; Figure 4C).  
 
Figure 4A: Skeletal muscle Akt serine 473 phosphorylation before (Basal) and after (Fed) 
the administration of 21 g of amino acids and a 3 hr euglycaemic hyperinsulinaemic (100 
mU/L) clamp during 7 h intravenous infusion of saline (Control; white bars) or 10% 
Intralipid (Lipid; black bars) at a rate of 100 ml/h. Values represent means ± SEM. * P<0.05, 
Fed significantly greater from corresponding Basal values. 
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Figure 4B: Skeletal muscle mTOR serine 2448 phosphorylation before (Basal) and after 
(Fed) the administration of 21 g of amino acids and a 3 hr euglycaemic hyperinsulinaemic 
(100 mU/L) clamp during 7 h intravenous infusion of saline (Control; white bars) or 10% 
Intralipid (Lipid; black bars) at a rate of 100 ml/h. Values represent means ± SEM. ** 
P<0.01, * P<0.05, Fed significantly greater from corresponding Basal values. 
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Figure 4C 
Figure 4: Skeletal muscle 4E-BP1 threonine 37/46 phosphorylation before (Basal) and after 
(Fed) the administration of 21 g of amino acids and a 3 hr euglycaemic hyperinsulinaemic 
(100 mU/L) clamp during 7 h intravenous infusion of saline (Control; white bars) or 10% 
Intralipid (Lipid; black bars) at a rate of 100 ml/h. Values represent means ± SEM. †† 
P<0.01, Lipid significantly lower than corresponding Control value. *** P<0.001, Fed 
significantly greater from corresponding Basal values. 
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4.4 Discussion 
Anabolic resistance has been associated with ageing, insulin resistance and sarcopenia. 
Mechanisms underlying perturbations to anabolic signalling pathways are increasingly 
studied and unravelled. However, confounding factors such as physical inactivity (commoner 
with ageing) or obesity and diet (insulin resistance and ageing) may distract from establishing 
the cause of anabolic resistance per se. Therefore, the aim of this study was to examine the 
effect of acutely elevating fatty acid availability so as to induce insulin resistance of glucose 
metabolism on skeletal muscle signalling and protein synthesis in response to amino acid 
ingestion in the presence of a controlled, steady-state circulating insulin concentration. Under 
these conditions the present study showed that the insulin resistance observed following 
intravenous lipid infusion was associated with the inability of skeletal muscle to increase 
protein synthesis in response to insulin and amino acid administration ie anabolic resistance. 
This appeared to be partly mediated through the repression of translation initiation at the level 
of 4E-BP1. 
The association between insulin resistance and anabolic resistance has long been established 
and observed in animal models. Genetically obese, insulin-resistant rats exhibited decreased 
muscle protein synthesis in response to nutritional (Dunn and Hartsook 1980; Shargill, 
Ohshima et al. 1984; Chan, Hansen et al. 1985) and exercise stimuli (Friedman, Lemon et al. 
1990). Diet-induced obesity in mice (Anderson, Gilge et al. 2008) and rats (Masgrau, 
Mishellany-Dutour et al. 2012)  was shown to impair the activation of skeletal muscle protein 
synthesis in response to feeding, particularly in glycolytic muscle where there was chronic 
lipid infiltration (Masgrau et al. 2012).  
Whole body protein anabolic response to hyperinsulinaemia and hyperaminoacidaemia is 
blunted in obese women compared to lean (Chevalier, Marliss et al. 2005), and skeletal 
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muscle protein synthesis in response to insulin and amino acids appears to be negatively-
correlated to whole body fat mass in humans (Guillet, Delcourt et al. 2009). However the 
contribution of excess lipid and insulin resistance to anabolic resistance is unlikely to be 
determined from these studies as confounding factors such as physical inactivity or diet can 
also induce anabolic resistance (Friedman et al. 1990, Wall, Snijders et al. 2013). This study 
has demonstrated that an increase in fat availability or lipid-induced insulin resistance per se 
can induce protein synthesis resistance in response to insulin and amino acid ingestion 
independent of confounding factors. 
The ingestion of 21 grams of amino acids containing 10 g of essential amino acids including 
2.3g of leucine increased mixed muscle protein synthesis by 60% over 3 hours post-prandial, 
in concert with other studies (Cuthbertson et al. 2005; Luzi, Castellino et al. 1996). In the 
presence of elevated lipid availability this response was completely suppressed (Figure 3). In 
contrast, the study by Kotsanos et al. 2009 showed no blunting of the 50% increase in muscle 
protein synthesis in response to 7 g of essential amino acids, despite higher doses of lipid 
(nearly 4 times the dose of lipid used in this study). This may be because the lipid infused in 
Kotsanos’s study (20% Liposyn at 90 ml/h for 13.5 hr) had an insulin secretagogue effect 
resulting in a 4-fold higher circulating insulin concentration before and after amino acid 
ingestion compared to saline infusion. This level of insulin concentration could overcome any 
effect of insulin resistance on amino acid metabolism. When insulin was maintained at 
steady-state concentration above that known to physiologically stimulate muscle protein 
anabolism, in both the lipid and control arms of the present study, the lipid infusion resulted 
in a lower muscle protein synthetic rate in response to amino acid ingestion compared to 
control. This suggests that lipid per se can induce anabolic resistance of amino acid 
metabolism. Lipid infusion also reduced insulin stimulated peripheral glucose disposal and 
skeletal muscle PDC activation in the present study by 20 and 50% respectively, in concert 
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with studies administering a similar dose of lipid infusion (Stephens, Mendis et al. 2014) 
reflecting insulin resistance at the level of skeletal muscle. This raises the pertinent question 
as to whether a similar pathway in muscle exists that may cause lipid-induced insulin 
resistance and anabolic resistance.  
This and previous studies (Greenhaff, Karagounis et al. 2008) have shown that insulin and 
amino acid administration per se increased phosphorylation of skeletal muscle Akt, mTOR 
and 4E-BP1. However, despite causing impaired glucose uptake and protein synthesis, lipid 
infusion in this study did not appear to impair the phosphorylation of Akt or mTOR. This 
lack of effect on Akt phosphorylation has been reported before (Kruszynska, Worrall et al. 
2002) and may explain why there was no inhibitory effect of lipid infusion on 
phosphorylation of mTOR, a key regulator of protein synthesis and substrate for Akt. A 
major finding from this study was that lipid completely suppressed the ability of insulin and 
amino acid administration to phosphorylate 4EBP-1, which is normally essential to allow 
active eIF4F complex and translation initiation to occur. This indicates that an intracellular-
signalling defect causing lipid-induced anabolic resistance independent of the Akt-mTOR 
axis exists, but the exact mechanisms are not known. It may be that there is an alternative 
insulin or amino acid sensitive protein synthesis pathway that is impaired with lipid. It is also 
possible that the acute inhibition of protein synthesis in response to elevated NEFA is 
independent of insulin resistance.  As seen in this study, there was no effect of lipid on 
protein synthesis under basal conditions in the absence of insulin stimulation emphasising the 
importance of insulin availability in protein synthesis. Ceramide lipids have been 
demonstrated to impair amino acid-stimulated protein synthesis in L6 cells at the level of 
translation initiation as well as insulin-stimulated amino acid uptake via an independent 
mechanism from ceramide-induced insulin resistance of glucose uptake (Lang 2006). 
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Although muscle protein breakdown was not assessed, there was no effect of lipid on whole-
body protein breakdown (phenylalanine Ra) during the basal or fed period of the present 
study. These findings suggest that muscle loss occurring in conditions of elevated lipid 
availability and insulin resistance is likely due to reductions in the ability to synthesise 
muscle protein in response to anabolic stimuli, rather than accelerated muscle protein 
breakdown (Rennie, 2009; Wall et al., 2013).  
4.5 Conclusion       
This study has demonstrated that insulin resistance via increased lipid availability can induce 
anabolic resistance of skeletal muscle protein synthesis in humans in response to amino acid 
ingestion under steady state hyperinsulinaemic conditions without affecting post-absorptive 
muscle protein synthesis. This impairment appears to be located downstream of the Akt-
mTOR signalling pathway at the level of translation initiation, as phosphorylation of 4E-BP1 
in response to feeding was completely suppressed. Future studies should examine the effects 
of insulin resistance in overweight/obesity from long-term fat overfeeding and ageing on 
skeletal MPS.  
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Chapter 5: STUDY 3 
Investigating the effects of fat and carbohydrate overfeeding on liver fat and insulin 
sensitivity. 
5.1 Introduction 
One of the more pertinent issues of the 21
st
 century concerns the challenge of tackling 
growing obesity rates.  In 2014, more than 1.9 billion adults were overweight. Of these over 
600 million were obese (World Health Organisation, WHO). Current estimates are a 33% 
increase in obesity prevalence and a 130% increase in severe obesity prevalence over the next 
two decades (Finkelstein 2012). As the obesity rates escalate so will the number of people 
with insulin resistance and hence T2DM and related metabolic disease. This is clearly a huge 
public health concern.  
Ethan Sims’ well-known study of overfeeding prison inmates in Vermont (Sims et al. 
1970) sparked interest in examining the effects of overfeeding nutrients on human 
metabolism. His study primarily investigated changes in adipose tissue as a result of 
overfeeding and will perhaps never be replicated (in-mates were overfed for up to 200 days 
until they gained up to 25% excess of their initial body weight), but has provided insight and 
impetus to others in exploring metabolic adaptability and changes in response to increased 
energy intake and expenditure. 
A chronic positive energy balance is clearly the primary driver of obesity, but there 
may be an additional effect of dietary composition on weight gain and insulin resistance. 
Overconsumption of high energy nutrients such as fat and a sedentary lifestyle not only 
results in expansion of adipose tissue (Guilherme et al. 2008) but may also lead to fat 
accumulation in non-adipose tissues (visceral fat) such as skeletal muscle, liver and heart 
191 
 
(Bachmann et al. 2001; Schrauwen-Hinderling et al. 2005; van Herpen et al. 2011). 
Moreover, insulin resistance is not always accompanied by increased adiposity, such as in 
people with highly-active antiretroviral therapy (HAART), a condition characterised by 
insulin resistance, lack of subcutaneous tissue and increased liver fat (Yki-Jarvinen 2005). 
Mechanisms by which visceral fat is thought to modulate insulin action include increased 
portal release of FFAs (Bjorntorp P, 1990; Williamson JR et al. 1966) and abnormal 
expression and secretion of fat-derived peptides such as leptin and TNF-α (Hotamisligil et al. 
1996).  
Skeletal and hepatic insulin resistance occur following excess overfeeding (Wang et al. 
2001), whilst insulin sensitivity is enhanced following energy restriction (Kelley et al. 1993) 
and weight loss (McAuley et al. 2006), indicating that energy excess promotes adiposity and 
insulin resistance. Conversely, dietary composition, rather than total energy intake and body 
mass have been shown to have a significant influence on insulin sensitivity (Salans et al. 
1974; Krishnan et al. 2007; Villegas et al. 2007). This is also exemplified in the San Luis 
Valley Diabetes Study, where high total and saturated fat intake were shown to increase 
insulin resistance independent of weight, physical or sedentary lifestyles in a non-diabetes 
population (Marshall et al. 1997).   
Diets high in either fat or carbohydrate have been shown to be associated with 
development of insulin resistance, increased hepatic glucose production and T2DM (Marshall 
et al. 1991; Pereira et al. 1997; Schulze et al. 2004). The associated studies were presented in 
chapter 1. The issue of whether macronutrient consumption has a secondary influence on 
liver fat and insulin sensitivity remains contentious.  Is it the total energy consumption or 
individual macronutrients that are the real protagonists in the development of increased fat 
mass and insulin resistance? Are there differential effects of dietary carbohydrate or fat on 
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liver fat and insulin sensitivity? These questions provided impetus to the objectives of this 
study.    
5.2 Aims 
The present study compared the effect of high-fat versus high-carbohydrate hyperenergetic 
feeding on liver fat content and whole body and liver insulin sensitivity in healthy overweight 
participants. The primary objective was to test the hypothesis that a diet in excess of energy 
(+25%) will increase intrahepatic lipid (IHL) content and thus hepatic insulin resistance. The 
study further explored the hypothesis that a hyperenergetic high-fat diet (+25% energy in the 
form of fat) will increase IHL content, IMCL and thus hepatic and skeletal muscle resistance 
to a greater degree than a hyperenergetic high-carbohydrate diet (+25% excess energy in 
form of carbohydrate) as a result of an inability to increase resting energy expenditure.  
Given that the effect of high energy overfeeding is seen within 7 days in the majority of 
previous studies, it seemed likely that 2 weeks of 25% excess energy high fat or carbohydrate 
diets would be sufficient to produce effects on liver fat and insulin sensitivity. Overweight or 
obese healthy participants were recruited as they were more likely to have an initial degree of 
elevated liver fat and insulin resistance compared to healthy lean participants which is then 
more likely to be altered by dietary change.  
Based on studies seen in the current literature this is the first study to provide a 
comprehensive assessment of the effects of either hyperenergetic high fat or high 
carbohydrate on liver fat, whole body and peripheral insulin sensitivity (liver), lipid and liver 
metabolism.  
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5.3 Methods 
5.3.1 Participants 
24 healthy overweight/obese male participants were initially screened and consented to 
participating in the study according to the Declaration of Helsinki. Anyone who drank 
excessive alcohol (>28 units per week) or had elevated LFTs (AST or ALT three times above 
the upper range of normal) were excluded from participation. Participants completed a three 
day diet diary and International Physical Assessment Questionnaire (IPAQ) to determine 
their estimated daily total energy expenditure. They then consumed an isoenergetic diet 
meeting their usual total energy expenditure for a week before attending their first 
experimental visit. 
5.3.2 Experimental Visit 
Volunteers fasted from 2200 before the morning of the visit and first attended the Sir Peter 
Mansfield MR Centre, University Park, University of Nottingham at 0800 for scanning of 
their liver, abdominal subcutaneous tissue and thigh muscle. They then attended the 
MRC/ARUK David Greenfield Human Physiology Unit where they were weighed and 
underwent anthropometric assessments (callipers and bioelectric impedance analysis). At the 
start of the experimental study volunteers rested in a semi-supine position while cannulae 
were inserted into a superficial dorsal hand vein for arterialized-venous blood sampling and 
in both forearm veins for insulin, glucose and stable isotope infusions. Baseline blood was 
taken to measure liver transaminases, lactate, uric acid, beta-hydroxybutyrate, 
adipocytokines, inflammatory cytokines, lipid profile and free fatty acids. A 4.5 hour primed 
(4mg/kg) continuous infusion of [6, 6 
2
H2] glucose (40µg/kg/min) was infused from the start 
of the study to measure hepatic glucose production and thus assess hepatic insulin sensitivity. 
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Blood samples were taken every hour for the first 2 hours and every 30mins for the last 2.5 
hours to determine plasma [6,6
2
H2] glucose to allow subsequent calculation of endogenous 
hepatic production of glucose. Further blood samples were taken every 30 minutes for 
measurement of insulin and glucagon, and every 1 hour for measurement of C-peptide, 
plasma lipids, FFAs, lactate, uric acid, β-OHB, adipocytokines, CRP, IL-6 and TNF-α.  
After 2 hours of tracer infusion, the hyperinsulinaemic (30mu/m
2
/min) euglycaemic clamp 
was commenced for 2.5 hours. This rate of insulin infusion was chosen based on a previous 
study investigating the effects of either high fructose or glucose on hepatic insulin sensitivity 
(Johnston et al. 2013), where it was shown that this dose of insulin will partly but not 
completely suppress hepatic glucose output.  
Respiratory exchange measurements (oxygen consumption and carbon dioxide production) 
were recorded using a ventilated hood attached to a metabolic cart for 15 minutes at baseline, 
before the insulin clamp and 2.5 hours from the start of the clamp in order to indirectly 
calculate REE and RER to determine whole body carbohydrate and lipid oxidation rates. 
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Figure 5.1: Schematic design of High Fat High Carbohydrate (HFHC) protocol 
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5.3.3 Energy requirements 
Estimated energy intake for each subject was calculated using the Oxford (Henry-modified) 
equation. This method was chosen over the Schofield and Mifflin-St Jeor prediction 
equations for a number of reasons. The Schofield equation has been found to overestimate 
BMR in several populations (Henry C, 2005), and although this overestimate is small (<5%), 
the Oxford equation has been most vigorously tested and its use has been recommended by 
the Scientific Advisory Committee on Nutrition (SACN) (Dietary reference values for 
energy, SACN 2011) to predict estimated energy requirements in healthy populations. The 
use of the modified Henry equation is warranted particularly in the current growing 
population of overweight and obesity, where other prediction equations may underestimate 
energy requirements. Resting energy expenditure (REE) is influenced by body composition, 
thus in overweight people equations of REE may not give a true estimate. Although the 
Mifflin-Jeor equation appears to predict REE better than other equations in obese subjects 
(Frankenfield et al. 2003; Dobratz et al. 2007; Weijz et al. 2008 and 2010; de Oliviera et al. 
2012), values may deviate > 10% in as much as 30% of obese (Madden 2014).  Other than 
REE, the variation of physical activity may also influence and impact on TEE. TEE may be 
estimated by multiplying the REE with the physical activity level (PAL) which itself may be 
determined from population reference data (SACN 2011) or by individual assessment. The 
UK reference for PAL in adults is 1.63 (SACN 2011), assuming >60% of the population are 
overweight or obese and who participate in typical activity levels.    
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Henry Equation 
Males 
Age 18-30: REE (kcal/d) = 16.0W + 545  
Age 30–60: REE (kcal/d) = 14.2W + 593 
Where REE is in kcal/day and W denotes weight in kg 
Estimated TEE = REE estimated using the Henry Equation X PAL (1.63)  
5.3.4 Dietary plan 
24 healthy but overweight/obese (BMI 26-37 kg/m
2
) males aged 18-55 initially went on a 7 
day isoenergetic diet matched to the individual’s predicted TEE calculated using the Henry 
Equation (Henry 2005) and PAL questionnaire. They were then randomized to two groups, 
each of which received a high energy (+25% energy excess) diet with either high fat (HF - 
48-50% fat, 37% carbohydrate CHO, 13%-15% protein) or high-carbohydrate (HC - 24-26%-
28% fat, 59%-61% CHO and 13-15% protein) for  2 weeks before returning for the second 
experimental protocol visit. The HC group received extra carbohydrate in the form of a 
maltodextrin drink daily such that they were supplemented with an extra 25% excess energy 
daily. Similarly the HF group received 25% excess calories in the form of double cream that 
could be ingested with their desserts in the evening. Participants were also requested to 
complete a 3 day diet diary to determine actual total energy consumed per day and patterns of 
food consumption. This was done using “Microdiet” (Downlee Systems Ltd), a nutrient 
analysis software programme designed to analyse and calculate nutrient totals and 
contribution to meals designed for the study. An example of the contribution of energy from 
the nutrients for a calculated TEE as calculated using “Microdiet” can be found in the 
appendices section. 
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5.3.5 Example menu (See appendices) 
Menus were developed for each day for the 3 weeks with input by a dietitian. Breakfast 
consisted of cereals that were weighed (50 grams) at the physiology lab and provided to 
participants prior to the start of each week of the study. Skimmed milk powder (weight pre-
determined to balance protein contribution) was also measured and distributed to volunteers 
prior to the study. The rest of the food on the menu was delivered by a commercial 
supermarket one or two days prior to the start of the week of feeding.   
5.3.6 Measurable endpoints/statistical power of the study 
The primary endpoint of the study was liver fat content. Hepatic and peripheral insulin 
sensitivity (through deuterated glucose and glucose disposal during clamps respectively) was 
also examined. The repeated measures coefficient of variation for the insulin clamp technique 
is 10%. Based on isoenergetic high-fat feeding studies it was predicted that there would be a 
greater than 20% difference in glucose disposal from the high fat versus high carbohydrate 
diet. 8-10 participants would give an 80% chance of detecting a difference in insulin 
resistance equivalent of 1 standard deviation for that variable at p value <0.05. 12 participants 
for each group (HCHF or HCHC) were therefore recruited to allow for dropouts of 2-4 
participants per group. 
5.4 Results 
5.4.1 Participant demographics 
A total of 24 male White Europeans were recruited to the study, and randomised to either the 
high-fat (HF) or high carbohydrate (HC)-fed groups (12 per group). One subject from the 
high fat group did not complete his second hyperinsulinaemic euglycaemic clamp visit, 
therefore evaluations of peripheral insulin sensitivity and other metabolic data after the 2 
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week intervention period were performed on 11 participants in the HF group and 12 in the 
HC group. 
1
H MRS and MRI abdomen was only performed in 22 participants, 12 from the 
HF group, and 10 from the HC group. The 2 participants from the HC group were excluded 
due to contraindications to MRI (See Appendices section).   
All participants were overweight or obese with a mean body mass index of 30.6 ± 0.6 kg/m
2
 
ranging from 26.2 to 37.3 kg/m
2
. Percentage body fat as calculated using skin-fold thickness 
and the SIRI formula averaged 33.7%, ranging 22.9-42.0%. The participants were well-
matched in all parameters (see Table 5.1) bar skinfold thickness of biceps, and mean 
estimated TEE was 3200 kcal/day.    
5.4.2. Baseline Anthropometrics 
Table 5.1. Participant anthropometrics 
 Total (n=23) High Fat 
(n=11) 
High 
Carbohydrate 
(n=12) 
P value 
Age (years) 40.6 ± 1.6 39.1 ± 2.1 42.3 ± 2.4 0.34 
Weight (kg) 98.9 ± 2.0 100.2 ± 3.0 97.2 ± 2.6 0.51 
BMI (kg/m
2
) 30.6 ± 0.6 30.7 ± 0.9 30.1 ± 0.9 0.88 
Hip circumference (cm) 105.8 ±1.0 106.1 ± 1.5 105.4 ± 1.5 0.78 
Waist circumference (cm) 105.8 ± 1.4 105.5 ± 2.2 105.9 ± 1.8 0.79 
Waist > 102cm (n 
participants) 
16/23 8/11 8/12 0.70 
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Waist to hip ratio 0.99±0.01 0.99±0.01 1.00±0.01 0.45 
Fat (kg) 24 ± 1.2 25.0 ± 2.0 22.7 ± 1.4 0.37 
Lean (kg) 74.7 ± 1.4 74.8 ± 1.8 74.5 ± 2.3 0.93 
Biceps (mm) 8.5 ± 0.6 9.9 ± 0.8 6.9 ± 0.5 <0.01 
Triceps skinfold 
thickness(mm) 
17.3 ± 1.6 18.0 ± 2.2 16.5 ± 2.5 0.66 
Subscapular skinfold 
thickness(mm) 
26.5 ± 3.1 30.4 ± 5.3 21.7 ± 2.2 0.18 
Iliac crest skinfold 
thickness(mm) 
15.5 ± 1.0 16.3 ± 1.5 14.5 ± 1.1 0.37 
Abdominal skinfold 
thickness (mm) 
36.4 ± 1.4 37.5 ± 2.2 35.1 ± 1.8 0.43 
Bio-Impedance Analysis 
(BIA) 
 (% Fat) 
 
33.7 36.2 31.1 0.08 
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5.4.3 Baseline MRI of abdomen 
Table 5.2. Visceral and subcutaneous abdominal tissue 
 Total (n=22) High fat (n=12) High carbohydrate 
(n=10) 
P value 
Visceral 
abdominal tissue 
(VAT) volume (ml) 
1080.4±130 949.9 ±149.8 1223.9±115.1 0.17 
Abdominal volume 
(ml) 
7171.9±262.8 6998.7±273.1 7362.4±292.1 0.37 
Subcutaneous 
abdominal tissue 
(SAT) (ml) 
2759.3±154.7 2745.6±238.1 2775.7±199.1 0.95 
Ratio 
(VAT/Abdominal 
volume) 
0.15±0.01 0.13±0.02 0.16±0.01 0.15 
Ratio (VAT) / 
(SAT) 
0.28±0.02 0.25±0.03 0.30±0.02 0.24 
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5.4.4 Intrahepatic-cellular lipid (IHCL) 
 
Figure 5.2: Percentage liver fat fraction at 0 weeks and following overfeeding 25% excess 
energy of diets high in carbohydrate (n=10 subjects) and fat (n=11 subjects) at 2 weeks. 
*P<0.05 from 0 weeks. 
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Figure 5.3: Absolute liver fat fractions (%) in the high fat (n=11) and high carbohydrate 
groups (n=10) at 0 weeks and following 2 weeks of 25% excess energy of either high fat of 
high carbohydrate. *P < 0.05 from 0 weeks. 
Of the 21 participants who had MRI scan of their liver, 7/21 had fatty liver (defined as >5.6% 
liver fat content (Szczepaniak et al. 2005) (4 from HF, 3 from HC) at baseline. No difference 
in liver fat was seen in both groups following the 7 days of isoenergetic diet. Following 2 
weeks of excess energy feeding, 12/25 had fatty liver (6 participants from each group, 7 with 
pre-existing fatty liver) and there was an overall 34% increase in liver fat fraction in the 
whole group from 6.4 ±1.5 to 8.6 ± 1.6% (P<0.05). There was no difference in baseline liver 
fat fractions between the high fat vs. high carbohydrate groups (6.1±2.1 vs.7.4 ± 2.4%). After 
2 weeks, liver fat fractions increased to 7.8±1.8% and 11.0±2.7% in the high fat and high 
carbohydrate groups respectively. There was a significant increase of 49% in liver fat fraction 
at 2 weeks in the high carbohydrate group (+3.5±1.5%; P<0.05) compared to the high fat 
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group (+1.7 ± 0.8%). No difference in changes between the high fat and carbohydrate groups 
were seen (P=0.3). 
5.4.5 Hepatic insulin sensitivity 
5.4.5.1 Fasted and post-prandial hepatic glucose production 
Table 4.3 Hepatic glucose production (mg/kg/min) fasted and steady state of 
hyperinsulinaemic (30mu/m
2
/min) euglycaemic clamp at 0 weeks and after 2 weeks of high 
fat or high carbohydrate overfeeding. 
  Whole group 
n=18 
High Fat 
n=10 
High 
carbohydrate 
n=8 
P value 
Difference 
between 
groups  
Baseline 
mg/kg/min 
Fasted  2.27±0.14 2.22±0.18 2.35±0.19  
0.4 Steady state 
insulin 
1.02±0.24 0.83±0.15 1.25±0.51 
2 weeks 
mg/kg/min 
Fasted 2.18±0.08 2.26±0.38 2.08±0.10 0.5 
Steady state 
insulin 
0.96±0.21 0.73±0.33 1.25±0.22 
 
Rates of fasting hepatic glucose production remained unaltered in the whole group after 2 
weeks of overfeeding 25% excess energy. There was no difference in fasted rates between the 
fat and carbohydrate overfeeding groups after 2 weeks (Table 4.3). In the whole group, 
hepatic glucose production was suppressed by 55% and 56% by the end of the clamp at 
baseline and following 2 weeks of overfeeding respectively. There was no difference in 
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hepatic glucose production suppression rates at baseline and after 2 weeks of fat overfeeding 
(62% vs. 68%), whereas hepatic glucose production was suppressed by 47% and 40% at 
baseline and after 2 weeks of carbohydrate feeding.  
5.4.6 Baseline insulin sensitivity 
Table 5.4: Baseline measurement of insulin sensitivity  
 Total 
n=22 
High Fat 
n=10 
High 
Carbohydrate 
n=12 
Difference 
between 
groups 
GDR (µmol/kg 
mass/min) 
25.0±1.7 26.1±2.7 24.2±2.3 0.6 
Fasting Glucose 
(mmol/L) 
4.4±0.1 4.6±0.1 4.2±0.1 0.01 
Fasting Insulin  
(mU/L) 
11.7±1.2 11.6±1.5 11.8±1.8 0.9 
HOMA-IR 2.1±0.2 2.2±0.4 2.1±0.2 0.3 
C-peptide 
(ng/mL) 
0.83±0.09 0.82±0.12 0.84±0.14 0.9 
Insulin/C-peptide 
ratio 
0.0021±0.0002 0.002±0.0003 0.002±0.0002 0.39 
Glucagon 
(pg/ml) 
112.6±6.2 105.1±9.0 119.5±7.9 0.25 
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5.4.7 Baseline lipid, liver and inflammatory markers 
Table 5.5: Baseline lipid, liver and inflammatory markers 
 Total 
n=21 
High fat 
n=10 
High 
carbohydrate 
n=11 
Difference 
between groups 
FFA (mmol/L) 0.50±0.03 0.46±0.05 0.53±0.05 0.27 
Cholesterol (mmol/L) 5.0±0.2 5.1±0.3 5.0±0.3 0.8 
HDL(mmol/L) 1.01±0.04 1.01±0.04 1.01±0.05 1.0 
LDL(mmol/L) 3.39±0.21 3.46±0.29 3.32±0.28 0.74 
Apolipoprotein A1 (g/L) 1.11±0.03 1.09±0.04 1.14±0.06 0.7 
Apolipoprotein B (g/L) 1.02±0.06 0.96±0.09 1.05±0.07 0.8 
AST (U/L) 24.3±1.7 21.6±1.5 26.8±2.6 0.1 
ALT (U/L) 15.6±1.9 14.2±2.2 16.9±2.9 0.47 
TAG (mmol/L) 1.37±0.11 1.26±0.15 1.47±0.16 0.34 
CRP (mg/L) 2.28±0.69 2.27±0.9 2.29±0.93 0.99 
IL-6 (pg/mL) 4.9±1.7 6.6±3.1 3.3±1.4 0.3 
Lactate (mmol/L) 1.1±0.1 0.9±0.1 1.2±0.1 0.22 
TNF-α (pg/mL) 6.6±2.4 8.6 ±4.3 4.7±2.3 0.4 
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5.4.8 Effect of high fat or carbohydrate overfeeding after 2 weeks 
Table 5.6: Insulin sensitivity and lipid, liver and inflammatory markers at baseline and after 2 weeks of high fat and high carbohydrate 
diets. (Where specifically indicated, total n=22, high fat n=10 and high carbohydrate n=12). *P<0.05; **P<0.01; ^P= 0.07; 
†
P=0.09 
compared to week 0. 
 Total 
n=22 
High Fat 
n=10 
High Carbohydrate 
n=12 
Differential 
effects 
P value 
 0 weeks 2 weeks 0 weeks 2 weeks 0 weeks 2 weeks  
GDR µmol/kg mass/min)  25.0±1.7 23.7±1.9 26.1±2.7 24.5±2.3 24.2±3.0 23.1±2.9 0.59 
M Value (mg/kg 
mass/min)  
4.51±0.31 4.44±0.37 4.70±0.48 4.89±0.51 4.35±0.40 4.08±0.52 0.38 
Fasting Glucose 
(mmol/L) 
4.4±0.1 4.5±0.1 4.6±0.1 4.5±0.1 4.2±0.1 4.5±0.1 0.04 
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Fasting Insulin (mU/L) 10.2±0.9 10.5±1.1 10.4±1.7 10.8±2.4 10.0±0.8 10.2±0.5 0.85 
HOMA-IR  2.0±0.2 2.1±0.2 2.2±0.4 2.2±0.5 1.9±0.2 2.0±0.1 0.49 
C-peptide (ng/ml) 0.83±0.09 0.83±0.11 0.82±0.13 0.84±0.16 0.84±0.14 0.82±0.17 0.78 
Insulin/C-peptide ratio 0.002±0.0002 0.002±0.0003 0.002±0.0003 0.002±0.0005 0.002±0.0002 0.002±0.0002 0.31 
Glucagon (pg/ml)n=21 114.3±5.9 108.9±6.4 105.1±9.4 110.5±14.1 119.5±7.9 114.5±9.4 0.48 
FFA (mmol/L) 0.50±0.03 0.44±0.03 0.46±0.05 0.45±0.03 0.53±0.05 0.43±0.05^ 0.65 
Leptin (ng/mL) 9.9±1.0 11.5±1.7* 9.1±1.1 10.0±1.1 10.6±1.6 12.8±2.1^ 0.49 
Cholesterol  (mmol/L) 5.0±0.2 5.1±0.2 5.0±0.3 5.2±0.3 5.0±0.3 5.1±0.3 0.8 
HDL (mmol/L) 1.01±0.03 1.01±0.05 1.02±0.04 1.09±0.07 1.01±0.05 0.96±0.05 0.3 
LDL (mmol/L) 3.3±0.2 3.5±0.2 3.3±0.3 3.5±0.3 3.3±0.3 3.5±0.3 0.5 
Apolipoprotein A1 (g/L) 1.10±0.03 1.18±0.02** 1.09±0.04 1.22±0.03* 1.14±0.06 1.17±0.04** 0.79 
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Apolipoprotein B(g/L) 1.01±0.06 1.08±0.05** 1.00±0.09 1.10±0.09* 1.03±0.07 1.07±0.06** 0.98 
AST (U/L) 24.3±1.7 26.7±2.4 21.6±1.5 22.5±1.7 26.8±2.6 30.5±3.9 0.2 
ALT (U/L) 15.6±1.9 17.7±1.5 14.2±2.2 15.7±2.2 16.9±2.9 19.5±2.0 0.3 
TAG (mmol/L) 1.37±0.11 1.72±0.16* 1.23±0.15 1.47±0.16 1.47±0.16 1.95±0.25* 0.49 
CRP (mg/L) 2.3±0.7 1.9±0.4 2.3±0.9 1.6±0.4 2.1±0.9 2.0±0.7 0.91 
IL-6 (pg/mL) 4.6±1.5 4.7±1.2 6.6±3.1 6.8±2.3 3.1±1.3 3.0±0.9 0.9 
Lactate (mmol/L) 1.07±0.07 1.22±0.09* 0.98±0.10 1.05±0.08 1.15±0.09 1.37±0.13
†
 0.08 
TNF-α (pg/mL) 6.6±2.4 7.3±2.5^ 8.6±4.3 9.4±4.5 4.4±2.2 5.0±2.4
†
 0.38 
Uric acid 350.5±14.6 348.1±14.1 331.5±21.4 333.3±15.9 369.5±21.4 362.8±25.0 0.24 
β-OH butyrate n=21 0.18±0.02 0.17±0.02 0.15±0.03 0.18±0.02 0.21±0.03 0.17±0.04 0.38 
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Markers of insulin sensitivity in the high carbohydrate and high fat-fed groups at baseline 
were matched apart from fasting glucose. There were no changes in fasting plasma glucose, 
serum insulin, glucagon, glucose disposal rates, HOMA-IR or adipose tissue-IR following 2 
weeks of energy excess. There were also no differential effects between dietary groups at 2 
weeks. 
5.4.9 Lipid, liver and inflammatory markers 
Lipid profile, liver function and inflammatory markers were well-matched between the two 
groups at baseline. Fasting TAG increased in the whole group following 2 weeks of excess 
energy intake. This was particularly noted in the carbohydrate-fed group where TAG 
increased by 23% from week 0. Fasting liver enzymes (AST, ALT), total, high density 
lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol did not change following 2 
weeks of excess energy in the HF and HC diets.  After 2 weeks of energy excess, there were 
increases in Apolipoproteins A (Apo A) and B1 (Apo B1) in the whole group, but this was 
only significant in the HF group. Fasting serum leptin increased following 2 weeks of excess 
overfeeding and a trend was seen (P=0.07) after consumption of a high carbohydrate diet. 
Plasma lactate and TNF-α increased in the group as a whole after 2 weeks of excess energy, 
with a trend of an increase seen with both (P=0.09) in the high carbohydrate fed group. No 
difference was seen with the systemic inflammatory markers CRP and IL-6, uric acid and 
beta-hydroxybutyrate across the groups.  
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5.4.10    Plasma measurements during the hyperinsulinaemic euglycaemic clamp  
5.4.10.1 Insulin 
 
 
Figure 5.4: Serum insulin before and during the hyperinsulinaemic (30mu/m
2
/min) 
euglycaemic clamp 
In the first 2 hours of the study (pre-insulin), fasting serum insulin averaged 11.8mU/L. 
During the hyperinsulinaemic euglycaemic clamp, serum insulin rose to and plateaued at 
59mU/L for the following 2.5 hours.  
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5.4.10.2 Free fatty acids  
 
Figure 5.5: Serum FFA before and during the hyperinsulinaemic (30mu/m
2
/min) 
euglycaemic clamp 
 
During the 2 hours pre-insulin, whole group fasting FFA concentrations averaged 0.50 ± 0.03 
mmol L
-1
 at baseline with no difference after 2 weeks of overfeeding at 0.44±0.03 mmol L
-1
. 
Post-insulin, FFA levels were suppressed at 0.06±0.01 and 0.07±0.01mmolL
-1
 at baseline and 
after 2 weeks respectively. There were no differential effects of carbohydrate and fat 
overfeeding on FFA levels.    
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5.4.11 Indirect Calorimetry 
Table 5.7: Indirect calorimetry fasted and at steady-state insulin at 0 weeks and after 2 weeks of high carbohydrate or fat. 
Data from only 7 and 11 participants from the high fat and high carbohydrate groups respectively were obtained due to technical/incomplete data 
retrieval. *P<0.05 different from fasting values, week 0 
 High Fat n=7 High Carbohydrate n=11 
 Week 0 
(Fasting) 
Week 0 
Post-clamp 
Week 2 
Fasting 
Week 2 
Post-
clamp 
Week 0 
Fasting 
Week 0 
Post-clamp 
Week 2 
Fasting 
Week 2 
Post-clamp 
Cox (J/kg/min) 6.6 ± 1.1 17.6±4.4* 8.4± 2.4 14.3±2.9 7.2±2.1 12.0±4.2 10.1±4.1 18.6±2.8 
Fox(J/kg/min) 62.6 ± 3.2 52±5.7 58.8±3.3 50.9±2.7 54.5±2.8 49.3±3.6 52.1±4.6 43.6±2.3 
EE(J/kg/min) 69.2 ± 2.9 68.8±2.5 66.6±1.8 64.6±1.7 61.8±1.3 62.3± 1.7 61.3±1.6 62.1±0.9 
RER 0.73±0.01 0.78±0.02 0.77±0.02 0.78±0.02 0.74±0.01 0.76±0.02 0.75±0.02 0.78±0.01 
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Carbohydrate oxidation at rest increased post-insulin in the high fat group at 2 weeks. No 
significant changes in carbohydrate or fat oxidation, EE and RER were seen after 2 weeks of 
either fat or carbohydrate overfeeding.  
5.4.12 Intramyocellular and extramyocellular lipid content 
 
Figure 5.7: Intramyocellular (IMCL) and extramyocellular lipid (EMCL) fractions using 
magnetic resonance spectroscopy at 0 weeks and after 2 weeks of fat and carbohydrate 
(CHO) overfeeding. 
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5.4.12.1 Intramyocellular Lipid (IMCL) 
IMCL did not change from baseline after 2 weeks of fat or carbohydrate overfeeding, nor 
were there differences between the dietary groups. 
5.4.12.2 Extra-myocellular lipid (EMCL) 
There were no significant changes in EMCL with either diet (Figure 5.7). 
5.4.13 Intervention outcomes 
5.4.13.1 Tolerability/Side-effects 
There were no study participant drop-outs. The reasons for incomplete study visits are 
outlined below (Table 5.8). 
No major side-effects from consuming the meals during the overfeeding period were reported 
by participants. Minor side-effects reported included headache (likely secondary to caffeine 
or fluid restriction in one participant in the HC group), nausea and vomiting 2 hours after 
completing the hyperinsulinaemic clamp visit (may be secondary to increased food intake 
post-clamp), constipation (subject in HC group possibly secondary to changes in dietary 
intake), bloating and fullness (subject in HC group secondary to increased intake in addition 
to carbohydrate drink). These effects were self-limiting and did not last beyond the period of 
overfeeding. No major complications from the cannulation, blood-taking or scanning were 
reported; any concerns were brought up by participants and communicated to the study 
investigator and resolved completely.  
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Table 5.8: Participants excluded from MRI/MRS liver and muscle 
Subject ID Group Reason 
10 High fat Did not complete second visit of insulin 
clamp as problems with cannulation and 
subject was not keen to proceed further 
8 High carbohydrate Did not have MRI /MRS as deemed 
unsafe to have magnetic imaging given 
participant’s job working with steel and 
risk of exposure of metal fragments in 
eyes 
23 High carbohydrate Did not have MRI/MRS because of a 
metallic implant in subjects’ spine-this 
would have interfered with MR signalling 
and data interpretation over abdominal 
area. 
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5.5 Discussion 
5.5.1 Effects of overfeeding on liver fat content  
2 weeks of high energy feeding increased percentage liver fat content from baseline in the 
group as a whole, but no difference in liver fat content between HF and HC groups were 
seen. There was an increase in liver fat by 3.52 ± 1.45% from baseline in the HC-fed group. 
This is consistent with several studies (Ngo Sock et al. 2010, Sobrecases 2010, van Herpen et 
al. 2011, Sevastianova et al. 2013, Westerbacka 2005) but contradicts others (Le et al. 2006, 
Silbernagel et al. 2011). The studies involving carbohydrate feeding and which did not 
observe increased liver fat content were conducted in lean people (Le et al. 2006 and 
Silbernagel et al. 2011). In the present study, overweight or obese males were recruited as 
they are likely to have an initial degree of liver fat and insulin resistance compared to healthy 
lean participants. They are therefore likely to have a greater predisposition to metabolic 
perturbations from dietary change, compared to leaner people.     
5.5.2 Effect of hyperenergetic high carbohydrate and high fat diets on hepatic glucose 
production 
Although overfeeding with 25% excess energy increased liver fat content it did not affect 
hepatic insulin sensitivity or insulin suppression on hepatic glucose production over a 2 week 
period. However the scatter of hepatic glucose production data (standard deviation) is notable 
so the possibility of a type 2 statistical error should be considered.      
5.5.3 Effects of hyperenergetic high carbohydrate and high fat diets on insulin 
sensitivity 
2 weeks of excess energy of either carbohydrate or fat did not result in changes to whole-
body insulin sensitivity as measured by the hyperinsulinaemic–euglycaemic clamp. This may 
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be the result of several factors.  It may be that there is indeed no influence of either diet on 
insulin sensitivity. In a recent study involving overweight participants over a 12 week period 
of consuming a high energy high fructose diet, there was a trend for decreased hepatic insulin 
sensitivity, increased fasting glucose and insulin; however this did not result in whole-body 
insulin resistance (Tappy et al 2015). Stanhope et al (2009) however showed changes in 
hepatic insulin sensitivity and liver fat content following a similar period of fructose 
overfeeding. Changes in whole-body insulin sensitivity may not be appreciable until 
participants gained significant weight. In this study neither weight gain nor a significant 
increase in RER were seen using indirect calorimetry. A recent study (Boden et al. 2015) 
involved overfeeding healthy males with a 6000 kcal/day typical Western diet (50% CHO, 
35% fat and 15% protein) for 1 week. Participants gained weight (+3.5kg), had raised insulin 
levels and developed insulin resistance (increased HOMA-IR). It may also be that early 
changes at a cellular level that alter insulin signalling may occur before manifesting as whole 
body insulin sensitivity, as seen in the study by Adochio et al. 2009. This was not assessed in 
the present study but calls for further investigation in future studies.  It has also been 
suggested that there may be differences in how individuals respond to overnutrition based on 
their baseline insulin sensitivity (Adochio et al. 2009). In that study there was significant 
heterogeneity in baseline measures of insulin sensitivity (M-value: 7.68 to 17.71 mg/kg 
FFM/min).       
5.5.4 Effects of hyperenergetic high carbohydrate and high fat diets on FFA, lipids and 
liver enzymes 
The accumulation of fat in the liver is recognised as a major contributor to metabolic disease 
(Marchesini et al. 2001). It has been postulated that when fatty acids exceed the liver’s 
capacity to secrete or oxidise excess fat, these are stored as triglycerides. Net retention of 
triglycerides is the pre-requisite for development of NAFLD (Yki-Jarvinen, 2013). At 
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baseline, triglycerides, liver enzymes, cholesterol, HDL, LDL, Apolipoprotein A1 (HDL) and 
B (non-HDL) did not differ between the two groups. Subsequently following 2 weeks of 25% 
excess energy, triacylglyceride levels increased by 24% overall, with a greater effect seen in 
the high-carbohydrate fed group.  Apolipoprotein A1 and B increased in the group after 2 
weeks of overfeeding with significance in the high-fat group but without concomitant rise in 
total cholesterol, HDL or LDL. Contrary to Stanhope’s study (Stanhope et al. 2011), fasting 
Apolipoproteins A1 and B were increased to a greater degree (p<0.01) following 2 weeks of 
overfeeding in the high fat-fed participants.  High triglyceride levels are commonly seen in 
consumption of high-carbohydrate diets, from fatty acids generated from DNL that drive 
hepatic triglyceride overproduction (Nestel et al. 1998, Boberg et al. 1972). Similar effects 
are seen in other studies of high carbohydrate, low fat studies (Parks et al. 1999, Purkins 
2004). Parks utilised a whole-food, high-fibre diet as opposed to others using liquid forms of 
high carbohydrate or diets high in mono or disaccharides. This study used carbohydrates in 
the form of maltodextrin (a form of soluble polysaccharide produced from starch through 
partial hydrolysis), which has been used successfully as a carbohydrate supplement in other 
human studies (Teunissen–Beekman et al. 2013, Detko 2013).  Schwartz et al. 2013 showed 
that consumption of a high-fat, low-carbohydrate diet for 5 days did not affect plasma TAG 
concentrations, however after 5 days of low-fat, high-carbohydrate diet there was a 
significant 1.5-fold increase in plasma TAG concentrations.  The major mechanism proposed 
for raised TAG as a result of high-carbohydrate feeding observed from Parks’s study was 
reduced clearance of VLDL-TAG from plasma as opposed to increased secretion as 
determined from plasma palmitate kinetics. It would also appear that the type of carbohydrate 
(simple vs complex) influences fatty acid synthesis, production and clearance rate. Simple 
sugars are more effective than complex carbohydrate in stimulating DNL (Hudgins et 
al.1996).  Barter and Nestel 1973 showed that the majority of VLDL-fatty acids were not 
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derived from NEFA in obese individuals but that elevated BMI correlates with lower 
contributions of plasma NEFA to VLDL-lipid. Many studies have established previously that 
high-carbohydrate diets increase TAG concentrations (Nagle et al. 2009). In addition to 
confirming these findings, data from this study, as well as those of others (Schwarz et al. 
2003, Nagle et al. 2009), support the hypothesis that hepatic DNL contributes to this process. 
When normoinsulinaemic and hyperinsulinaemic participants consume a low-fat, high-
carbohydrate diet with more than half of the carbohydrate in the form of simple sugars, in 
particular fructose, hepatic DNL, plasma and liver TAG concentrations are increased. The 
underlying mechanisms for increased TAG following high carbohydrate intake include 
overproduction or reduced clearance of TAG from plasma (Parks et al. 1999). Previous 
studies have shown that carbohydrate rather than energy cause the significant increase in 
triglycerides. In concert with other studies (Purkins et al. 2004) there was no effect on 
cholesterol levels, and may be because the diets were not maintained for an adequate period 
of time.  
Contrary to studies exhibiting significant effects of diets on liver enzymes, this study 
did not show an effect of the high fat nor high carbohydrate diets on the transaminases AST 
and ALT. Purkins et al. 2004 showed that 9 days of high energy (doubling of energy 
requirements) high carbohydrate diet caused marked increases in transaminases compared to 
isoenergetic high fat diet. A clear relationship to the number of days on the diet was also 
seen, demonstrating the importance of the carbohydrate component rather than high energy 
content as a major determinant on liver enzymes. Porkos and Van Itallie (1983) showed that 
it was the surplus of energy and high sucrose which contributed to the rise in transaminases. 
However the difference between these studies and the present study is the increased amounts 
of surplus energy provided in previous studies fed more than a week, and reflects the greater 
effect of increased energy and weight gain on liver enzymes.  
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No difference in the contribution of fatty acids to liver and VLDL-TG from differing sources 
such as systemic NEFA, DNL, or diet was found in the study by Donnelly et al. 2005. 
However incorporation of 
13
C tracer from the test meal into liver showed (through MRS) that 
this occurred more rapidly and to a greater extent in diet-controlled T2DM compared with 
age and BMI-matched controls. This may be that the rapid fluxes of fat into and out of liver 
protects the body from excessive plasma TAG fluxes in the immediate post-prandial period. 
Another possible explanation is that the buffering capacity of adipose tissue in insulin 
resistance is impaired leading to overspill into liver and accumulation of TAG. Previous 
studies have either shown an increase (Stanhope et al 2009), no increase (isocaloric diet of 
high fructose) or normal levels of triglycerides in normal weight and obese individuals. In 
Bravo’s study (2013), change in triglyceride levels correlated with a change in weight, BMI 
and fat mass, with no correlation to change in total energy intake or sugar intake or an effect 
on liver and muscle fat.   
5.5.5 Effect of hyperenergetic HF and HC intake on inflammatory markers and 
adipokines 
Low-grade inflammation is frequently observed in obese adults, which has been proposed as 
a potential cause of increased risk for T2DM and cardiovascular disease (Emanuela 2012). 
The present study showed that excess energy consumption increased TNF-α in the whole 
group. There was also a tendency for TNF-α to increase after carbohydrate overfeeding 
compared to the high fat-fed group. No effect of the diets on IL-6 or CRP was seen amongst 
groups. Several studies of carbohydrate and glucose loading have shown an effect on 
increasing inflammatory markers (Kasim-Karakas 2006). Intravenous glucose administration 
increased concentrations of inflammatory markers IL-6 and TNF-α (Esposito et al. 2002). 
Direct correlations between carbohydrate overfeeding and IL-6 and CRP were seen and 
attributed to increased oxidative stress, triacylglycerol production in the liver causing hepatic 
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steatosis (Solga et al. 2004; Kerner et al. 2005). The CRP and IL-6 production in this study 
did not change contrary to the studies above. The adipokine leptin, produced by adipose 
tissue is a mediator of energy balance and is elevated in the obese (Klok et al. 2007).  Leptin 
concentrations in both high-fat and carbohydrate-fed groups in this study increased after 2 
weeks of energy excess as expected. 2-8 weeks overfeeding increased adipocyte leptin 
expression and circulating leptin in healthy human subjects (Kolaczynski et al. 1996, Levine 
et al. 1999).  A trend for increased levels was seen in the high-carbohydrate group. However 
this did not correspond to an increase in energy expenditure. High-fat meals are shown to 
lower 24-hour circulating leptin levels relative to high-carbohydrate meals (Havel 1999).    
5.5.6 Effects of overfeeding on IMCL  
IMCL is an early marker for the development of insulin resistance (Schrauwen-Hinderling, 
Hesselink et al. 2006). An increased IMCL content is the result of either increased circulating 
fatty acid delivery or reduced oxidation, possibly mediated through intermediary metabolites 
of triglycerides (Machann, Haring et al. 2004). This study, consistent with several other 
overfeeding studies has failed to show muscle fat accumulation. This appears to occur in 
studies of less than 10 weeks duration. Maersk et al. (2012) showed that liver fat and muscle 
fat accumulation increased over 6 months and it may well be that intramuscular fat 
accumulates long after liver fat accumulation. In concert with the absence of changes seen in 
intra-abdominal and subcutaneous fat mass seen in Westerbacka’s  study  (2005) and this 
present study suggest that the liver may be the first organ to store excess fatty acids.  
5.5.7 Effects of overfeeding on EMCL 
The extra-myocellular lipid (EMCL) content was measured as part of the process of 
determining IMCL content. EMCL is ectopic lipid stored within adipocytes which are 
interspersed between muscle fibres and reflects total body adiposity (Machann, Haring et al. 
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2004). EMCL was unlikely to change as there were no changes in weight or adiposity in this 
study. 
5.5.8 Study limitations 
5.5.8.1 Participants and anthropometrics 
Participants divided into the two groups were well-matched at baseline apart from a 
difference in skinfold biceps thickness; this did not appear to influence overall percentage 
total body fat calculated using the Siri formula. Moreover, despite the tendency towards a 
difference in percentage body fat between both groups there was no evidence to suggest that 
this impacted on study outcomes as no difference was seen in metabolic measures at baseline.  
Although baseline measurements of anthropometric, metabolic, and insulin clamp were 
obtained from all 24 participants, data from the insulin clamp were only possible from 10 vs 
12 participants in the high fat and high carbohydrate groups after the 2 week intervention 
period, respectively. This was due to a subject not completing the post 2 week intervention 
insulin clamp, and another where there was a technical issue with the insulin pump and thus 
data from the clamp study were likely unreliable. 
1
H MRS of the liver and muscle were 
performed in a total of 22 participants, 12 in the HF group and 10 in the HC group. The 2 
participants from the HC group did not proceed for scanning as they had contraindications to 
MRI. Participants were recruited through mailshots sent locally and advertisements in the 
local newspaper.  Only White European males were recruited to exclude variations in liver fat 
content at baseline that may be associated with ethnicity and that may confound results. 
Browning et al. reported a significant difference in the incidence of hepatic steatosis 
depending on ethnic origin from the multi-ethnic Dallas population Heart Study (Browning et 
al. 2004). Furthermore there were differences in intra-abdominal fat accumulation, insulin 
resistance, and lipid metabolism (Guerrero et al. 2009). Another study showed that a high 
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energy high fat diet rapidly induced insulin resistance in healthy South Asians compared to 
White European men (Bakker et al. 2014). 
5.5.8.2 Study design 
Some issues of this study will need to be given cautious consideration prior to the 
interpretation of the data obtained. As with human nutritional studies, factors such as 
compliance, subject phenotype, total number of participants, environmental control and diets 
prescribed and when these are taken during the day may influence outcomes and data 
interpretation.  
The variability of baseline liver fat may have also affected overall liver fat accumulation and 
hepatic glucose production post-intervention, thus a greater number of participants should be 
considered in future studies to reduce the scatter. Compliance will also need to be considered 
as a major contributor particularly in the outpatient/community setting. Although participants 
were requested to note down any failure to consume the food provided, it is difficult to 
entirely control total dietary intake and changes in activity in the absence of a controlled 
environment.  Markers of overfeeding include weight gain, change in TAG levels and fasting 
carbohydrate oxidation rates. 25% excess energy in the form of either carbohydrate or fat 
after 2 weeks was expected to increase weight in participants. Contrary to expectations, this 
only occurred in half of the participants. 6 of 11 and 6 of 12 participants gained weight in the 
high-fat and high-carbohydrate groups respectively. However triacylglycerols increased after 
2 weeks of overfeeding in the whole group (16/24), more so in the HC group (9/12) 
indicating a degree of overfeeding success. However no changes in fasting carbohydrate and 
fat oxidation rates were seen at 2 weeks compared to baseline.   
The relatively small change in weight and individual variation in the deposition of fat during 
overfeeding may have contributed to the variation of weight after 2 weeks. Sims’ overfeeding 
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study showed large variations in weight gain amongst subjects despite being fed similar 
amounts of energy (Sims et al. 1978). Nonetheless, overall little or no weight gain was seen 
in this study and may have been a result of several factors. Underreporting of dietary intake, 
changes to activity levels, concerns with weight gain and even errors with weight 
measurement may have influenced the apparent lack of weight gain in this study’s subjects. 
The absence of changes seen in intra-abdominal and SC fat mass seen in Westerbacka’s study 
(2005) and this present study suggest that the liver may be the first organ to store excess fatty 
acids. Although this postulation cannot yet be substantiated by other studies as similar 
experiments are relatively scarce, this finding parallels that seen in animal studies. Rats fed a 
high fat diet had increased hepatic triglycerides that induced hepatic insulin resistance but not 
muscle insulin resistance. No changes in weight or SC fat were seen (Samuel et al. 2004).  
Carbohydrate and lipid oxidation rates, and FFAs remained unchanged after 2 weeks and 
these findings were also seen in studies of Westerbacka et al. 2005 and Bischop et al. 2001.   
Although most of the participants in this study had baseline IHCL values at >95
th
 percentile 
for the general population (>5.6%; Szczepaniak et al. 2005), data generated from this 
relatively small study with generally healthy but overweight males may not be truly 
representative of the disease pathology seen in the population at risk of NAFLD. The 
overfeeding period was relatively short considering a median follow up of 3 weeks for other 
high energy studies (see Chapter 1, Table 1.1) and thus may not have been long enough for 
an appreciable effect to be seen in liver or muscle. However based on current studies 
observed in literature, 2 weeks have, in the majority of cases, been found to produce effects 
on liver and muscle fat.  Assessing fatty liver via liver biopsies was also not utilised, however 
this method is invasive and poses a greater risk of complications and will not appeal to many 
subjects.  A liver biopsy is also primarily used in clinical practice for diagnostic purposes and 
is unable to measure liver fat content to the degree of detail as MRS can. Finally to eliminate 
226 
 
any possible effects of the isoenergetic diet on baseline liver fat and exclude subjects with 
low liver fat content, subjects should have undergone baseline MRI of their liver before the 
isoenergetic feeding period, however this was not feasible from a logistics point of view. 
Participants resting metabolic rate should also be ideally quantified using indirect calorimetry 
to estimate energy requirements when developing their diets. As with most nutrition and 
feeding studies total compliance with food intake and activity levels may not have been 
strictly controlled in free-living conditions. Ideally studies such as this should be undertaken 
under controlled laboratory environment; however this is not always feasible, requires 
intensive research staffing levels and deviates from studying individuals in their normal 
environment.     
5.6 Conclusion 
In conclusion, this study has shown that 25% excess energy intake over a 2-week period can 
increase liver fat content but there was no differential effect between the overfed 
carbohydrate and high fat groups. There was no effect on IMCL for both groups. The 
metabolic effects of moderate excess energy consumption per se are therefore greater than 
any differential effects of fat vs. carbohydrate overfeeding. Although liver fat increased from 
baseline in the high carbohydrate arm, 2 weeks of overfeeding did not affect hepatic or whole 
body insulin insensitivity. There was no significant liver fat accumulation following high-fat 
overfeeding. Future studies should investigate the effects of high fat vs. high carbohydrate on 
liver fat and skeletal muscle in people with pre-diabetes or impaired glucose tolerance (IGT), 
and examine further the underlying mechanisms of the association between macronutrients 
and insulin sensitivity.   
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Chapter 6: STUDY 4 
Investigating the effect of carnitine on fatty acid oxidation and insulin sensitivity in 
older healthy males. 
 
6.1 Introduction 
 
As alluded to in chapter 3, IMCL oxidation during exercise is impaired in older compared to 
young individuals, albeit these are overweight subjects. Therefore one of the underlying 
factors affecting insulin sensitivity in the elderly may be reduced fat oxidation capacity.  
Improving understanding in mechanisms involved in ageing, fatty acid oxidation, insulin 
resistance and strategies to improve insulin sensitivity in this age group is clearly warranted. 
Energy restriction and weight loss have been shown to reduce insulin and glucose 
concentrations (Wing, Blair et al. 1994) whereas increasing physical activity is clearly of 
benefit to reducing the risk of insulin resistance in ageing (Mayer-Davis, D'Agostino et al. 
1998; Castaneda, Layne et al. 2002). In particular exercise training studies involving older 
individuals appear to improve basal fat oxidation and mitochondrial content and function 
suggesting an increase in IMCL utilisation (Solomon, Sistrun et al. 2008). However many of 
these training sessions involve exercising at moderate to high intensities (>60% VO2 max) for 
many hours per week that may prove unrealistic for the majority of older individuals. 
Moreover, the benefits of energy restriction in older individuals will need to be weighed 
against quality of life concerns. For example, individuals subjected to long-term energy 
restriction encountered issues such as reduction in bone mineral density, muscle mass, and 
lethargy (Speakman and Hambly 2007). In later stages of life particularly in frail individuals 
with sarcopenia, energy restriction may even be counterproductive. 
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Taking all the above into consideration strategies to improve IMCL utilisation and thereby 
insulin sensitivity in older individuals whilst ensuring an attainable and realistic regimen are 
ideal.  
6.1.2 Rationale behind the hypothesis that carnitine improves insulin sensitivity 
Carnitine’s primary role in regulating fatty acid metabolism raises prospects that the 
availability of this quaternary ammonium compound in skeletal muscle could be manipulated 
to improve insulin sensitivity (Stephens et al. 2007).  
Carnitine (3-hydroxy-4-N-trimetyl-aminobutyric acid) has been found to play a central role in 
mitochondria specifically in fatty acid oxidation. Carnitine facilitates transport of long-chain 
fatty acids into mitochondria for subsequent beta-oxidation under the influence of the rate-
limiting carnitine-palmitoyltransferase 1 (CPT-1) reaction (Fritz et al. 1959). It is also 
involved in buffering excess acyl-coA by shuttling these (as acylcarnitines) and other 
shortened chained products out of the mitochondria formed during conditions of increased 
pyruvate dehydrogenase complex (PDC) flux such as high intensity exercise. As intracellular 
accumulation of acyl-coA derivatives have been implicated in the development of insulin 
resistance it is thought that carnitine supplementation might overcome this. A reduction in 
muscle lactate content following carnitine infusion and hyperinsulinaemia was associated 
with decreased pyruvate dehydrogenase activity and increase glycogen synthesis, suggesting 
a carnitine- mediated increase in fat oxidation (Stephens et al. 2006, Mingrone et al 1999). 
Indeed it has been shown that carnitine deficiency is associated with insulin resistance, 
diabetes (Tamamogullari et al. 1999), ageing and obesity (Noland et al. 2009).  Carnitine 
improved insulin-stimulated glucose disposal in mice with genetically and diet-induced 
diabetes (Power, Hulver et al. 2007). In human studies involving acute intravenous carnitine 
administration in combination with euglycaemic insulin clamp, whole body glucose disposal 
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improved in normal healthy participants (Mingrone 1999) and in individuals with T2DM 
(Capaldo et al. 1991, Mingrone 1999).  
When combined with a beverage containing large quantities of carbohydrate, oral carnitine 
supplementation in young healthy humans increased muscle total carnitine content and 
resulted in a significant switch from carbohydrate to fat oxidation, reduction in muscle 
glycogen utilisation and PDC inactivation during low intensity exercise. The increased fatty 
acid oxidation was thought to prevent accumulation of fat mass, enhance energy expenditure 
and exercise performance and upregulate expression of genes related to fat metabolism and 
insulin signalling (Wall et al. 2011, Stephens et al. 2013). The rationale behind ingesting oral 
carnitine and a carbohydrate supplement lies with several studies that have successfully 
demonstrated increment of total carnitine in plasma and muscle in subjects when serum 
insulin levels were elevated. Studies involving carnitine supplementation have shown a 
significant increment and maintenance in total muscle carnitine with carbohydrate 
supplement compared to those without (Wall et al. 2011, Stephens et al. 2013). The 
underlying mechanism could be explained by the premise that carnitine uptake is insulin-
mediated. Under conditions where insulin and carnitine levels are elevated, muscle OCTN2 
(skeletal muscle carnitine transporter protein) expression and sarcolemmal Na
+
/K
+
 ATPase 
pump activity are increased. Na-coupled carnitine transport is thus augmented by its action of 
stimulating intracellular Na flux (Stephens et al. 2006). 
Research outcomes thus far strongly suggest that carnitine supplementation can increase fat 
oxidation and it is further reasonable to speculate that carnitine can influence insulin 
sensitivity by promoting fat oxidation rates, prevent accumulation of intramuscular lipid and 
its intermediate metabolites from interfering with insulin signalling pathways.  
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Figure 6.1: Carnitine’s role in fatty acid metabolism. Carnitine transports long-chain acyl 
groups from fatty acids into the mitochondrial matrix by the rate-limiting Carnitine 
Palmitoyltransferase 1 (CPT1) located on the outer mitochondrial membrane. Acylcarnitine is 
shuttled inside by carnitine-acylcarnitine translocase (CACT), and then converted to acyl 
CoA by carnitine acyltransferase II (CPT II). Long chain acyl-CoA subsequently undergoes 
beta-oxidation before being fed into the TCA cycle. 
 
6.2 Aims of Study 
The aim of this study was to examine if muscle total carnitine content of older people could 
be increased over a 24-week period via ingestion of daily oral L- carnitine in combination 
with an insulinogenic beverage and twice weekly 1 hour light-intensity exercise. The study 
also aimed to determine the effects of increasing skeletal muscle carnitine content on body 
composition, substrate oxidation utilisation during rest and exercise and whole body glucose 
disposal in older healthy people. 
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It was hypothesised that skeletal muscle total carnitine (TC) is reduced in older compared to 
younger healthy men and that chronic L-carnitine in combination with light intensity exercise 
(as maximal fat oxidation rates are elicited at this intensity (Romijn et al. 1993) in older 
healthy male volunteers can increase skeletal muscle TC to a similar degree seen in studies 
involving carnitine supplementation to young volunteers. It was also postulated that 
increasing skeletal muscle carnitine content and improving fat metabolism during light-
intensity exercise in older people would improve insulin sensitivity in older people.  
Whilst previous studies of carnitine supplementation in young volunteers utilised beverages 
high in carbohydrate to augment the effects of carnitine, this study used a beverage lower in 
carbohydrate content but with additional protein to avoid the detrimental effects of high 
carbohydrate overfeeding in older participants whilst maintaining an insulin response.    
6.3 Methods 
6.3.1. Human participants and ethical approval: 
Fourteen healthy males (69.1±0.6 years, body mass 78.2 ±2.7kg) were recruited to the study. 
All participants underwent medical screening and blood testing and gave informed consent as 
described in the common methods section (Chapter 2).  
The incremental maximal oxygen consumption (VO2 max) test was performed to determine 
the workload or intensity participants were cycling equivalent to 50%VO2 max. Participants 
completed a health related quality of life (QoL) questionnaire (Short Form-36 SF36v2™),  
incremental shuttle walk test (ISWT) and experimental visits at the start and end of the study. 
Participants were then randomised in a double-blinded manner to two groups ingesting either 
4.5 grams of L-carnitine-L tartrate (Carnipure, Lonza) (CARN) or 4.5 grams placebo (CON) 
in combination with an insulinogenic beverage (44.4 g carbohydrate, 13.4 g protein; 220mls 
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Ensure Plus Milkshake, Abbott, Illinois, USA) daily and completed a supervised twice 
weekly one hour bout of low-intensity exercise at 50% VO2 max for a total of 24 weeks. 
6.3.2 Protocol  
 
6.3.2.1 Resting visit 
Participants arrived at the MRC/ARUK Centre for Musculoskeletal Ageing Research 
laboratory at 0800 after an overnight fast. A dual energy x-ray absorptiometry (DEXA) scan 
(Lunar Prodigy, GE Healthcare, US) was performed to assess body composition. They rested 
semi-supine on a bed while cannulae were inserted retrograde into a superficial vein on the 
back of the hand for arterialized blood sampling and forearm veins for insulin, glucose and 
2DG infusions. The hand was then placed in a hand-heated box throughout the experiment 
to allow for arterialised blood sampling (Gallen & Macdonald, 1990). A 3 hour 
hyperinsulinaemic euglycaemic clamp at 60 mU kg lean mass 
-1
 min
-1
 was carried out to 
assess insulin sensitivity. 2DG was infused at a rate of 6mg kg
-1
hr
-1
 at the same time. Blood 
glucose concentrations during the clamp were determined using an autoanalyser (Yellow 
Springs Instrument YSI, US). Indirect calorimetry was performed before and during steady 
state of the hyperinsulinaemic euglycaemic clamp (90 mins from start of clamp) using GEM 
(Gas Exchange Measurement, GEMNutrition Ltd, Cheshire, UK). Muscle biopsy samples 
using the technique described by Bergstrom were obtained from the vastus lateralis of each 
participant at rest before and immediately after the clamp to determine total muscle 
carnitine content.  
6.3.2.2 Exercise Visit 
At least a week after the resting study visit, participants reported to the laboratory and rested 
semi-supine on a bed while cannulae were inserted retrograde into a superficial hand vein 
for arterialised blood sampling and into a forearm vein for infusion of  [U-
13
C] palmitate, at 
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a concentration of 0.19mg kg
-1
 hr 
-1
for 2 hours. Breath samples were collected via one-way 
valve bags and introduced into breath tubes for subsequent 
13
CO2 enrichment analysis 
before the start of the infusion and every hour of the resting period. Plasma samples for 
palmitate tracer and FFAs were collected hourly during resting. At the end of the second 
hour, percutaneous biopsy from the vastus lateralis muscle was performed before 
participants went on to cycle on the ergometer at 50% VO2 max equivalent workload.  The 
[U-
13
C] palmitate infusion concentration was increased to 0.28 mg kg
-1
 hr
-1
 at the onset of 
exercise. Blood plasma for FFAs, palmitate tracer and breath samples for 
13
CO2 were 
obtained every 10 mins. During the last 10 mins of exercise, indirect calorimetry was 
determined Quark CPET system, Cosmed, Italy). A muscle biopsy of the vastus lateralis 
was taken at the end of the 1 hour exercise. 
Preparation of [U-
13
C] palmitate (99% enriched; Cambridge Isotope Laboratories, Andover, 
MA, USA) involved dissolving the palmitate in heated sterile water and passed through a 0.2 
μm filter into 4.5 % warmed (55°C) human serum albumin to obtain a palmitate to albumin 
ratio of approximately 3:1 (1.94:0.64 µmol l
-1
) . The solution was allowed to cool to room 
temperature. Prior to infusion, sodium [
13
C] bicarbonate at 0.06375mg kg
-1
 was injected as a 
bolus to prime the bicarbonate pool (Sidossis et al.1996). 
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Figure 6.2a: Schematic overview of protocol 
 
Figure 6.2b:  A –Resting visit involved 3 hr hyperinsulinaemic clamp and 2DG infusion, B-
Exercise visit involved a 3 hr palmitate tracer infusion and 1 hr cycling at 50% VO2 max. 
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6.3.3 Sample collection and analysis 
All DEXA scans were analysed by a single operator to avoid inter-operator variability. The 
scans were analysed for trunk, leg and arm composition using standardized regions 
conforming to specifications.  Blood samples were collected in tubes containing EDTA and 
centrifuged at 1000g at 4°C for 10 mins. Plasma aliquots were subsequently stored at -80
◦
C 
until analysis. Blood serum and plasma were collected at baseline and every 30 minutes 
during the clamp, allowed to clot and then centrifuged (1400 RCF at 4°C for 10 mins) for 
subsequent storage at -80°C until use for determination of insulin concentrations and 2DG 
tracer respectively.  
Biopsied muscle samples were immediately snap frozen in liquid nitrogen after the biopsy, 
freeze-dried and stored at -80°C. Muscle was dissected free of visible blood and connective 
tissue, powdered and used to determine muscle free carnitine, acetylcarnitine and long-chain 
acylcarnitine using the radioenzymatic method previously described by Cederblad and 
Lindstedt (Cederblad and Lindstedt 1972).   
6.3.4 Calculations 
Total fat and carbohydrate oxidation rates were calculated using the non-protein respiratory 
quotient (Frayn 1983). 
Fat oxidation rate = 1.695 VO2  X 1.701 VCO2 g/min 
Carbohydrate oxidation rate = 4.585 x VCO2-3.226 x VO2 g/min 
EE = 15.9 x VO2 + 5.2 x VCO2 J/min 
Where VO2 and VCO2 are expressed as litres per min and oxidation rates as grams per 
minute. 
Breath and plasma enrichments are expressed as the tracer/tracee ratio (TTR);  
TTR = (
13
C/
12
C)sa - (
13
C/
12
C)bk 
where sa denotes the sample and bk the background value. 
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The rate of appearance (Ra) and rate of disappearance (Rd) of palmitate was calculated using 
the single-pool non steady- state Steele equations adapted for stable isotope methodology as 
described by Wolfe & Jahoor 2006. 
 
Ra =  F – V[(C2 + C1)/2][(E2 – E1)/(t2-t1)] 
(E2-E1)/2 
        Rd = Ra – V (C2-C1) 
t2-t1 
where F denotes the infusion rate (μmol kg-1 min-1), V is the distribution volume for palmitate 
(40 ml kg
-1
), C1 and C2 are the palmitate concentration (mmol l
-1
) at times 1 (t1) and 2 (t2), 
respectively, and E1 and E2 are the plasma palmitate enrichments (TTR) at times t1 and t2, 
respectively. 
13
CO2 production (Pr
13
CO2; mol min
-1
) from the infused palmitate tracer was 
calculated as: 
Pr
13
CO2 = (TTRCO2
 x
 VCO2) 
where TTRCO2 is the breath 
13
C/
12
C ratio at a given time point, k is the volume of 1 mol of 
CO2 (22.4 l mol
-1
). 
Plasma palmitate oxidation (Rox; mol min
-1
) can subsequently be calculated as: 
Rox palmitate = Rd palmitate x (Pr
13
CO2/F x 16) 
where Rd palmitate is the rate of disappearance of palmitate (mol min
-1
), F is the palmitate 
infusion rate (mol min
-1
) and 16 is the number of carbon atoms in palmitate. Total plasma 
FFA oxidation was calculated by dividing palmitate oxidation rate by the fractional 
contribution of plasma palmitate to total plasma FFA concentration. 
The contribution of plasma FFA oxidation to total fat oxidation was determined by assuming 
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that the molecular mass of triglyceride is 860 gmol
-1
 and every TG molecules contain three 
fatty acids. 
The contribution of other fat sources was hence calculated by subtracting plasma FFA 
oxidation from total fat oxidation. 
Insulin sensitivity index clamp was calculated using the equation SIClamp = M/(G × ΔI) 
where M is normalized for G (steady-state blood glucose concentration;mmol 
-1) and ΔI 
(difference between fasting and steady-state plasma insulin concentrations,mUl-1). 
 
6.3.5 Power calculations 
From previous studies on increasing muscle total carnitine content (Wall et al. 2011, 
Stephens et al. 2013) a 20% difference in muscle total carnitine was expected to be seen in 
older and young participants and following 24 weeks of L-carnitine feeding a difference 
should be able to be detected in 7 older participants with a power of 80% at 5% significance 
level on a paired t-test basis. The repeated measures coefficient of variation for the insulin 
clamp technique is 10%, therefore a 15-20% difference in insulin sensitivity should be able to 
be detected in 7 participants. Therefore we aimed to recruit 10 volunteers for each group 
(Carnitine and Control) to allow for a 30% dropout.  
6.3.6 Statistical analysis 
Values presented in text, tables and figures are expressed as mean ± the standard error of 
mean (S.E.M). The level of significance for statistical tests was set at P < 0.05 and analyses 
were performed using the statistical package Graphpad Prism version 6.0.  Differences within 
and between groups were analysed using two-way ANOVA for repeated measures (time and 
treatment effects). When a significant time or treatment effect was observed post-hoc analysis 
using Sidak’s multiple comparison test was performed to identify individual differences. 
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6.4 Results 
Table 6.1: Participant characteristics at 0 and 24 weeks in the control (CON) (ingesting 4.5g 
placebo and insulinogenic beverage 44.4g CHO and 13.8g protein) and carnitine (CARN) 
groups (ingesting 4.5g L-carnitine L-tartrate and insulinogenic beverage 44.4g CHO and 
13.8g protein) in conjunction with twice weekly 1 hour exercise performed at VO2max 50% 
workload. 
 
Parameters Range CON (n=7) CARN (n=7) 
0 weeks 12 weeks 0 weeks 12 weeks 
Age (years) 65-73 68.4±1.0  69.9±0.6  
Body mass (kg) 60.2-
92.5 
77.6±3.7 79.6±3.0 78.9±4.0 78.1±3.6 
BMI (kgm
-2
) 21.2-
32.6 
25.7±1.2 26.5±1.0 27.2±1.2 27.1±1.2 
Lean body mass (kg) 42.7-
59.1 
49.4±1.0 49.3±0.8 51.3±2.3 50.6±2.1 
Fat mass (kg) 6.1-33 20.1±3.6 22.0±2.8 19.4±2.2 19.3±2.0 
Fasting Glucose (mmol
-1
) 4.2-5.6 4.7±0.1 4.8±0.2 5.0±0.1 4.7±0.2
 
Fasting Insulin (mIUL
-1
) 2.2-
18.1 
10.6±1.6 12.0±3.0 9.5±1.9 7.9±1.6 
VO2 max (ml kg
-1
min
-1
) 34.9-
49.6 
41.2±1.9  41.9±1.9  
Workload at 50% VO2 
max (W) 
22-75 53.7±5.7 53.7±5.7 48.4±7.1 48.4±7.1 
ISWT (m) 420-
690 
558.6±36.
1 
555.7±33.9 562.9±27.9 588.6±17.9 
SF36v2™score (%)  89.0 89.6 86.0 87.4 
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6.4.1 Muscle total carnitine content 
 
Figure 6.3: Skeletal muscle total carnitine content in control and carnitine groups at baseline 
and at 24 weeks. All values are expressed as means ± s.e.m. * P<0.05, 
+ 
P<0.05 
Skeletal muscle TC content at baseline were 17.5± 1.5 and 21.1± 1.3 mmol kg
-1
 dm in the 
control and carnitine groups respectively. These baseline values and skeletal muscle TC 
content at 24 weeks are presented in Figure 6.3. There were no differences between or 
within groups at baseline. After 24 weeks muscle TC was 38% greater in the carnitine 
group compared to control (24.5 ± 1.3 vs 17.5±1.5 mmolkg
-1
dm; *P<0.01).There was a 
16% increase in muscle TC from baseline (21.1 ± 1.3 to 24.5 ± 1.3 mmolkg
-1
dm; 
+
P<0.05) in 
the carnitine group, whilst skeletal muscle TC remained unchanged in the control group 
(17.5±1.5 to 17.8±1.5 mmolkg
-1
 dm). 
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6.4.2 Subsarcolemmal and intermyofibrillar lipid 
 
 
 
 
Figure 6.4. Subsarcolemmal (SSL) and intramyofibrillar (IMF) lipid droplet (% fibre area) 
pre and post exercise at 0 weeks and after 24 weeks of placebo (Control) or carnitine 
supplement (Carnitine) 
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SSL lipid content was not different pre and post-exercise in both the control and carnitine 
groups at baseline; 3.1 ± 0.9 vs.3.3±0.8 % fibre area pre and post-exercise 
respectively(Control), and  3.4 ± 1.1 vs. 4.1 ± 1.0% fibre area pre and post-exercise 
respectively (Carnitine). At 24 weeks,  SSL lipid content did not decrease post exercise in 
both the control and carnitine groups; 3.9±1.0 to 2.4±0.6 % fibre area in control compared to 
carnitine; 3.3±1.0 to 2.6±0.5% fibre area.  IMF lipid content was  comparable pre and post 
exercise in the control and carnitine groups at 0 weeks; 0.79±0.11 vs.0.72 ± 0.18 % fibre area 
pre and post-exercise respectively (Control), and  0.61±0.09 vs.0.41 ± 0.06% fibre area pre 
and post-exercise respectively (Carnitine). After 24 weeks, there was a tendency for IMF 
lipid content to reduce post-exercise (0.86±0.23 to 0.44±0,11%; P=0.1) in the carnitine group 
whilst no changes were seen in the control group (0.87±0.20 to 0.71±0.15% fibre area) pre 
and post-exercise respectively.  
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6.4.3 Exercise substrate utilisation 
 
Figure 6.6: Contribution of fat (plasma FFA, black bar; other fat, striped bar)  and 
carbohydrate (white bar) to energy expenditure during exercise at 50% VO2max in control 
(Con) and Carnitine (Carn) groups before and after 24 weeks. All values are described as 
means ± s.e.m. **P<0.01, fat oxidation greater than 0 weeks. 
 
There was no difference in the relative contribution of fat to total energy expenditure during 
exercise (Fig 6.6) at baseline in both groups, and at baseline and 24 weeks in the control 
group.  
However, exercise at 50% VO2 max and carnitine supplementation after 24 weeks were 
associated with a 21% (P<0.01; Fig 6.6) increase in total fat oxidation during exercise (181.1 
± 15.0 to 220.4 ± 19.6 J/kg lean mass/min), despite no change in plasma fatty acid Rd or 
oxidation (7.1 ± 1.3 vs. 7.3 ± 1.0 µmol/kg/min at 0 and 24 weeks respectively). Exercise at 
50% VO2 max alone did not alter carbohydrate or fat oxidation rates of older people in the 
control group. 
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6.4.4 Exercise metabolism 
 
 
Figure 6.7: Plasma lactate during rest (first 120 minutes) and exercise at 50%VO2 max (last 
60 minutes) of participants in the carnitine group (n=7) at baseline (Carn V1) and after 24 
weeks (Carn V2) of once daily 4.5 grams L-carnitine-L tartrate and insulinogenic beverage 
and twice weekly 1 hour cycling at 50%VO2 max. 
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Figure 6.8: Muscle lactate concentrations pre and post-exercise in control (Con; n=7) and 
carnitine (Carn; n=7) groups at 0 and 24 weeks.*P<0.01 from pre-exercise at 0 weeks. 
 
 
Figure 6.9: Muscle glycogen concentrations pre and post exercise in control (Con; n=7) and 
carnitine (Carn; n=7) groups at 0 and 24 weeks. *P< 0.05 from pre-exercise at 0 weeks. 
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Figure 6.10A 
 
Figure 6.10B 
Figures 6.10A and B: Sympathetic activity (noradrenaline and adrenaline concentrations) at 
rest for first 120 mins and exercise at 50% VO2 max for the final 60 minutes at 0 and after 24 
weeks in carnitine and control groups. 
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At steady state (last 10 minutes of an hour of cycling at 50% VO2 max), plasma lactate 
concentrations in the control group were lower compared to baseline after 24 weeks (delta 
mean of 0.38 mmol/l; 1.57±0.23 compared with 1.19±0.15mmol/L). This was lower in the 
carnitine group (delta mean 0.59 mmol/L; 1.69±0.39 compared with 1.10±0.18mmol/L).  
Skeletal muscle lactate concentration tended to increase post-exercise in the carnitine but not 
in the control group at 0 weeks (4.4 ± 1.1 to 11.6 ± 4.2mmol/L; P=0.07 and 4.1 ± 0.8 to 7.5 ± 
1.5 mmol/L) respectively. The effect appeared to be obliterated in the carnitine group post-
exercise after 24 weeks (6.9±1.1 to 6.7±1.3 mmol/L) as opposed to a tendency to an increase,   
3.6 ± 0.8 to 7.8 ± 2.2 mmol/L; P=0.09 in the control group. 
After 24 weeks, the degree of muscle glycogen depletion was significant in both carnitine and 
control groups (295±27.5 to 216.9 ± 20.8 mmol/kg dm and 311±50.3 to 197.8 ± 43.4 
mmol/kg dm) respectively.  
Sympathoadrenal activity represented by noradrenaline and adrenaline concentrations 
remained similar during exercise before and after 24 weeks in the carnitine and control 
groups; Figure 5.10A and B. 
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6.11 Insulin sensitivity 
 
 
Figure 6.11: Glucose disposal rates (GDR) of participants ingesting either 4.5 g L-carnitine 
L-tartrate (CARN ) or 4.5 g placebo (CON) with insulinogenic beverage (44.4g CHO, 13.6g 
protein)and twice-weekly 1 hr cycling at 50%VO2 max at 0 and 24 weeks. 
 
Figure 6.12: Muscle 2DG uptake in control and carnitine groups at baseline and 24 weeks 
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There was no difference in glucose disposal rates of participants randomised to the Carnitine 
and Control groups at baseline (51.2 ± 7.5 vs 48.3±4.9 µmol kg
-1
 lean mass min
-1
). After 24 
weeks of treatment, no difference in mean glucose disposal rates were seen in both groups 
48.9 ± 5.9 and 46.6 ± 6.5µmol kg
-1
 lean mass min
-1
 respectively; Figure 6.11. Similarly there 
was no difference in 2DG uptake in muscle between Carnitine and Control at baseline and at 
24 weeks; Figure 6.12. Muscle 2DG uptake was 44.3 and 43.7 mmol.kgdw
-1
.min
-1 
in the 
control group and 48.2 and 51.0 mmol.kgdw-1.min-1 in the carnitine group at 0 and 24 weeks 
respectively.   
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6.6 Substrate oxidation at rest under fasted and insulin-stimulated conditions  
Table 6.13: Carbohydrate and fat oxidation rates, respiratory exchange ratio (RER) and energy expenditure in control (n=5) and carnitine groups 
(n=6) during the resting hyperinsulinaemic 60mu m
-2
min
-1
 euglycaemic clamp. *P<0.05 compared to pre-insulin values 
ф
 p=0.06 compared to 
pre- insulin values. 
 Control (n=5) Carnitine (n=6) 
 0 weeks 24 weeks 0 weeks  24 weeks 
 Pre-Insulin Post-Insulin Pre-Insulin Post- 
Insulin 
Pre- 
Insulin 
Post- 
Insulin 
Pre- 
Insulin 
Post- 
Insulin 
Carbohydrate 
Oxidation 
(J/kg/lbm/min) 
46.5±8.1 44.8±11.7 63.8±8.4 84.8±4.5 57.0±6.1 70.5±6.6 51.8±2.6 67.8±3.1* 
Fat Oxidation 
(J/kg lbm/min) 
42.0 ±7.3 49.7±9.4 34.0±9.9 17.4±3.4
 
32.7 ±7.3 23.0±4.1 44.1±3.8 30.4±2.9
ф 
RER 0.85±0.03 0.83±0.03 0.91±0.03 0.94±0.01
 
0.89±0.02 0.92±0.01 0.86±0.01 0.90±0.01*
 
Energy 
Expenditure 
(J/kg lbm/min) 
88.5±4.4 94.5±8.2 97.8±8.2 100.2±5.6 89.8±3.2 93.5±3.1 95.9±2.0 98.2±1.5 
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At rest, carbohydrate oxidation rates increased by 31% upon insulin stimulation at 24 weeks 
in the carnitine group whilst there was a trend for a reduction in fat oxidation rates (44.1±3.8 
to 30.4 ± 2.9 J kg lean body mass 
-1
 min
-1 
, P=0.06 ). Accordingly, an increase in respiratory 
exchange ratio (RER) after 24 weeks was seen during the insulin clamp in the carnitine group 
(0.86±0.01 to 0.90±0.01, P<0.05). There were no associated changes in basal fasted oxidation 
rates. No changes in fasted or fed states were seen in the control group (Figure 6.13).  
 
6.4.7 Body composition 
  
Figure 6.14: Fat mass (kg).Trunk (black bars), leg (grey bars) and arm (opened bars) fat 
mass before (0) and 24 weeks after once daily oral ingestion of either 4.5 grams placebo 
(Control)and insulinogenic beverage ( n=7) or 4.5 grams l-carnitine-l-tartrate  (Carnitine) and 
insulinogenic beverage (n=7). All values are means ±SEM. 
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After 24 weeks of twice weekly 1 hour cycling at 50% VO2 max, no difference was seen in 
body mass, BMI, lean body mass or fat mass and fasting plasma glucose in both Carnitine 
and Control groups.  
6.4.8 Incremental shuttle walk test 
The ISWT did not differ in both groups at baseline and after 24 weeks.  
6.4.9 SF36v2 
Table 6.2: SF 36v2™ Health Questionnaire Scores (%) completed by participants in 
carnitine (n=6) and control (n=6) at week 0 and week 24. NS non-significant 
 
 
 
 
 
 
 
 
 
SF36v2 scores only improved in the functional physical role domain in the carnitine group 
after 24 weeks. 
 
 
Health domains  Control  Carnitine 
 Week 0 Week 24 Week 0 Week 24 p value 
Physical function 95.8 94.3 90.8 95.0 NS 
Physical role 
functioning 95.8 96.4 79.2 90.6 
P<0.001 
Emotional role 
functioning 98.6 98.8 95.8 91.7 
NS 
Vitality 75.0 76.8 75.0 77.1 NS 
Mental Health 80.8 83.6 88.3 88.3 NS 
Social functioning 97.9 98.2 97.9 97.9 NS 
Bodily Pain 89.2 90.7 85.4 82.5 NS 
General Health 79.2 77.9 75.8 75.8 NS 
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6.5 Discussion 
 
As demonstrated in Chapter 3, older people exhibited lower fatty acid oxidation (most likely 
secondary to impaired IMCL utilisation) during light-intensity exercise and reduced glucose 
disposal rates compared to young. This study proposed that ingestion of carnitine with an 
insulinogenic beverage may improve fatty acid oxidation rates in older people and that this 
may translate to improving insulin sensitivity and body composition in this age group. A 
major finding from this study was that a 16% increase in muscle total carnitine improved 
total fatty acid oxidation, in particular IMCL oxidation. The improvement in IMCL oxidation 
however did not affect insulin sensitivity or body composition in older individuals. The 
ability of carnitine to improve fatty acid oxidation in older people during low-intensity 
exercise is advantageous as it demonstrates that fatty acid oxidation in older people can 
improve without undertaking high-intensity exercise or training many times per week that 
may prove unrealistic and unattainable in the majority of the older population. Previously 12 
weeks of aerobic training at 75%VO2 max 5 days per week was shown to improve IMCL and 
insulin sensitivity in older, obese and sedentary individuals (Pruchnic et al. 2004). 
This study is the first to show that total muscle carnitine content can be successfully 
increased in older healthy men after 24 weeks of oral carnitine ingestion in combination with 
an insulinogenic supplement. In previous studies, an increment in total muscle carnitine was 
only observed following intravenous infusion of carnitine and oral carbohydrate 
supplementation (Stephens et al. 2006) and more recently via oral ingestion of L-carnitine in 
young healthy recreational athletes (Wall et al. 2011,Stepehens et al. 2013). It would appear 
that the daily insulinogenic beverage in this study was effective in elevating insulin to levels 
that facilitated uptake of carnitine into muscle, in concert with previous studies of carnitine 
supplementation (Stephens et al. 2006, Wall et al. 2011, Stephens et al. 2013). A total of 80 g 
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of carbohydrate supplement  twice daily was required to increase retention and facilitate 
uptake of carnitine in muscle (Wall et al. 2011) but this may prove deleterious and cause a 
positive energy balance and fat mass accumulation in older individuals, as observed with the 
control group in the study by Stephens et al. 2013. Therefore, a compromise of 44.4 g of 
carbohydrate and addition of 13.8 g of protein, which can stimulate a modest rise in insulin 
secretion without increasing blood glucose levels (Krekozski et al. 1986), was considered and 
proved successful in retaining total carnitine content in muscle. 
Although there is considerable research examining carnitine status in populations these 
tended to be measurements of blood and urine, whilst those of muscle were mostly carried 
out in younger individuals (Carlin et al. 1986, Harris et al. 1987, Janssen et al. 1989, Arenas 
et al.1991). Of the few examining muscle carnitine levels, regression data by Costell et al. 
(1989) indicated an inverse relationship between age and carnitine levels in healthy humans 
and mice. Whereas skeletal muscle free carnitine levels increased from adolescence to 
adulthood in rats, levels then tended to decline with advancing age. The underlying cause of 
why carnitine levels are reduced in ageing is not entirely known but low carnitine levels have 
been associated with insulin resistance (Noland et al. 2009), which in turn is associated with 
increasing age. Reduced free carnitine levels in muscle were found to be a feature in rat 
models of insulin resistance including ageing (Bernard et al. 2008). Previous studies reported 
baseline mean levels of 20-25 mmol kg dm
-1
 in young healthy individuals (Wall et al. 2011, 
Stephens et al. 2013) but there are limited studies examining total carnitine content in muscle 
of older human volunteers. In concert with this study, Starling et al. (1995) showed that 
resting free and total muscle carnitine were similar in older vs. younger people (20.3 ± 0.9 vs 
21.6 ± 0.7 and 26.1±0.9 vs 26.4 ± 0.6 mmol kgdm
-1
) respectively. However the older 
volunteers in Starling’s study had an age range lower than the present study (47.6 ± 8.8 
vs.69.2±0.6 years respectively).  
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Having demonstrated that skeletal muscle total carnitine content can be successfully 
increased after 24 weeks supplementation in healthy older people, another major finding from 
this study was that carnitine increased fat oxidation (most likely IMCL) during low-intensity 
exercise. The ability of carnitine loading to promote fatty acid oxidative capacity in humans 
has been shown before in young healthy individuals (Stephens et al. 2013, Wall et al. 2011). 
This may be the result of adaptations leading to diversion of carbohydrate oxidation towards 
storage and favouring fat oxidation, and is likely to occur because carnitine is rate-limiting to 
CPT-1.  
Carnitine appeared to improve muscle metabolism during exercise as muscle lactate did not 
increase post exercise compared to baseline. Indeed, in a previous study by Stephens et al 
(2006), muscle lactate content reduced following L-carnitine infusion at rest and was 
associated with blunting of PDC activity. However contrary to findings from the same study 
and a study by Wall et al (2011) (whereby carnitine reduced muscle glycolysis and increased 
glycogen storage in muscle at rest and during exercise in young healthy people, respectively, 
there appeared to be greater glycogen utilisation during exercise not only in the control group 
but also in the carnitine-fed group.Therefore oral supplementation of carnitine for 6 months 
does not appear to have an effect on reducing muscle glycogen utilisation in older people.  
The notion that carnitine may influence insulin sensitivity stem from observations that insulin 
resistant states are often associated with lower (~25%) carnitine concentrations 
(Tamamogullari et al. 1999) and carnitine supplementation improved glucose homeostasis in 
healthy (Galloway 2011) and insulin-resistant humans (Rahbar et al. 2005). Perturbations in 
muscle mitochondrial fuel metabolism in animal models of glucose intolerance including 
incomplete fatty acid oxidation as a result of carnitine insufficiency were reversed by 
administration of oral carnitine and further improved whole body glucose tolerance 
(Mingrone et al. 1999). Indeed low rates of fatty acid oxidation due to decreased function of 
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CPT-1 involved in the carnitine shuttle in mitochondria is associated with insulin resistance, 
possibly caused by accumulation of IMCL intermediates that interfere with insulin signalling 
(Dobbins et al. 2011). Human studies examining the effect of carnitine supplementation on 
glucose disposal or insulin sensitivity are limited and mostly involved acute intravenous 
administration of L-carnitine. These studies demonstrated that L-carnitine infusion during the 
hyperinsulinaemic euglycaemic clamp in insulin-resistant individuals with diabetes increased 
peripheral glucose disposal (Capaldo 2005), whole body glucose disposal and glucose 
oxidation (Mingrone et al. 1999). A bolus of L-carnitine was also shown to increase glucose 
disposal, carbohydrate oxidation and respiratory quotient in people with T2DM by means of 
the intravenous glucose tolerance test (analysed via the minimal model technique). Insulin 
sensitivity index remained unchanged (De Gaetano et al. 1999). It is worth pointing out that 
these studies involved adults aged less than 60 years of age and that carnitine was 
administered intravenously.  
Despite an increase in the ability to utilise IMCL, increasing muscle total carnitine and fat 
oxidation in older healthy males in this study did not appear to affect skeletal muscle insulin 
sensitivity as demonstrated by unchanged glucose disposal rates and 2DG uptake in skeletal 
muscle at 24 weeks. Fasting plasma glucose concentrations were however reduced after 24 
weeks of ingesting carnitine. Exercise at 50% VO2 max twice weekly for an hour did not 
affect fat oxidation or insulin sensitivity in the control group. Whereas other studies have 
showed an improvement in markers of insulin sensitivity (fasting insulin, HOMA-IR) 
(Pruchnic et al., 2004) and via the insulin-glucose clamp (Goodpaster 2003), these were most 
likely exercise training-induced effects of exercise up to 75% VO2 max (Hughes et al. 
1995,Cox et al. 1999) or vigorous endurance exercise training (Kirwan et al. 1993).  
This study further showed that under insulin-stimulated conditions fat oxidation rates at rest 
in the carnitine group remained unaltered but carbohydrate oxidation rates increased in 
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addition to an increase in resting energy expenditure pre-insulin after 24 weeks of daily 
supplementation with carnitine. Oral supplementation of carnitine may have improved the 
metabolic flexibility of switching substrates in response to insulin.  Besides carnitine’s main 
involvement with mitochondrial transport and subsequent beta-oxidation of long-chain fatty 
acids it also functions to sequester and export inhibitory acetyl-coenzyme A units as acetyl 
carnitine, which favours glucose oxidation (McGarry and Brown 1997).  
Taken together the findings indicate that although increasing the bioavailability of carnitine 
was able to improve beta-oxidation particularly during low-intensity exercise, this may not 
have reached levels sufficient to affect whole body glucose disposal.  
There was a tendency for SSL lipid droplets to reduce post exercise at 24 weeks in the control 
group indicating perhaps an exercise training effect. Lipid droplets in the IMF region tended 
to reduce post exercise in the carnitine group. As demonstrated in study 1 (Chapter 3), lipid 
was seen to accumulate to a greater extent in the SSL regions of muscle of older overweight 
participants during light-intensity exercise and this was attributed to blunting of IMCL 
oxidation capacity. However despite an improvement in fatty acid oxidation in the carnitine 
group, and comparable body fat mass, there was less of a reduction of percentage lipid 
droplet accumulation within the SSL region of muscle post-exercise compared to control. The 
significance of this cannot be entirely reconciled without further examination of the lipid 
moieties involved and reasons for the difference in the degree of accumulation. However 
carnitine appeared to prevent the accumulation of IMF lipid during light-intensity exercise, 
perhaps indicating a role for carnitine on this distinct pool. Again the significance of this is 
unknown, and the lipid moieties involved should be examined further.  No changes in body 
composition were seen in both the carnitine and control groups after 24 weeks of ingesting 
either carnitine or placebo in combination with daily supplement of 220mls of an 
insulinogenic beverage (44.4 grams and 13.8g protein) equating to 330kcals extra energy. In 
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a study involving carnitine and insulinogenic beverage in young healthy volunteers, fat mass 
accrual was prevented with oral supplementation of carnitine (Stephens et al. 2013). The 
investigators postulated that ingesting carnitine may have obviated the effect of increased 
energy intake from the carbohydrate supplement by increased fuel utilisation during exercise. 
Lean mass was also similar in both groups at 24 weeks. It may be that a longer period of 
carnitine loading and sustainability of exercise may be required to see significant changes in 
body composition in older individuals, for this to occur individuals may have to train for 
longer and at higher activity levels as the Wall et al. (2011) and Stephens et al. (2013) studies 
used triathletes who were regularly training at higher exercise intensities. 24 weeks of light-
intensity exercise twice weekly (control group) also did not appear to improve lean nor fat 
mass. Nevertheless fat oxidation in volunteers in this study increased despite exercising at the 
same exercise intensities before and after carnitine.  
No changes were seen with regards to the incremental shuttle walk test (which is an indicator 
of VO2 peak) in both groups although there was a perceived improvement in the physical 
functioning role in the carnitine group at 24 weeks. The incremental shuttle walk test (ISWT) 
is a reproducible, standardised exercise test originally developed to evaluate functional 
capacity in patients with chronic progressive obstructive disease (Singh et al. 1992) and later 
validated for use in other chronic diseases (ATS Committee on Proficiency Standards for 
Clinical Pulmonary Function Laboratories). When compared to the few studies examining the 
ISWT in older healthy individuals the mean distance walked (560 ± 22 m) in this study was 
comparable to distance walked in a study by Jurgensen et al. (2011) (508 ±160m, mean age 
58± 10 yrs ) and Lee et al. (2005) (440m (range 360-520m, mean age 61 ± 10 yrs). However 
Dyer et al. (2002) reported a much lower mean distance walked in much older subjects 
(243±21m, age range 70-85) indicating the negative correlation of age with ISWT that may 
be influenced by gradual reduction in muscle mass, strength and maximal oxygen uptake in 
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parallel with ageing (Fleg et al.1998, Evans et al. 1993). This corresponds with the lower 
maximal oxygen uptake (VO2 max) seen in older volunteers in this study compared to 
younger healthy controls. No difference was seen after 24 weeks in mean distance walked in 
both groups in this study, although participants in the carnitine group walked an average 
25.7m further than at 0 weeks.  
The overall SF36v2 scores did not differ between participants in the carnitine and control 
groups at baseline, participants in the carnitine group on average scored better in the physical 
role functioning health domain. The improvement was related to an increase in the ability to 
accomplish more and having less difficulties and limitations with work and daily activities of 
living (Users Manual SF36v2TM, QualityMetric, Lincoln USA).  
 
6.6 Conclusions  
    In conclusion, this study has shown for the first time that oral carnitine supplementation 
taken with an insulinogenic beverage for 6 months can increase skeletal muscle total carnitine 
content in older healthy humans. The increased carnitine availability promoted fatty acid 
oxidation during low-intensity exercise, presumably from IMCL.  Perhaps a longer period of 
carnitine feeding and exercise is required to appreciate an improvement in insulin sensitivity, 
or an underlying mechanism that resists the increased fatty acid oxidation from translating to 
increasing insulin sensitivity is yet unknown, and remains to be elucidated. Future studies 
should also control for confounding factors such as habitual activity and dietary intake in 
participants, as these may also impact on the overall effect on insulin sensitivity. Finally as 
carnitine has been shown to improve glucose tolerance in insulin-resistant states other than 
ageing, the role of carnitine supplementation in overweight/obese individuals and T2DM 
should also be explored. 
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Chapter 7: Final Summary and Discussion 
 
Two major pertinent issues affecting the 21
st
 century are the growing ageing 
population and overweight and obesity rates. Over 10 million people in the UK are aged 65 
and above, with numbers expected to almost double by 2050. By then obesity is predicted to 
affect 60% of adult men, 50% of adult women and 25% of children (Foresight 2007).  In line 
with this, the number of people with diabetes is expected to more than double worldwide 
(Wild et al. 2004) as a result of the ageing population, with the largest rise in people aged 65 
and over.  Clearly these numbers pose major public health concerns and hugely impact on 
healthcare costs. A key issue of the 2015 Parliament was once more focussed on addressing 
the growing social and economic impact of ageing and related chronic conditions on 
healthcare and social systems in the UK (www.parliament.uk / business/ publications/ 
research/ key-issues-parliament-2015). Over 10 billion pounds annually are spent on 
management of T2DM. The growing literature on studies related to insulin resistance is 
testament that this issue is significant and strategies to improve insulin sensitivity are 
warranted. Efforts to tackle these problems are clearly still hampered by outstanding issues 
concerning nutrition and insulin resistance.  
The studies presented in this thesis set out to explore these important issues; in particular the 
effects of overfeeding macronutrients and of specific micronutrient supplementation on 
insulin sensitivity, and sought to investigate the influence of age and overweight/obesity on 
insulin sensitivity in healthy people. The general literature on these subjects is inconclusive 
on several questions that the studies have endeavoured to answer: 
1) Does ageing per se cause insulin resistance, or are there other factors associated with 
ageing that contributes to the decline in insulin sensitivity? 
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2) As ageing is associated with insulin resistance and sarcopenia, is there an effect of reduced 
insulin sensitivity on muscle protein metabolism and what are the underlying mechanisms? 
3) Is increased liver fat content and perturbations to carbohydrate and fat metabolism due to 
energy excess or is it macronutrient specific? 
4) Can micronutrients that are specific to influencing fatty acid metabolism, ie fat oxidation,   
impact on improving impaired fat utilisation and insulin sensitivity particularly in the elderly? 
With the emergence of increased obesity rates and the ageing population, there is growing 
interest as to whether it is age, physical inactivity or body composition per se that affects 
insulin sensitivity in older healthy people. This question was explored in the first study 
(Chapter 3), where fat metabolism, insulin sensitivity and skeletal muscle metabolism were 
compared in old and young healthy men. It was proposed that it is factors associated with 
ageing and not ageing per se that contributes to the decline in insulin sensitivity. Ageing and 
insulin resistance is also associated with sarcopenia, a significant risk factor of disability in 
the ageing population. It was also demonstrated in Chapter 3 that older overweight and less 
insulin-sensitive men have lower functional capacity as demonstrated with the Incremental 
shuttle walk test (ISWT), a feature of sarcopenia or inactivity. The following chapter 
(Chapter 4) presented results from examining the effect of insulin resistance, induced by 
acutely elevating lipid concentrations in young healthy men, on MPS, providing insight to the 
likely mechanisms involved in perturbed MPS and insulin sensitivity.  Besides physical 
inactivity, diets are clearly a driver in the development of central obesity, visceral fat and 
hence insulin resistance. The third study (Chapter 5) thus investigated to what extent liver fat 
and hepatic insulin sensitivity were affected by 2 weeks of increased energy intake of fat, and 
how this compared to high carbohydrate feeding with the premise that liver fat accumulation 
and hepatic insulin resistance are energy, rather than macronutrient -mediated. Novel 
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strategies are therefore warranted in addressing the growing rates of obesity and insulin 
resistance. The final study (Chapter 6) aimed to investigate the effects of carnitine 
supplementation on skeletal muscle fat metabolism and insulin sensitivity in older healthy 
men. The main findings are chapter specific and were summarised within the chapters 
themselves.  This section will amalgamate the empirical findings and discuss further research 
required to further increase our understanding of current issues.     
Ageing is associated with metabolic perturbations, exacerbated by increasing visceral 
fat, skeletal muscle lipid accumulation, sarcopenia and reduced insulin sensitivity. However 
there is mounting evidence including findings from this thesis to suggest that it is not age per 
se but body composition and physical inactivity that affects insulin sensitivity and skeletal 
muscle metabolism. As revealed from data presented in chapter 3, older healthy men have 
greater predisposition to lipid accumulation, reduced fat metabolism and insulin resistance, 
and these appear to be largely influenced by body fat and to a certain extent, physical 
inactivity. The general impression of the current literature is that although ageing is often 
implicated in perturbations to metabolism and insulin sensitivity, it would appear that it is 
mostly factors associated with ageing such as increasing adiposity, reduced lipid utilisation 
and impaired metabolism and a sedentary state that increases insulin resistance. More often 
than not, studies involving older groups and investigating insulin sensitivity do not control for 
these factors that may influence results. The findings from this thesis assert the importance 
and influence of adiposity and habitual physical activity on skeletal muscle insulin 
sensitivity. Thus, people do not necessarily develop insulin resistance simply because they 
are ‘growing older’, but this is likely to be due to development of obesity, accumulation of 
IMCL and associated reduction in physical activity with ageing. Therefore strategies should 
be targeted at encouraging increased activity, a healthy balanced diet and therapies to prevent 
accumulation of excess fat; visceral or skeletal. The findings would also fit with the general 
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consensus that increased adiposity, liver fat deposition and IMCL accumulation all 
predispose to a decline in insulin sensitivity and hepatic metabolism. Along the line of 
physical inactivity and insulin resistance is the increasing incidence of sarcopenia, a decline 
in muscle mass and functional capacity. A stark difference between the ISWT of the older 
lean and overweight older men was observed in Chapter 3 and as Chapter 4 demonstrated, 
insulin resistance led to perturbations of MPS in response to amino acid ingestion under 
hyperinsulinaemic euglycaemic conditions, associated with an impairment of signalling 
located downstream of the Akt-mTOR signalling pathway at the level of translation initiation. 
Closely associated with increasing overweight and obesity rates, controversy surrounding 
energy excess vs. macronutrient influence on fat accumulation and insulin resistance persists 
but provides strong impetus to research, even dominating headlines in social media in recent 
years.  With various conflicting information on which is worse, carbohydrate, fat or energy 
excess the ultimate conclusions are not so clear-cut thus dividing public and indeed research 
community opinions alike. Newspaper headlines such as ‘Butter is NOT bad for you’ and 
‘Saturated fat is ok after all’ are likely to confuse and lead to increased consumption of 
processed foods high in fat. On the other hand, replacing saturated fat with refined 
carbohydrates would also have potentially negative side-effects. The studies in this thesis 
were designed to examine the effects of modulating macronutrients on liver and muscle fat, 
metabolism and insulin sensitivity. The general consensus generated from current research 
appears to indicate that energy excess leading to overweight or obesity is associated with 
insulin resistance. Although the effect of high fat diets on insulin resistance is inconclusive, 
carbohydrate excess, in particular fructose has been shown to promote insulin resistance 
(Stanhope et al 2009). The effects of high fat vs high carbohydrate diets are scarce so no 
definitive conclusion have been ascertained. The study presented in this thesis showed that 2 
weeks of energy excess per se caused a  significant increase in liver fat content and fasting 
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plasma TAGs, most likely due to the process of DNL when overfed with a diet high in 
carbohydrate, with a (borderline) greater increase of liver fat from baseline compared to the 
high-fat fed group. Whilst the findings of this study support the notion that energy excess can 
increase liver fat content in 2 weeks the results did not show a significant differential effect 
between carbohydrate and fat overfeeding. Carbohydrate excess appears to increase liver fat 
from baseline, with a trend seen following fat overfeeding. Nevertheless, the change in 
metabolites normally associated with liver fat accumulation appears to indicate a greater 
deleterious effect of high carbohydrate intake on liver fat, whereas high fat contributed to a 
rise in ApoB (thought to be a contributor to cardiovascular risk) and ApoA1 (perhaps as an 
indicator of the liver’s response to the rise in ApoB concentrations). Contrary to expectations, 
the increase in liver fat did not lead to a difference in hepatic or whole body insulin resistance 
as a consequence of energy excess or manipulation of carbohydrate or fat content. This is 
similar to outcomes seen in the study by Johnston et al (2013), whereby diets high in glucose 
and fructose increased liver fat content but did not affect hepatic insulin resistance. Several 
reasons could explain this outcome. It could be that 25% excess energy of fat and 
carbohydrate for 2 weeks is insufficient to increase insulin resistance. Stanhope et al (2009) 
shown that a 10 week 25% excess energy diet in the form of fructose-sweetened beverages 
increased DNL and visceral adiposity, resulting in dyslipidaemia and reduced insulin 
sensitivity in overweight/obese healthy humans.  Perhaps given a longer period of time, 
chronic ingestion of nutrients whether in excess of carbohydrate or fat may eventually lead to 
hepatic and skeletal muscle insulin resistance. A greater feeding stimulus may therefore be 
required to appreciate the effects of a short-term moderate dietary excess that correlates with 
insulin resistance. The ingestion of diets with greater energy excess than that used in this 
study have been investigated (Westerbacka et al. 2005, Le et al. 2009, Horton et al., Brons et 
al. 2011, Sevastionova et al. 2012). Whilst some of these studies showed significant effects 
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with liver fat or insulin sensitivity, it should be borne in mind that these diets may not be 
entirely representative of typical intakes in the general population. Diets in this study were 
designed to be realistic and simulate that of which might be consumed under habitual 
circumstances in the present population. Furthermore, the ethical concerns relating to 
prolonged or excessive overfeeding in humans would preclude studies involving excessive or 
prolonged dietary intakes.      
      Acknowledging the studies in the current literature and indeed from findings of studies 
undertaken for this thesis, the increasing prevalence of overweight, obesity and insulin 
resistance either from overnutrition or as a consequence of factors that accompany ageing 
warrant strategies to overcome these problems. This would include novel use of nutrients that 
may modulate metabolism, energy expenditure and insulin sensitivity. Dietary restriction, 
weight loss and exercise have been advocated in concerted efforts to improve insulin 
sensitivity in older people, and yet the number of elderly people with insulin resistance 
continues to rise. Realising that physical inactivity declines and adiposity increases with age, 
increased resources and focus have been placed in encouraging the older generation to 
exercise and eat healthier. Although training and exercise programmes are clearly beneficial 
in promoting weight loss, cardiorespiratory fitness and even insulin sensitivity in older 
people, in most cases, these regimens can be difficult for most to sustain. Various nutrients 
have been shown to improve insulin sensitivity but studies are limited and contradictory. 
Carnitine has been shown to increase the relative contribution of muscle fat oxidation to total 
fat oxidation during light intensity exercise in older people (Chapter 5), and appears to exert 
positive effects on skeletal muscle metabolism and metabolites. Older healthy people retained 
skeletal muscle total carnitine, however contrary to expectations ingestion of carnitine for 6 
months did not improve skeletal muscle insulin sensitivity. There was a tendency for the 
accumulation of lipid to decrease post-exercise in both control and carnitine-fed groups, 
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indicating that exercise, even at low-intensities can reduce the accumulation of lipid in 
muscle, but more importantly increase fatty acid oxidation in the carnitine group. It may be 
that a longer period, greater amount of carnitine or other ways of increasing the 
bioavailability of carnitine are required to appreciate a robust effect, or that there are still 
underlying mechanisms involved in ageing muscle not yet explored.  Nevertheless the 
findings show promise and future studies to extend on data are warranted, including 
investigation into the use of carnitine in overweight and people with pre-diabetes.    
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Figure 7.1: Tricycle hypothesis; amalgamation of Taylor’s twin cycle hypothesis (Taylor 2008) and the skeletal muscle cycle.  
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  Findings from the overfeeding study stress the importance of the deleterious effects of 
a positive energy balance on liver fat content and metabolism. Skeletal muscle lipid 
accumulation contributes to insulin resistance in ageing as seen in the study comparing young 
vs. older subjects. To reconcile the twin cycle hypothesis of Taylor (who acknowledges 
muscle insulin resistance as a factor implicated in development of T2DM), and De Fronzo’s 
postulation of skeletal muscle resistance as an important contributor to T2DM, a combined 
three cycle (tricycle) hypothesis is proposed (Figure 7.1). In addition to the twin cycle 
hypothesis that chronic energy excess leads to accumulation of liver fat with eventual spill-
over into the pancreas, over time, (ageing and continuous ingestion of energy excess) 
accumulation of skeletal muscle lipid could overwhelm the capacity of muscle to oxidise 
fatty acids. Ageing, reduced physical activity and decline in skeletal muscle mitochondrial 
content can all lead to muscle insulin resistance and contribute to a reduction in skeletal 
muscle glucose uptake and thus increased insulin secretion. Indeed this would presumably 
also occur in younger people who are in chronic positive energy balance. Considerably more 
studies in future should explore the effects of chronic nutrient overfeeding on hepatic and 
skeletal muscle insulin sensitivity, adipose tissue and pancreatic fat concurrently to further 
understand the interplay between these tissues and of which precedes the other. This would 
conceivably influence targeted strategies in the prevention of insulin resistance in at-risk 
groups of the population. For example strategies to reduce lipid delivery (particularly during 
exercise) and improve adipose tissue function, such as the use of acipimox (Daniele 2014) 
and pioglitazone (Bajaj et al. 2003), and further examination of the use of carnitine are  
justified. This should be in conjunction with the continued emphasis on ‘eating less, 
exercising more’.          
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7.1 Study limitations 
Several limitations to studies undertaken in this study are acknowledged. The major 
limitations of the high fat vs. high carbohydrate study was that it was not a cross-over design 
and did not involve an isoenergetic-fed control group per se; rather the participants presented 
as their own controls having completed an isoenergetic diet prior to embarking on the overfed 
period. On the other hand a cross-over study may pose issues with compliance and retention 
of participants for longer periods of overfeeding.  Body composition was assessed using body 
impedance analysis and subcutaneous fat analyses. 
1
H MRS of liver and skeletal muscle was 
also not performed at the beginning of the isoenergetic period. This would ascertain baseline 
liver and muscle fat, but the isoenergetic diet was not designed to provide excess energy so it 
has to be assumed liver fat remained the same during that period. Utilising indirect 
calorimetry at baseline would have been ideal for assessing energy expenditure and 
requirements as opposed to estimating basal metabolic rate and energy intake using diet 
diaries and energy equations. The study was also performed exclusively in male White 
European men and not under strict controlled conditions, thus activity levels were not 
controlled for and may be a confounding factor.  The intervention was relatively short and so 
the possible effects of a longer dietary regimen cannot be excluded, however this will need to 
be balanced between practicality, adherence to dietary regimen and ethics. Power calculations 
were made for the primary outcome measures but not for the secondary outcomes.  
Several limitations in the carnitine study are also acknowledged.  Diets and day to day 
habitual activities of participants were not controlled for so may have influenced outcomes of 
the study. On the other hand, this represents the use of carnitine within a habitual setting. 
Compliance may have been an issue; however participants attended over 75% of their twice 
weekly cycling sessions at the laboratory and regular measurements of serum carnitine levels 
were undertaken.      
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7.2   Future directions 
There is certainly still a lot of scope for increasing our understanding and exploration in the 
effects of nutrients and ageing on insulin sensitivity.  
The observations and findings of studies undertaken have unraveled several questions that 
warrant further investigation and should be addressed in the future: 
 
1) Explore the underlying mechanisms and insulin pathways contributing to the accumulation 
of lipid in specific regions of skeletal muscle in older vs. young people. Why does 
subsarcolemmal lipid accumulation mostly occur in muscle of overweight/obese and older 
people and how does it affect insulin sensitivity? Importantly, are there ways to avert or slow 
down this phenomenon? 
2) Further investigate the role of physical activity and body composition including the 
contribution of subcutaneous fat/visceral fat in pre-diabetes or T2DM on skeletal muscle lipid 
and metabolism. 
3) Explore the effects of high fat vs high carbohydrate on liver fat and skeletal muscle in 
people with pre-diabetes or impaired glucose tolerance (IGT). 
4) To further investigate in detail the effects of the type of carbohydrate (polysaccharide vs 
monosaccharides) and fat (PUFA vs MUFA and saturated) on insulin sensitivity.  
5) To not only investigate the effects of diet on liver fat but further determine if participants 
are genetically insulin sensitive or resistant. Investigating pancreatic fat via MRI/
1
H MRS 
would also be beneficial to further understand the cross talk between fatty liver, pancreatic fat 
cells and inflammation that may accentuate beta-cell dysfunction. 
6) Investigating the interplay of effects of diets on muscle, liver, pancreas and adipocytes in 
elucidating the pathogenesis of insulin resistance.    
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7) Investigate the effects of intravenous vs oral carnitine in older and younger subjects, older 
lean and overweight/obese, controlling for habitual physical activity and diets.  
8) Exploration of gene expressions of insulin signalling pathways and fat metabolism in 
carnitine-fed subjects. 
9) Examine skeletal muscle protein synthesis of older healthy people in response to lipid-
induced insulin resistance and whether this can be improved with carnitine supplementation. 
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Appendices 
Breakfast              Weight (g) 
Medium sliced bread 50 
Skimmed milk 1 pint 293 
Flora butter 
 
20 
Cereal 
  
50 
Skimmed milk powder 9 
  
   Lunch 
   Large cornish pasty 
 
227 
Crisps 
  
30 
Peach 
  
100 
  
   Dinner 
   Chicken in white wine with 
mash 450 
Garden Peas 
 
80 
Jelly 
  
175 
  
     
   Snacks 
   Chocolate digestive biscuits 51 
Crisp biscuits   44 
   
Figure 1 :Example food menu 2200 kcals 
Table 1: Example breakdown of energy composition 2200kcal menu 
Nutrient Quantity Energy Percentage 
Protein 90.5 362 16 
Carbohydrate 286 1072.6 49 
Fat 85.6 770.7 35 
    2205.3 100 
        
Composition of 
CHO       
Sugars 71.2 266.9 12.1 
Starch 84.4 316.6 14.4 
        
Composition of 
Fat       
SFA 38 342.1 15.5 
MUFA       
PUFA       
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Table 2: Example breakdown of energy composition of high fat diet  
HF diet       
Nutrient Quantity Energy Percentage 
Protein 90.5 362.3 13.5 
Carbohydrate 286.2 1073.1 40 
Fat 138.7 1248.2 46.5 
    2683.6 100 
        
Composition of 
CHO   267.4 10 
Sugars   316.6 11.8 
Starch       
        
Composition of 
Fat       
SFA   643.5 24 
MUFA       
PUFA       
 
Table 3: Example breakdown of energy composition of high carbohydrate diet  
  
HC Diet       
Nutrient Quantity Energy Percentage 
Protein 90.5 362 13.2 
Carbohydrate 430.4 1614 58.8 
Fat 85.6 770.7 28 
    2746.7 100 
        
Composition of 
CHO       
Sugars   266.9 9.7 
Starch   316.6 11.5 
        
Composition of 
Fat       
SFA 38 342.1 12.5 
MUFA       
PUFA       
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Table 4: Example energy requirements during isoenergetic and 2 week hyperenergetic 
periods 
 TEE 
(kcal) 
Energy 
from 
fat(kcal
/day) 
Energy 
from 
fat (%) 
Energy 
from CHO 
(kcal/day) 
Energy 
from 
CHO 
(%) 
Energy 
from 
protein 
(kcal/day) 
Energy 
from 
protein 
(%) 
Isoenergetic 
period 
2200 800 35 1100 55 300 15 
Hyper- 
energetic 
(+25%)HC 
2750 800 28 1650 60 300 12 
Hyper-
energetic 
(+25%) HF 
2750 1300 46 1125 41 325 13 
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Table 5: Dropouts from Study 4 (Chapter 6) 
 
Participant Age Comments 
2 Older Died due to cholangiocarcinoma 
unrelated to study (Severe Adverse 
Event – SAE) 
5 Older Discontinued following vasovagal 
event post muscle biopsy 
7 Older Developed arrythmia following light-
intensity exercise 
9 Older Discontinued as averse to chronic 
intake of nutritional drink 
14 Older Developed deceleration of heart rate 
during light-intensity exercise 
 
 
16 
Older Developed vasovagal episode during 
light-intensity exercise during study 
visit 
18 Older Decided to discontinue with study  
due to inability to complete exercise 
during study visit 
8 Young Decided to discontinue study after 
painful muscle biopsy 
9 Young Did not return for follow-up study 
visit 
10 Young Did not return for follow-up study 
visit 
 
